nct_id,status,start_date,completion_date,primary_completion_date,phase,enrollment,study_type,allocation,intervention_model,primary_purpose,masking,conditions,intervention_types,intervention_names,sponsor,sponsor_type,has_results,num_outcome_measures,num_primary_outcomes,num_secondary_outcomes,num_p_values_in_primary,enrollment_missing,trial_duration_months,is_top_pharma,sponsor_trial_count,has_placebo,design_quality_score
NCT04465877,COMPLETED,2020-06-15,2021-02-17,2021-02-17,PHASE1,37.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","JTT-662, Placebo",Akros Pharma Inc.,INDUSTRY,True,4,4,0,9,0,8.0,0,3,1,4
NCT03617081,COMPLETED,2018-08-09,2018-12-13,2018-12-13,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","NNC0113-2023, Placebo (NNC0113-2023)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,4.0,1,126,1,5
NCT01427257,COMPLETED,2012-02-15,2012-09-15,2012-09-15,PHASE1,10.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Single Dose PB1023, Single Dose PB1023, Single Dose PB1023",PhaseBio Pharmaceuticals Inc.,INDUSTRY,False,0,0,0,0,0,7.0,0,4,0,2
NCT01068730,COMPLETED,2010-02-15,2010-04-15,2010-04-15,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","metformin (Diabex), metformin (Glucophage™), metformin (Glucophage™), metformin (Diabex)",AstraZeneca,INDUSTRY,True,12,2,7,0,0,2.0,1,79,0,2
NCT00839683,COMPLETED,2009-02-15,2009-03-15,2009-03-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","simvastatin, Dapagliflozin, simvastatin, valsartan",AstraZeneca,INDUSTRY,False,0,0,0,0,0,1.0,1,79,0,2
NCT02353975,COMPLETED,2014-05-15,2014-09-15,2014-07-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,DRUG,SHR3824,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,2.0,0,15,0,2
NCT03646721,COMPLETED,2018-08-29,2020-05-07,2020-05-07,PHASE1,108.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","DA-1241, Placebo, Sitagliptin","Dong-A ST Co., Ltd.",INDUSTRY,False,0,0,0,0,0,20.0,0,6,1,4
NCT01916174,COMPLETED,2013-08-15,2013-11-15,2013-11-15,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG","insulin degludec/liraglutide, insulin degludec/liraglutide",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,3.0,1,126,0,3
NCT05363774,COMPLETED,2022-04-20,2024-04-02,2024-04-02,PHASE1,161.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,TRIPLE,"Healthy Volunteers (Diabetes Mellitus, Type 2)","DRUG, DRUG","NNC0519-0130, Placebo (NNC0519-0130)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,23.0,1,126,1,4
NCT03738449,COMPLETED,2019-01-08,2019-01-24,2019-01-18,PHASE1,23.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","CKD-387, D484",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,0.0,0,32,0,2
NCT05731544,COMPLETED,2022-08-17,2025-07-08,2024-11-18,PHASE1,443.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,DRUG,BMF-219,Biomea Fusion Inc.,INDUSTRY,False,0,0,0,0,0,27.0,0,1,0,4
NCT01302028,COMPLETED,2010-01-22,2010-06-26,2010-06-26,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,DRUG,ASP1941,Astellas Pharma Inc,INDUSTRY,False,0,0,0,0,0,5.0,0,4,0,2
NCT00704132,COMPLETED,2007-02-14,2010-04-28,2010-04-28,PHASE1,57.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG","Comparator: sitagliptin phosphate, Comparator: placebo (unspecified)",Merck Sharp & Dohme LLC,INDUSTRY,True,1,1,0,1,0,38.0,1,55,1,5
NCT05113693,COMPLETED,2021-11-25,2021-12-10,2021-12-06,PHASE1,33.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","CKD-393, CKD-501, D759, H053",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,0.0,0,32,0,2
NCT02201199,COMPLETED,2014-08-15,2014-11-15,2014-11-15,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,Type 1 Diabetes Mellitus,"DRUG, DRUG, DRUG","insulin glargine U200 HOE901, insulin glargine U500 HOE901, insulin glargine U100 HOE901",Sanofi,INDUSTRY,False,0,0,0,0,0,3.0,1,25,0,2
NCT04259801,COMPLETED,2020-02-17,2022-03-16,2022-03-16,PHASE1,152.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Healthy Volunteers, Overweight, Obesity, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","NNC0480-0389, Semaglutide, Placebo (NNC0480-0389), Placebo (semaglutide)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,25.0,1,126,1,5
NCT01477567,COMPLETED,2011-11-15,2012-03-15,2012-03-15,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3009385, Placebo",Eli Lilly and Company,INDUSTRY,True,7,1,6,0,0,4.0,1,64,1,4
NCT04857398,COMPLETED,2021-04-28,2022-04-06,2022-04-06,PHASE1,24.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,insulin icodec,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,11.0,1,126,0,1
NCT05762471,COMPLETED,2023-01-09,2024-04-11,2024-04-11,PHASE1,142.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Overweight or Obesity, Type2 Diabetes Mellitus","DRUG, DRUG","GSBR-1290, Placebo","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics",INDUSTRY,False,0,0,0,0,0,15.0,0,1,1,5
NCT01128985,COMPLETED,2010-03-15,2010-07-15,2010-07-15,PHASE1,39.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Canagliflozin 50 mg, Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0,4.0,0,9,1,5
NCT03387657,COMPLETED,2018-01-03,2018-03-02,2018-03-02,PHASE1,16.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Sotagliflozin (SAR439954), Hydrochlorothiazide",Sanofi,INDUSTRY,False,0,0,0,0,0,2.0,1,25,0,1
NCT06333977,COMPLETED,2022-03-25,2023-12-14,2023-12-14,PHASE1,100.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,"Healthy, Diabetes Mellitus, Type 2","DRUG, DRUG","LC542019, Placebo",LG Chem,INDUSTRY,False,0,0,0,0,0,21.0,0,3,1,4
NCT01856881,TERMINATED,2013-03-15,2015-03-15,2014-11-15,PHASE1,86.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetes Mellitus,DRUG,AMG 876,Amgen,INDUSTRY,False,0,0,0,0,0,20.0,1,3,0,4
NCT01383356,COMPLETED,2011-06-15,2011-12-15,2011-12-15,PHASE1,58.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Metformin Single Tablet, Linagliptin/Metformin Combo, Linagliptin Single Tablet",Boehringer Ingelheim,INDUSTRY,True,3,2,1,0,0,6.0,1,19,0,1
NCT01088594,COMPLETED,2010-02-15,2010-03-15,2010-03-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","pioglitazone/rosiglitazone/placebo, rosiglitazone/pioglitazone/placebo, placebo/pioglitazone/rosiglitazone, pioglitazone/placebo/rosiglitazone, rosiglitazone/placebo/pioglitazone, placebo/rosiglitazone/pioglitazone",Solvay Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,1.0,0,2,1,3
NCT02169531,COMPLETED,2014-03-15,2016-01-15,2015-06-15,PHASE1,25.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Hyperglycemia",DRUG,ex vivo Activated Immune Cells,B & Y Technologies,INDUSTRY,False,0,0,0,0,0,15.0,0,1,0,1
NCT06124495,COMPLETED,2023-01-13,2023-02-13,2023-02-13,PHASE1,58.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,"Bioequivalence, Diabetes Mellitus, Type 2",DRUG,Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet,Galenicum Health,INDUSTRY,False,0,0,0,0,0,1.0,0,6,0,1
NCT06124547,COMPLETED,2023-01-16,2023-02-13,2023-02-13,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,"Bioequivalence, Diabetes Mellitus, Type 2",DRUG,Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet,Galenicum Health,INDUSTRY,False,0,0,0,0,0,1.0,0,6,0,1
NCT05887999,COMPLETED,2023-06-12,2024-02-21,2024-02-21,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 1","DRUG, DRUG","LY3532226, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,8.0,1,64,1,3
NCT01240252,COMPLETED,2012-03-15,2012-07-15,2012-07-15,PHASE1,14.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,DRUG,Human insulin,Mayo Clinic,OTHER,False,0,0,0,0,0,4.0,0,2,0,1
NCT05893576,COMPLETED,2023-05-15,2023-09-04,2023-09-04,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","HRS9531, HRS9531","Fujian Shengdi Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0,4.0,0,7,0,3
NCT04957914,COMPLETED,2021-07-14,2022-10-17,2022-10-17,PHASE1,54.0,INTERVENTIONAL,NON_RANDOMIZED,SEQUENTIAL,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Insulin Glargine, LY3209590",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,15.0,1,64,0,0
NCT01555008,COMPLETED,2012-03-15,2013-08-15,2013-08-15,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Type 2 Diabetes Mellitus, Renal Impairment","DRUG, DRUG","LX4211, LX4211 Placebo",Lexicon Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,17.0,0,4,1,5
NCT01507285,COMPLETED,1999-08-15,1999-11-15,1999-11-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG","liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,3.0,1,126,1,5
NCT00437606,TERMINATED,2007-03-15,2007-06-15,2007-06-15,PHASE1,2.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","GK Activator (2), Ethanol",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0,3.0,1,15,0,2
NCT03347968,COMPLETED,2017-11-27,2018-04-09,2018-04-09,PHASE1,22.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,Healthy Volunteers,"BIOLOGICAL, DRUG, DRUG","MEDI0382, Warfarin, Esmolol",MedImmune LLC,INDUSTRY,False,0,0,0,0,0,4.0,0,3,0,1
NCT00625859,COMPLETED,2008-01-16,2008-04-10,2008-04-10,PHASE1,27.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","GSK189075, Bupropion, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,3.0,1,35,1,4
NCT05510245,TERMINATED,2022-08-29,2023-07-20,2023-07-20,PHASE1,18.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Type 2 Diabetes, Renal Impairment",DRUG,PF-07081532,Pfizer,INDUSTRY,True,9,5,4,0,0,11.0,1,42,0,1
NCT04838405,COMPLETED,2021-04-29,2024-08-02,2024-06-18,PHASE1,129.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,TRIPLE,Diabetes,"DRUG, DRUG","CT-388, Placebo","Carmot Therapeutics, Inc.",INDUSTRY,False,0,0,0,0,0,38.0,0,2,1,4
NCT00933972,COMPLETED,2009-06-15,2010-09-15,2010-09-15,PHASE1,36.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetes Mellitus Type 2,DRUG,RO4998452,Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0,15.0,1,15,0,2
NCT05435677,COMPLETED,2022-06-22,2023-04-25,2023-04-25,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","IcoSema, insulin icodec, semaglutide",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,10.0,1,126,0,3
NCT03686722,COMPLETED,2017-09-09,2017-12-06,2017-10-30,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,DOUBLE,"Diabetes Mellitus, Type 2, Hepatitis C, Drug Interactions","DRUG, DRUG","Metformin, Daclatasvir",Mohamed Raslan,OTHER,False,0,0,0,0,0,2.0,0,1,0,2
NCT05152277,COMPLETED,2021-12-06,2022-08-24,2022-08-24,PHASE1,90.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes,"DRUG, OTHER, DRUG, OTHER","HRS9531, placebo, HRS9531, placebo","Fujian Shengdi Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0,9.0,0,7,1,4
NCT03444467,COMPLETED,2018-02-05,2018-05-24,2018-05-24,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","NNC9204-1513, Glucagon, Placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,4.0,1,126,1,5
NCT02686281,TERMINATED,2012-09-15,2014-04-15,2013-07-15,PHASE1,19.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Healthy,"DRUG, OTHER","GMC-252-L-Lysine, Placebo",Genmedica Therapeutics S.L.,INDUSTRY,False,0,0,0,0,0,10.0,0,2,1,4
NCT00541983,COMPLETED,2007-09-15,2010-02-15,2009-07-15,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","XOMA 052, Placebo",XOMA (US) LLC,INDUSTRY,False,0,0,0,0,0,22.0,0,2,1,5
NCT01497600,COMPLETED,2004-02-15,2004-08-15,2004-08-15,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","insulin detemir, insulin NPH",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,6.0,1,126,0,3
NCT04345107,COMPLETED,2020-05-01,2021-09-21,2021-04-29,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","SY-009, SY-009 matching placebo","Suzhou Yabao Pharmaceutical R&D Co., Ltd.",INDUSTRY,False,0,0,0,0,0,12.0,0,4,1,4
NCT03169959,COMPLETED,2017-05-29,2017-08-03,2017-08-03,PHASE1,85.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR",AstraZeneca,INDUSTRY,False,0,0,0,0,0,2.0,1,79,0,2
NCT01664624,COMPLETED,2012-07-15,2012-11-15,2012-11-15,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG","Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin",AstraZeneca,INDUSTRY,True,6,1,5,3,0,4.0,1,79,1,5
NCT02367066,COMPLETED,2015-03-15,2015-05-15,2015-05-15,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, OTHER","AR-C165395XX, Placebo",AstraZeneca,INDUSTRY,True,27,3,24,3,0,2.0,1,79,1,3
NCT03292185,COMPLETED,2017-09-29,2018-01-02,2018-01-02,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","insulin degludec/liraglutide, insulin degludec, liraglutide",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,3.0,1,126,0,3
NCT03789578,COMPLETED,2019-01-17,2019-10-10,2019-10-10,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","NNC0148-0287sema, Semaglutide, NNC0148-0287",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,9.0,1,126,0,3
NCT05134662,COMPLETED,2022-02-01,2023-03-09,2023-02-03,PHASE1,55.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, OTHER","ALT-801, Placebo","Altimmune, Inc.",INDUSTRY,False,0,0,0,0,0,12.0,0,1,1,5
NCT01868529,COMPLETED,2008-01-15,2008-06-15,2008-06-15,PHASE1,63.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1","DRUG, DRUG","insulin degludec, insulin glargine",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,5.0,1,126,0,3
NCT05377333,COMPLETED,2022-06-02,2023-11-22,2023-11-22,PHASE1,94.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","LY3457263, Placebo, Dulaglutide",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,18.0,1,64,1,4
NCT00933062,COMPLETED,2009-03-23,2009-05-12,2009-05-12,PHASE1,10.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","SRT2104, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,2.0,1,35,1,4
NCT01147861,COMPLETED,2010-07-01,2010-09-07,2010-09-07,PHASE1,39.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, OTHER","GSK256073, GSK256073, GSK256073, GSK256073, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,2.0,1,35,1,3
NCT02913703,COMPLETED,2017-01-11,2018-12-15,2018-12-15,PHASE1,80.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,SINGLE,Type 2 Diabetes,"DRUG, OTHER","Ghrelin, Saline","Jenny Tong, MD, MPH",OTHER,False,0,0,0,0,0,23.0,0,2,0,1
NCT04068272,COMPLETED,2019-09-07,2022-05-20,2022-05-20,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetes Mellitus,"DRUG, DRUG","Bosentan, Placebo",Retinset SL,INDUSTRY,False,0,0,0,0,0,32.0,0,1,1,5
NCT05694741,TERMINATED,2022-12-20,2023-05-10,2023-05-10,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","AZD0186, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,5.0,1,79,1,4
NCT02716610,COMPLETED,2013-10-15,2014-01-15,2014-01-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","INH 69 U (low), INH 69 U (high), INH 139 U, INH 208 U, LIS 18 U",Dance Biopharm Inc.,INDUSTRY,False,0,0,0,0,0,3.0,0,2,0,2
NCT03211195,COMPLETED,2017-06-29,2017-08-22,2017-08-22,PHASE1,76.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,Sotagliflozin (SAR439954),Sanofi,INDUSTRY,False,0,0,0,0,0,2.0,1,25,0,2
NCT03170544,COMPLETED,2017-08-16,2018-11-08,2018-11-08,PHASE1,69.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, OTHER, BIOLOGICAL","MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin",Merck Sharp & Dohme LLC,INDUSTRY,True,26,3,23,0,0,15.0,1,55,1,5
NCT02791867,TERMINATED,2014-12-15,2017-07-15,2017-07-15,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,TRIPLE,"Diabetes Mellitus, Type 2",DRUG,AphoelineBrake,Dasman Diabetes Institute,OTHER,False,0,0,0,0,0,31.0,0,1,0,2
NCT00642538,COMPLETED,2008-02-15,2008-09-15,2008-09-15,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","MKC253 Inhalation Powder, Technosphere Inhalation Powder, subcutaneous injection",Mannkind Corporation,INDUSTRY,False,0,0,0,0,0,7.0,0,3,0,3
NCT00508287,COMPLETED,2007-08-15,2007-11-15,2007-11-15,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG, DRUG","BMS-686117, Byetta, Placebo",Bristol-Myers Squibb,INDUSTRY,False,0,0,0,0,0,3.0,1,7,1,4
NCT00494767,COMPLETED,2006-09-29,2007-06-07,2007-06-07,PHASE1,27.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2, Obesity","DRUG, DRUG, DRUG, DRUG","GW869682, GSK189075, GSK189075-Placebo, GW869682-Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,8.0,1,35,1,4
NCT01619332,COMPLETED,2012-03-15,2013-09-15,2013-09-15,PHASE1,220.0,INTERVENTIONAL,UNKNOWN,PARALLEL,TREATMENT,QUADRUPLE,Type II Diabetes,"DRUG, DRUG, DRUG","Placebo, Sitagliptin, LEZ763",Novartis Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,18.0,1,4,1,4
NCT06132204,COMPLETED,2023-12-21,2024-03-13,2024-03-13,PHASE1,16.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,DRUG,HRS-7535 Tablets,"Shandong Suncadia Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,3.0,0,5,0,2
NCT01835730,COMPLETED,2013-04-15,2014-05-15,2014-05-15,PHASE1,37.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG","PE0139 Injection, Placebo",PhaseBio Pharmaceuticals Inc.,INDUSTRY,False,0,0,0,0,0,13.0,0,4,1,4
NCT03367377,COMPLETED,2018-01-03,2018-10-03,2018-10-03,PHASE1,70.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3209590, Insulin Glargine",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,9.0,1,64,0,2
NCT02223065,COMPLETED,2014-09-15,2014-12-15,2014-12-15,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Saxagliptin, Dapagliflozin",AstraZeneca,INDUSTRY,True,6,6,0,6,0,3.0,1,79,0,1
NCT01572753,COMPLETED,2012-04-12,2012-09-08,2012-09-08,PHASE1,161.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","semaglutide, semaglutide, semaglutide, semaglutide, semaglutide, semaglutide, semaglutide, semaglutide",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,5.0,1,126,0,3
NCT01302145,COMPLETED,2009-02-25,2009-12-09,2009-12-09,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","ASP1941, Metformin, Placebo",Astellas Pharma Inc,INDUSTRY,False,0,0,0,0,0,9.0,0,4,1,4
NCT01474161,COMPLETED,2011-11-15,2012-11-15,2012-11-15,PHASE1,96.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases, Cardiovascular Diseases, Obese, Dyslipidemia","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","GFT505 120mg - old formulation, GFT505 120mg - new formulation, GFT505 180mg - new formulation, GFT505 240mg - new formulation, GFT505 300mg - new formulation, Placebo",Genfit,INDUSTRY,False,0,0,0,0,0,12.0,0,1,1,5
NCT02009488,COMPLETED,2014-09-08,2017-01-03,2017-01-03,PHASE1,59.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo","Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0,28.0,1,10,1,5
NCT06293742,COMPLETED,2024-02-08,2024-04-15,2024-04-15,PHASE1,48.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","ECC5004, Midazolam, Rosuvastatin, Digoxin, Atorvastatin",Eccogene,INDUSTRY,False,0,0,0,0,0,2.0,0,3,0,1
NCT00899470,COMPLETED,2009-06-15,2009-08-15,2009-08-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Co-administration of Saxagliptin and Metformin IR, Fasted, Saxagliptin/Metformin, Fasting, Co-administration of Saxagliptin and Metformin IR, Fed, Saxagliptin/Metformin, Fed",AstraZeneca,INDUSTRY,True,17,8,9,0,0,2.0,1,79,0,2
NCT05227196,COMPLETED,2022-02-04,2023-08-08,2023-06-28,PHASE1,546.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Healthy Volunteers, Type 2 Diabetes","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Semaglutide D Dose 1, Semaglutide D Dose 2, Semaglutide D Dose 3, Semaglutide Dose 4, Semaglutide Dose 5, Semaglutide Dose 6",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,17.0,1,126,0,2
NCT00897390,COMPLETED,2009-06-15,2009-07-15,2009-07-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Saxagliptin, Metformin IR (glucophage), Saxagliptin + Metformin IR (FDC)",AstraZeneca,INDUSTRY,True,20,10,10,0,0,1.0,1,79,0,2
NCT04466904,COMPLETED,2020-09-12,2021-05-28,2021-05-28,PHASE1,42.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG, DRUG","IBI362, Placebo, Dulaglutide",Innovent Biologics (Suzhou) Co. Ltd.,INDUSTRY,False,0,0,0,0,0,8.0,0,1,1,4
NCT06483243,COMPLETED,2024-04-04,2024-05-17,2024-04-29,PHASE1,45.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,"Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,1.0,0,32,0,2
NCT01525225,TERMINATED,2012-09-15,2013-06-15,2013-06-15,PHASE1,4.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","Metformin immediate release (IR), Saxagliptin, Metformin IR, Saxagliptin/Metformin XR FDC, Metformin XR",AstraZeneca,INDUSTRY,True,2,1,1,0,0,9.0,1,79,0,1
NCT04698018,COMPLETED,2021-04-20,2023-04-25,2023-04-25,PHASE1,23.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","DRUG, DRUG","Faster Aspart, Novo Rapid",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,24.0,1,126,0,3
NCT02806973,COMPLETED,2015-01-15,2015-04-15,2015-04-15,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2",DRUG,Nasal Glucagon,Eli Lilly and Company,INDUSTRY,True,7,6,0,0,0,3.0,1,64,0,1
NCT02121483,COMPLETED,2014-06-15,2016-02-15,2016-02-15,PHASE1,27.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","empagliflozin medium dose, empagliflozin high dose, empagliflozin low dose",Boehringer Ingelheim,INDUSTRY,True,8,5,3,0,0,20.0,1,19,0,3
NCT00404963,COMPLETED,2006-10-15,2007-05-15,2007-05-15,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,DIAGNOSTIC,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","placebo, GSK376501",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,7.0,1,35,1,3
NCT06652971,COMPLETED,2024-11-05,2024-12-17,2024-12-04,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes Mellitus,DRUG,CKD-379,Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,1.0,0,32,0,2
NCT01097681,COMPLETED,2010-02-16,2010-06-18,2010-06-18,PHASE1,25.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,OTHER,NONE,Type 2 Diabetes Mellitus,DRUG,ASP1941,Astellas Pharma Inc,INDUSTRY,False,0,0,0,0,0,4.0,0,4,0,1
NCT04276428,COMPLETED,2020-02-28,2020-11-28,2020-11-28,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3209590, Insulin Degludec",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,9.0,1,64,0,2
NCT05385575,COMPLETED,2022-08-09,2024-02-29,2023-12-22,PHASE1,46.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","KN056 (0.1mg), KN056 (0.3mg), KN056 (1.0mg), KN056 (3.0mg), KN056 (6.0mg), KN056 (12.0mg), KN056 (18.0mg)","Suzhou Alphamab Co., Ltd.",INDUSTRY,False,0,0,0,0,0,16.0,0,1,0,3
NCT00607945,COMPLETED,2008-01-15,2012-05-15,2012-05-15,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT","Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant, conjugated linoleic acid (CLA), conjugated linoleic acid (CLA)",Ohio State University,OTHER,False,0,0,0,0,0,52.0,0,1,0,4
NCT05327595,COMPLETED,2022-05-09,2024-04-22,2024-04-22,PHASE1,80.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","LY3549492, Placebo, Atorvastatin, Midazolam",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,23.0,1,64,1,4
NCT00530309,COMPLETED,2007-08-01,2008-04-17,2008-04-17,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","GSK716155 for injection, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,9.0,1,35,1,4
NCT01407276,COMPLETED,2011-08-08,2012-03-23,2012-03-23,PHASE1,49.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Chronic Renal Insufficiency, Type 2 Diabetes Mellitus",DRUG,Omarigliptin,Merck Sharp & Dohme LLC,INDUSTRY,True,13,11,2,0,0,7.0,1,55,0,2
NCT04354090,COMPLETED,2018-04-26,2019-06-22,2018-12-27,PHASE1,41.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,OTHER,DOUBLE,"Diabetes Mellitus, Type 2",DRUG,JY09,"Beijing Dongfang Biotech Co., Ltd.",INDUSTRY,False,0,0,0,0,0,8.0,0,2,0,2
NCT01607385,COMPLETED,2012-05-18,2012-12-03,2012-12-03,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","GSK2330672, Placebo, GSK1614235",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,7.0,1,35,1,5
NCT05943886,COMPLETED,2021-08-11,2023-02-17,2023-02-17,PHASE1,164.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,"Healthy Subjects, Obesity, T2DM (Type 2 Diabetes Mellitus)","DRUG, DRUG","HEC88473 injection, Placebo","Dongguan HEC Biopharmaceutical R&D Co., Ltd.",INDUSTRY,False,0,0,0,0,0,18.0,0,1,1,4
NCT00886366,TERMINATED,2009-04-15,2009-09-15,2009-09-15,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG","AZD6714, Placebo, AZD6714, AZD6714",AstraZeneca,INDUSTRY,False,0,0,0,0,0,5.0,1,79,1,3
NCT00754143,COMPLETED,2008-03-15,2009-12-15,2009-12-15,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Diabetic Nephropathy","DRUG, DRUG, DRUG","FG-3019, FG-3019, FG-3019",FibroGen,INDUSTRY,False,0,0,0,0,0,21.0,0,2,0,4
NCT00811460,COMPLETED,2008-11-15,2009-08-15,2009-08-15,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG, DRUG","Placebo, taspoglutide, taspoglutide",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0,9.0,1,15,1,4
NCT05816759,COMPLETED,2023-05-26,2023-06-22,2023-06-04,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","CKD-383, CKD-501, D744, D150",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,0.0,0,32,0,2
NCT01948986,COMPLETED,2013-10-01,2014-10-16,2014-10-06,PHASE1,36.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Renal Impairment, Type 2 Diabetes Mellitus",DRUG,Ertugliflozin,Merck Sharp & Dohme LLC,INDUSTRY,True,30,29,1,0,0,12.0,1,55,0,2
NCT01272973,COMPLETED,2011-01-15,2011-07-15,2011-07-15,PHASE1,96.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG","semaglutide, placebo, semaglutide",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,6.0,1,126,1,5
NCT03745885,COMPLETED,2018-12-04,2019-12-13,2019-06-10,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Supaglutide injection, Placebo","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.",OTHER,False,0,0,0,0,0,6.0,0,1,1,5
NCT00511108,COMPLETED,2007-07-11,2009-02-24,2009-02-24,PHASE1,211.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG, DRUG, DRUG","Comparator: sitagliptin phosphate, Comparator: pioglitazone, Comparator: placebo to pioglitazone, Comparator: placebo to sitagliptin",Merck Sharp & Dohme LLC,INDUSTRY,True,3,2,1,2,0,20.0,1,55,1,5
NCT03462017,COMPLETED,2018-03-07,2018-12-22,2018-12-22,PHASE1,54.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,BASIC_SCIENCE,TRIPLE,Microvascular Coronary Artery Disease,"DRUG, DRUG, DRUG, DRUG","SAR247799, Placebo, Sildenafil, Acetylcholine",Sanofi,INDUSTRY,False,0,0,0,0,0,10.0,1,25,1,3
NCT01576328,COMPLETED,2012-04-15,2015-10-15,2013-10-15,PHASE1,61.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Type 2 Diabetes,"DRUG, DRUG, DRUG","Mesenchymal Precursor Cells (MPCs), Mesenchymal Precursor Cells (MPCs), Mesenchymal Precursor Cells (MPCs)","Mesoblast, Ltd.",INDUSTRY,False,0,0,0,0,0,18.0,0,1,0,3
NCT00606112,COMPLETED,2008-01-15,2009-04-15,2008-06-15,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Obesity",DRUG,Trodusquemine (MSI-1436),Genaera Corporation,INDUSTRY,False,0,0,0,0,0,5.0,0,2,0,3
NCT06256523,COMPLETED,2022-06-29,2023-09-28,2023-09-28,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, OTHER","GZR18, Placebo","Gan and Lee Pharmaceuticals, USA",INDUSTRY,False,0,0,0,0,0,15.0,0,5,1,5
NCT04990427,COMPLETED,2022-01-10,2023-01-26,2023-01-26,PHASE1,6.0,INTERVENTIONAL,UNKNOWN,SEQUENTIAL,TREATMENT,NONE,Chronic Kidney Diseases,DRUG,CLBS201,"Lisata Therapeutics, Inc.",INDUSTRY,False,0,0,0,0,0,13.0,0,1,0,1
NCT02603510,COMPLETED,2015-11-15,2016-04-15,2016-04-15,PHASE1,27.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 1 Diabetes Mellitus,"DRUG, DRUG","SAR342434, insulin lispro",Sanofi,INDUSTRY,False,0,0,0,0,0,5.0,1,25,0,2
NCT06548997,COMPLETED,2021-12-02,2022-10-20,2022-10-20,PHASE1,57.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,"Type 2 Diabetes, Overweight and Obesity","DRUG, OTHER","GZR18, Placebo","Gan and Lee Pharmaceuticals, USA",INDUSTRY,False,0,0,0,0,0,11.0,0,5,1,4
NCT00032474,COMPLETED,2001-12-15,2005-05-15,2005-05-15,PHASE1,150.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,DRUG,Ginkgo biloba extract,National Center for Complementary and Integrative Health (NCCIH),NIH,False,0,0,0,0,0,41.0,0,1,0,3
NCT02813863,COMPLETED,2015-12-15,2016-03-15,2016-03-15,PHASE1,24.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","SP2086, Metformin","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,3.0,0,15,0,1
NCT01396564,COMPLETED,2005-10-15,2011-07-15,2006-10-15,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Type 2 Diabetes,"DRUG, DRUG","Metformin, Pioglitazone","Coordinación de Investigación en Salud, Mexico",OTHER_GOV,False,0,0,0,0,0,12.0,0,1,0,4
NCT01794364,COMPLETED,2013-01-15,2013-03-15,2013-03-15,PHASE1,8.0,INTERVENTIONAL,UNKNOWN,CROSSOVER,BASIC_SCIENCE,DOUBLE,Healthy,"DRUG, OTHER","PF-06291874, placebo",Pfizer,INDUSTRY,False,0,0,0,0,0,2.0,1,42,1,2
NCT01238224,TERMINATED,2009-11-15,2011-11-15,2011-11-15,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes,DRUG,Tadalafil,Vastra Gotaland Region,OTHER_GOV,False,0,0,0,0,0,24.0,0,1,0,4
NCT05146869,COMPLETED,2021-12-30,2022-03-28,2022-03-28,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,DBPR108 tablets,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",INDUSTRY,False,0,0,0,0,0,3.0,0,2,0,3
NCT01545570,COMPLETED,2011-11-07,2012-12-23,2012-12-23,PHASE1,82.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","GSK2376497, 0.9% sodium chloride",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,14.0,1,35,0,4
NCT00810589,COMPLETED,2008-11-15,2008-12-15,2008-12-15,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Type I","DRUG, DRUG","Levemir, Humalog NPL Insulin",Medical University of Graz,OTHER,False,0,0,0,0,0,1.0,0,2,0,3
NCT00944450,COMPLETED,2004-08-15,2004-11-15,2004-09-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Sitagliptin phosphate anhydrous formulation, Comparator: sitagliptin phosphate monohydrate form",Merck Sharp & Dohme LLC,INDUSTRY,True,2,2,0,0,0,1.0,1,55,0,2
NCT02411929,COMPLETED,2014-10-29,2015-02-09,2015-01-30,PHASE1,8.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Unlabeled ertugliflozin for oral use, 14^C-labeled ertugliflozin for IV use, 14^C-labeled ertugliflozin for oral use",Merck Sharp & Dohme LLC,INDUSTRY,True,13,1,12,0,0,3.0,1,55,0,1
NCT00612794,COMPLETED,2007-09-15,2008-05-15,2008-05-15,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","exenatide once weekly, placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,8.0,1,79,1,5
NCT05762744,TERMINATED,2016-06-01,2022-10-31,2018-11-30,PHASE1,63.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,Type 2 Diabetes,"DRUG, DRUG","Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT)","University of Maryland, Baltimore",OTHER,True,8,2,6,2,0,30.0,0,1,0,1
NCT01620463,COMPLETED,2002-12-15,2003-03-15,2003-03-15,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,3.0,1,126,1,5
NCT01399346,COMPLETED,2011-04-15,2011-06-15,2011-06-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Type 1 Diabetes,"DRUG, DRUG","Insulin aspart, Insulin aspart",Medical University of Graz,OTHER,False,0,0,0,0,0,2.0,0,2,0,1
NCT02161588,COMPLETED,2014-06-15,2014-11-15,2014-11-15,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG","semaglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,5.0,1,126,1,5
NCT01146886,COMPLETED,2010-06-15,2010-09-15,2010-09-15,PHASE1,60.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Placebo to BI 135585, BI 135585",Boehringer Ingelheim,INDUSTRY,False,0,0,0,0,0,3.0,1,19,1,5
NCT00464880,COMPLETED,2005-09-15,2007-11-15,2007-11-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Diabetes Type 2,DRUG,Aliskiren,Novartis,INDUSTRY,False,0,0,0,0,0,26.0,1,5,0,3
NCT00099723,TERMINATED,2004-10-15,2005-12-15,2005-12-15,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Fatty Liver,DRUG,VSL#3,VSL Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,14.0,0,1,0,3
NCT01551446,WITHDRAWN,2012-04-30,2012-11-30,2012-11-30,PHASE1,0.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2",DRUG,Bardoxolone Methyl,Biogen,INDUSTRY,False,0,0,0,0,0,7.0,0,3,0,1
NCT06124573,COMPLETED,2022-11-07,2022-11-21,2022-11-21,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,"Bioequivalence, Diabetes Mellitus, Type 2",DRUG,Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet,Galenicum Health,INDUSTRY,False,0,0,0,0,0,0.0,0,6,0,1
NCT00949663,COMPLETED,2009-10-15,2014-02-15,2014-02-15,PHASE1,38.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25",Washington University School of Medicine,OTHER,False,0,0,0,0,0,52.0,0,3,1,2
NCT00933530,COMPLETED,2008-05-15,2008-11-15,2008-11-15,PHASE1,43.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2, Healthy Volunteer","DRUG, DRUG","SRT2104, Placebo","Sirtris, a GSK Company",INDUSTRY,False,0,0,0,0,0,6.0,1,5,1,2
NCT03638778,COMPLETED,2018-08-17,2018-12-05,2018-12-05,PHASE1,105.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Semaglutide 3 mg, Semaglutide 7 mg, Semaglutide B 3 mg, Semaglutide B 7 mg, Semaglutide C 3 mg, Semaglutide C 7 mg, Semaglutide D 3 mg, Semaglutide D 7 mg",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,4.0,1,126,0,3
NCT01496443,COMPLETED,2012-01-15,2012-05-15,2012-05-15,PHASE1,28.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,SINGLE,Pharmacokinetics,DRUG,TAK-875 and Glimepiride,Takeda,INDUSTRY,False,0,0,0,0,0,4.0,1,4,0,1
NCT00532610,COMPLETED,2007-09-15,2008-02-15,2008-02-15,PHASE1,78.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2",DRUG,GSK189075,GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,5.0,1,35,0,3
NCT04334213,COMPLETED,2020-05-07,2020-08-05,2020-08-05,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG","CKD-501, D745, D150, CKD-501, D745, D150",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,3.0,0,32,0,2
NCT01512849,COMPLETED,2012-01-15,2012-09-15,2012-09-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","TA-7284 Low, TA-7284 High",Mitsubishi Tanabe Pharma Corporation,INDUSTRY,True,8,4,4,0,0,8.0,0,2,0,2
NCT01196728,COMPLETED,2010-09-15,2010-11-15,2010-11-15,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,TRIPLE,Type II Diabetes Mellitus,DRUG,CM3.1-AC100,"CellMed AG, a subsidiary of BTG plc.",INDUSTRY,False,0,0,0,0,0,2.0,0,1,0,2
NCT01449019,COMPLETED,2006-12-15,2010-07-15,2007-08-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, OTHER, OTHER","exendin(9-39)amide, saline, duodenal meal, duodenal saline",Ludwig-Maximilians - University of Munich,OTHER,False,0,0,0,0,0,8.0,0,2,0,2
NCT01240980,COMPLETED,2010-11-15,2012-01-15,2012-01-15,PHASE1,104.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","BMS-903452, BMS-903452, BMS-903452, BMS-903452, BMS-903452, BMS-903452, BMS-903452, Placebo, Placebo, BMS-903452, BMS-903452, Placebo, BMS-903452, BMS-903452, BMS-903452",Bristol-Myers Squibb,INDUSTRY,False,0,0,0,0,0,14.0,1,7,1,5
NCT02915250,COMPLETED,2016-10-15,2017-06-15,2017-06-15,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","BioChaperone® Combo, Humalog® Mix25, Humalog®, Lantus®, Placebo",Adocia,INDUSTRY,False,0,0,0,0,0,8.0,0,9,1,4
NCT01165268,COMPLETED,2010-08-15,2010-12-15,2010-12-15,PHASE1,24.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,DRUG,Dapagliflozin,AstraZeneca,INDUSTRY,False,0,0,0,0,0,4.0,1,79,0,1
NCT03928379,COMPLETED,2019-10-27,2021-07-08,2021-07-08,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3305677, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,20.0,1,64,1,3
NCT01483781,COMPLETED,2011-12-15,2012-08-15,2012-08-15,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2, Plasma Volume","DRUG, DRUG","Canagliflozin, Placebo","Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0,8.0,1,10,1,5
NCT01933256,COMPLETED,2013-08-15,2014-12-15,2014-09-15,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","HIP2B, Placebo",CureDM,INDUSTRY,False,0,0,0,0,0,13.0,0,1,1,4
NCT05654831,COMPLETED,2022-12-01,2023-11-01,2023-11-01,PHASE1,69.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Placebo, ECC5004",Eccogene,INDUSTRY,False,0,0,0,0,0,11.0,0,3,1,4
NCT00853151,COMPLETED,2009-02-15,2010-05-15,2010-05-15,PHASE1,131.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","LY2428757, TT223, Placebo for LY2428757, Placebo for TT223",Eli Lilly and Company,INDUSTRY,True,40,1,39,2,0,15.0,1,64,1,5
NCT01341392,COMPLETED,2011-04-15,2011-08-15,2011-08-15,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","CKD-501, amlodiopine, CKD-501 amlodipine",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,4.0,0,32,0,3
NCT01464099,COMPLETED,2008-06-15,2008-11-15,2008-11-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1","DRUG, DRUG","insulin aspart, insulin aspart",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,5.0,1,126,0,3
NCT06890299,COMPLETED,2024-12-05,2025-01-12,2025-01-12,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG","BR3006, BR3006A, BR3006B, BR3006C","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0,1.0,0,9,0,2
NCT01369602,COMPLETED,2011-07-15,2012-02-15,2012-02-15,PHASE1,27.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Type 2 Diabetes Mellitus, Healthy","DRUG, DRUG, DRUG, DRUG","PF-04991532, PF-04991532, PF-04991532, PF-04991532",Pfizer,INDUSTRY,False,0,0,0,0,0,7.0,1,42,0,1
NCT03061981,COMPLETED,2017-03-29,2017-10-11,2017-10-11,PHASE1,60.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Placebo, Metformin, DA-1241","Dong-A ST Co., Ltd.",INDUSTRY,False,0,0,0,0,0,6.0,0,6,1,4
NCT01827735,COMPLETED,2013-03-15,2014-05-15,2014-05-15,PHASE1,40.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,Type 1 Diabetes,DRUG,Aldesleukin (Proleukin),Cambridge University Hospitals NHS Foundation Trust,OTHER,False,0,0,0,0,0,14.0,0,2,0,0
NCT01298518,COMPLETED,2011-02-15,2011-05-15,2011-05-15,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Type 2 Diabetes Patients,"DRUG, DRUG, DRUG","PF-04620110, PF-04620110, Placebo",Pfizer,INDUSTRY,True,17,1,16,0,0,3.0,1,42,1,5
NCT00989079,COMPLETED,2009-10-16,2009-12-11,2009-12-11,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Ertugliflozin, Placebo to Ertugliflozin",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0,2.0,1,55,1,3
NCT03895996,COMPLETED,2019-06-20,2023-12-19,2022-05-17,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 1 Diabetes Mellitus,"DRUG, OTHER","AVT001, Placebo",Avotres Inc.,INDUSTRY,True,9,6,3,0,0,35.0,0,1,1,5
NCT01044017,COMPLETED,2009-12-15,2010-08-15,2010-08-15,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,PREVENTION,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG","Placebo, RO4998452",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0,8.0,1,15,1,3
NCT02284425,TERMINATED,2014-10-15,2015-12-15,2015-12-15,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","REGN1193, Placebo",Regeneron Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,14.0,0,1,1,4
NCT01127308,COMPLETED,2010-06-15,2010-07-15,2010-07-15,PHASE1,6.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus (T2DM),DRUG,Ertugliflozin,Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0,1.0,1,55,0,0
NCT01923389,TERMINATED,2013-09-15,2013-12-15,2013-12-15,PHASE1,4.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,QUADRUPLE,Type 2 Diabetes Mellitus (T2DM),"OTHER, DRUG","Placebo, 100 mg PF-05231023",Pfizer,INDUSTRY,True,13,4,9,0,0,3.0,1,42,1,4
NCT00963768,COMPLETED,2007-06-15,2007-12-15,2007-12-15,PHASE1,116.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","JNJ 28431754, Placebo","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0,6.0,0,9,1,5
NCT01789788,COMPLETED,2013-03-15,2013-09-15,2013-09-15,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG","Placebo, RO6811135",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0,6.0,1,15,1,5
NCT04823208,COMPLETED,2021-05-24,2022-06-23,2022-06-23,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3437943, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,13.0,1,64,1,4
NCT04970940,COMPLETED,2020-07-02,2020-12-31,2020-10-07,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,T2DM (Type 2 Diabetes Mellitus),"DRUG, DRUG, DRUG","Treatment A, Treatment B, Treatment C","AJU Pharm Co., Ltd.",INDUSTRY,False,0,0,0,0,0,3.0,0,2,0,2
NCT01101568,COMPLETED,2010-04-14,2010-06-24,2010-06-24,PHASE1,28.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,OTHER,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Simvastatin, Rosuvastatin, GSK1292263",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,2.0,1,35,0,0
NCT02536859,COMPLETED,2015-08-31,2016-04-14,2016-04-14,PHASE1,60.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1","DRUG, DRUG","insulin degludec, insulin glargine",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,7.0,1,126,0,3
NCT03176524,COMPLETED,2017-06-06,2017-09-04,2017-09-04,PHASE1,27.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Type 1 Diabetes Mellitus,"DRUG, DRUG, DRUG","BioChaperone® glucagon formulation 1, BioChaperone® glucagon formulation 2, GlucaGen® HypoKit®",Adocia,INDUSTRY,False,0,0,0,0,0,3.0,0,9,0,3
NCT04080596,COMPLETED,2017-10-13,2017-12-05,2017-12-05,PHASE1,18.0,INTERVENTIONAL,UNKNOWN,SEQUENTIAL,TREATMENT,NONE,Drug Interaction,DRUG,Dorzagliatin,Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0,2.0,0,10,0,1
NCT03510624,COMPLETED,2018-11-09,2021-04-01,2021-04-01,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Rebaudioside A, Placebo",Universitaire Ziekenhuizen KU Leuven,OTHER,False,0,0,0,0,0,29.0,0,1,1,3
NCT01458210,COMPLETED,2011-10-15,2012-02-15,2012-02-15,PHASE1,22.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, BIOLOGICAL","Ortho-Cyclen, Dulaglutide",Eli Lilly and Company,INDUSTRY,True,6,6,0,0,0,4.0,1,64,0,1
NCT02514850,COMPLETED,2015-07-15,2015-11-15,2015-11-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","Biochaperone Combo, Humalog Mix25, Humalog, Lantus, Placebo",Adocia,INDUSTRY,False,0,0,0,0,0,4.0,0,9,1,4
NCT03180710,COMPLETED,2017-06-06,2017-12-21,2017-08-28,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","BioChaperone® Combo 75/25 at 0.6 U/kg, BioChaperone® Combo 75/25 at 0.8 U/kg, BioChaperone® Combo 75/25 at 1.0 U/kg, Humalog® Mix25 at 0.8 U/kg",Adocia,INDUSTRY,False,0,0,0,0,0,3.0,0,9,0,3
NCT02411825,COMPLETED,2015-03-15,2016-01-15,2016-01-15,PHASE1,76.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","SAR425899, placebo, metformin",Sanofi,INDUSTRY,False,0,0,0,0,0,10.0,1,25,1,4
NCT02077803,COMPLETED,2014-03-15,2014-07-15,2014-07-15,PHASE1,47.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Healthy,"DRUG, DRUG, DRUG, DRUG","Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg, CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg","Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0,4.0,1,10,0,2
NCT00671424,COMPLETED,2008-03-15,2008-05-15,2008-05-15,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Hydrochlorothiazide (HCTZ), Remogliflozin etabonate (GSK189075), Furosemide",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,2.0,1,35,0,4
NCT00501462,COMPLETED,2007-07-15,2008-03-15,2008-03-15,PHASE1,29.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, Renal Insufficiency",DRUG,GSK189075,GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,8.0,1,35,0,2
NCT04889157,COMPLETED,2021-07-07,2022-02-17,2022-02-17,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","PF-06882961, Placebo",Pfizer,INDUSTRY,True,8,4,4,0,0,7.0,1,42,1,4
NCT01557504,COMPLETED,2012-07-18,2014-04-29,2014-04-29,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Sitagliptin/metformin XR, Placebo, Metformin, Thyroid hormone",Merck Sharp & Dohme LLC,INDUSTRY,True,15,15,0,0,0,21.0,1,55,1,4
NCT02445911,COMPLETED,2015-06-15,2016-02-15,2016-02-15,PHASE1,81.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","KQ-791, Placebo",Kaneq Bioscience Limited,OTHER,True,18,2,16,0,0,8.0,0,1,1,5
NCT00376038,COMPLETED,2006-08-15,2006-10-15,2006-10-15,PHASE1,13.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2","DRUG, DRUG","GSK189075 oral tablets, metformin tablets",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,2.0,1,35,0,2
NCT01076634,COMPLETED,2010-02-15,2010-07-15,2010-07-15,PHASE1,33.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1","DRUG, DRUG","insulin degludec, insulin degludec",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,5.0,1,126,0,3
NCT02713841,COMPLETED,2013-05-15,2013-07-15,2013-07-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 1 Diabetes Mellitus,"DRUG, DRUG","inhaled human insulin (INH), sc insulin lispro (LIS)",Dance Biopharm Inc.,INDUSTRY,False,0,0,0,0,0,2.0,0,2,0,2
NCT01526941,COMPLETED,2001-05-15,2001-07-15,2001-07-15,PHASE1,27.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1","DRUG, DRUG","biphasic insulin aspart 30, biphasic insulin aspart 70",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,2.0,1,126,0,3
NCT02485327,COMPLETED,2015-07-15,2015-11-15,2015-11-15,PHASE1,22.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 1 Diabetes Mellitus,DRUG,Technosphere Insulin SAR439065 Afrezza®,Mannkind Corporation,INDUSTRY,False,0,0,0,0,0,4.0,0,3,0,1
NCT05516966,COMPLETED,2022-10-12,2023-05-24,2023-05-24,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","HRS9531, Placebo, Dulaglutide Injection","Fujian Shengdi Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0,7.0,0,7,1,5
NCT05549583,COMPLETED,2018-04-15,2018-04-25,2018-04-25,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,"Bioequivalence, Type 2 Diabetes",DRUG,Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet,Galenicum Health,INDUSTRY,False,0,0,0,0,0,0.0,0,6,0,1
NCT00511667,COMPLETED,2007-05-15,2008-04-15,2008-04-15,PHASE1,70.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","MK0941, Comparator: Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,7,2,5,0,0,11.0,1,55,1,5
NCT00551564,COMPLETED,2007-07-31,2008-09-08,2008-09-08,PHASE1,36.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,DIAGNOSTIC,NONE,"Diabetes Mellitus, Type 2",DRUG,rosiglitazone maleate,GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,13.0,1,35,0,1
NCT00952198,COMPLETED,2009-08-15,2010-08-15,2010-08-15,PHASE1,128.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,TRIPLE,Type 2 Diabetes,"DRUG, DRUG","ARRY-403, glucokinase activator; oral, Placebo; oral","Array Biopharma, now a wholly owned subsidiary of Pfizer",INDUSTRY,False,0,0,0,0,0,12.0,1,1,1,4
NCT00825253,COMPLETED,2007-03-15,2007-05-15,2007-05-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","biphasic insulin aspart 30, biphasic human insulin 30",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,2.0,1,126,0,2
NCT00461136,COMPLETED,2005-08-15,2006-11-15,2006-11-15,PHASE1,18.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetes Type 2,DRUG,Aliskiren,Novartis,INDUSTRY,False,0,0,0,0,0,15.0,1,5,0,2
NCT00394030,COMPLETED,2006-10-16,2007-03-20,2007-03-20,PHASE1,63.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,GSK716155 subcutaneous injections,GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,5.0,1,35,0,3
NCT01924767,COMPLETED,2007-07-15,2007-11-15,2007-11-15,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","BI 10773 Placebo, BI 10773, BI 10773 Placebo, BI 10773, BI 10773 Placebo, BI 10773 Placebo, BI 10773, BI 10773",Boehringer Ingelheim,INDUSTRY,True,21,4,17,0,0,4.0,1,19,1,4
NCT04582435,COMPLETED,2020-10-16,2022-04-22,2022-04-22,PHASE1,46.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Insulin Icodec,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,18.0,1,126,0,1
NCT00830076,COMPLETED,2008-12-02,2009-05-14,2009-04-30,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","sitagliptin phosphate, metformin hydrochloride, Comparator: placebo sitagliptin, Comparator: placebo metformin",Merck Sharp & Dohme LLC,INDUSTRY,True,3,1,2,0,0,5.0,1,55,1,4
NCT02115347,COMPLETED,2014-09-19,2015-01-19,2015-01-10,PHASE1,16.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Hepatic Impairment",DRUG,Ertugliflozin 15 mg,Merck Sharp & Dohme LLC,INDUSTRY,True,7,2,5,0,0,4.0,1,55,0,2
NCT03790839,COMPLETED,2019-01-31,2019-08-30,2019-08-30,PHASE1,15.0,INTERVENTIONAL,UNKNOWN,SEQUENTIAL,TREATMENT,NONE,Patients,"DRUG, DRUG","Sitagliptin, Dorzagliatin",Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0,7.0,0,10,0,1
NCT06709807,COMPLETED,2024-11-08,2024-12-19,2024-12-07,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus (T2DM),DRUG,CKD-378 25/1000mg,Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,1.0,0,32,0,2
NCT02212951,COMPLETED,2014-05-15,2014-07-15,2014-07-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","BIOD-531, Humalog Mix 75/25, Humulin R U-500",Biodel,INDUSTRY,False,0,0,0,0,0,2.0,0,2,0,2
NCT00511472,COMPLETED,2007-07-15,2008-04-15,2008-04-15,PHASE1,70.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","MK-0941, Placebo, LANTUS insulin",Merck Sharp & Dohme LLC,INDUSTRY,True,5,1,4,0,0,9.0,1,55,1,5
NCT00972322,COMPLETED,2009-08-24,2010-01-26,2010-01-12,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","MK-8245, Comparator: placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,3,3,0,1,0,5.0,1,55,1,5
NCT01680328,COMPLETED,2012-08-15,2012-10-15,2012-10-15,PHASE1,82.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,SUPPORTIVE_CARE,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems","OTHER, DRUG","19 injections, sodium chloride 0.9% solution",Novo Nordisk A/S,INDUSTRY,True,6,1,5,0,0,2.0,1,126,0,2
NCT04907006,COMPLETED,2021-08-31,2021-10-11,2021-10-11,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,DRUG,SY-004 capsule,"Suzhou Yabao Pharmaceutical R&D Co., Ltd.",INDUSTRY,False,0,0,0,0,0,1.0,0,4,0,2
NCT07065032,COMPLETED,2024-02-19,2024-08-05,2024-07-22,PHASE1,27.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG, DRUG","ZT002 Injection, ZT002 Injection, ZT002 Placebo","Beijing QL Biopharmaceutical Co.,Ltd",INDUSTRY,False,0,0,0,0,0,5.0,0,2,1,5
NCT01522807,COMPLETED,2011-09-15,2011-11-15,2011-11-15,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","PF-05190457, PF-05190457, PF-05190457, PF-05190457, PF-05190457, PF-05190457, PF-05190457, PF-05190457",Pfizer,INDUSTRY,False,0,0,0,0,0,2.0,1,42,0,2
NCT06942923,COMPLETED,2025-04-22,2025-09-29,2025-09-29,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Healthy Participants,"DRUG, DRUG","AZD4144, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,5.0,1,79,1,5
NCT00153179,COMPLETED,2005-09-15,2013-03-15,2011-12-15,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","acipimox, placebo",Brigham and Women's Hospital,OTHER,True,2,2,0,0,0,75.0,0,1,1,4
NCT05232708,COMPLETED,2022-01-19,2022-08-30,2022-08-30,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Healthy Volunteers (Diabetes Mellitus, Type 2)","DRUG, DRUG, DRUG, DRUG","Semaglutide B, 1.34 mg/mL, Semaglutide D, 1.0 mg/mL, Semaglutide D, 1.0 mg/mL, Semaglutide B, 1.34 mg/mL",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,7.0,1,126,0,2
NCT05983289,COMPLETED,2018-05-08,2019-07-03,2019-07-03,PHASE1,62.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,T2DM (Type 2 Diabetes Mellitus),"DRUG, DRUG","HSK7653, Placebo","Haisco Pharmaceutical Group Co., Ltd.",INDUSTRY,False,0,0,0,0,0,14.0,0,2,1,4
NCT01719640,COMPLETED,2011-01-15,2020-01-15,2013-01-15,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","infusion of MSCs, infusion MCs, insulin",Fuzhou General Hospital,OTHER,False,0,0,0,0,0,24.0,0,2,0,3
NCT00726505,TERMINATED,2009-06-15,2009-08-15,2009-08-15,PHASE1,1.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,DIAGNOSTIC,NONE,"Diabetes, NOS",DRUG,Dapagliflozin,AstraZeneca,INDUSTRY,False,0,0,0,0,0,2.0,1,79,0,2
NCT00976729,COMPLETED,2009-05-15,2009-12-15,2009-12-15,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Chronic Inflammatory Diseases, Type 2 Diabetes Mellitus, Systemic Lupus Erythematosus","DRUG, DRUG, DRUG","NOX-E36, NOX-E36, Placebo",TME Pharma AG,INDUSTRY,False,0,0,0,0,0,7.0,0,2,1,5
NCT06498284,COMPLETED,2024-04-25,2024-09-06,2024-09-06,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type II",DRUG,HM-002-1005,Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0,4.0,0,10,0,4
NCT01915849,COMPLETED,2013-07-15,2014-01-15,2014-01-15,PHASE1,14.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","LIK066, Placebo",Novartis Pharmaceuticals,INDUSTRY,True,1,1,0,0,0,6.0,1,4,1,4
NCT00027287,COMPLETED,2001-11-15,2002-12-15,2002-12-15,PHASE1,60.0,INTERVENTIONAL,UNKNOWN,UNKNOWN,TREATMENT,NONE,"Diabetes Mellitus, Macular Edema",DRUG,Vitamin E,National Eye Institute (NEI),NIH,False,0,0,0,0,0,13.0,0,2,0,1
NCT01507311,COMPLETED,1999-09-15,1999-12-15,1999-12-15,PHASE1,11.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,3.0,1,126,1,4
NCT00910923,COMPLETED,2008-11-15,2009-04-15,2009-04-15,PHASE1,37.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2",DRUG,JNJ-38431055,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0,5.0,0,9,0,3
NCT01324388,COMPLETED,2011-03-15,2011-08-15,2011-08-15,PHASE1,51.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Diabetes Mellitus, Type 2","BIOLOGICAL, DRUG, DRUG, DRUG","LY2189265, Metoprolol, Lisinopril, Placebo",Eli Lilly and Company,INDUSTRY,True,8,4,4,0,0,5.0,1,64,1,4
NCT04660305,COMPLETED,2020-12-02,2021-06-11,2021-06-03,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 1","DRUG, DRUG","AT278, NovoRapid",Arecor Limited,INDUSTRY,False,0,0,0,0,0,6.0,0,2,0,3
NCT03232983,COMPLETED,2017-08-14,2017-11-09,2017-11-09,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY900014 (SC), LY900014 (IV)",Eli Lilly and Company,INDUSTRY,True,2,1,1,0,0,3.0,1,64,0,1
NCT02373150,COMPLETED,2015-02-15,2015-10-15,2015-10-15,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Imeglimin, Placebo",Poxel SA,INDUSTRY,False,0,0,0,0,0,8.0,0,1,1,5
NCT03681691,COMPLETED,2019-05-13,2021-07-19,2021-07-19,PHASE1,12.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,OTHER,NONE,"Diabetes Type 2, Dementia",DRUG,Estradiol patch,Wake Forest University Health Sciences,OTHER,True,22,5,14,0,0,26.0,0,1,0,1
NCT05437848,COMPLETED,2022-02-25,2022-12-12,2022-12-12,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Diabetes,"DRUG, OTHER","Experimental: Cotadutide, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,10.0,1,79,1,5
NCT02933853,COMPLETED,2016-10-14,2017-12-21,2017-12-21,PHASE1,61.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","Faster-acting insulin aspart, Insulin Aspart",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,14.0,1,126,0,3
NCT00929201,COMPLETED,2008-01-15,2008-05-15,2008-03-15,PHASE1,61.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Sitagliptin phosphate/metformin hydrochloride FDC, Sitagliptin phosphate, Metformin hydrochloride",Merck Sharp & Dohme LLC,INDUSTRY,True,2,1,1,0,0,2.0,1,55,0,2
NCT01469468,COMPLETED,2011-11-15,2011-12-15,2011-12-15,PHASE1,14.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Simvastatin, PF-05175157",Pfizer,INDUSTRY,False,0,0,0,0,0,1.0,1,42,0,0
NCT04869761,COMPLETED,2021-10-07,2023-04-26,2023-04-26,PHASE1,10.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,OTHER,NONE,"Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Diabetic Nephropathies","DRUG, DRUG","Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions",LaTonya J. Hickson,OTHER,False,0,0,0,0,0,19.0,0,1,0,1
NCT06890286,COMPLETED,2024-12-01,2025-01-03,2025-01-03,PHASE1,53.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG","BR3006, BR3006A, BR3006B, BR3006C","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0,1.0,0,9,0,2
NCT06199440,COMPLETED,2022-06-01,2023-03-30,2023-03-30,PHASE1,15.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,DIAGNOSTIC,SINGLE,"Periodontal Diseases, Type 2 Diabetes","DRUG, DRUG, DRUG","Group I, Group II, Group III",King Abdulaziz University,OTHER,False,0,0,0,0,0,10.0,0,1,0,2
NCT06792968,COMPLETED,2025-03-30,2025-04-08,2025-04-06,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Diabetes Mellitus Type 2,"DRUG, DRUG","Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets, Synjardy 5 mg/1000 mg film-coated tablets",Gedeon Richter Plc.,INDUSTRY,False,0,0,0,0,0,0.0,0,3,0,2
NCT05452525,COMPLETED,2022-07-26,2022-09-21,2022-08-27,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes Mellitus,"DRUG, DRUG, DRUG","CKD-379 I, CKD-379 II, D759+D745+D150",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,1.0,0,32,0,2
NCT01855321,COMPLETED,2010-08-15,2015-03-15,2015-03-15,PHASE1,76.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","Vitamin D, Placebo",University of Florida,OTHER,False,0,0,0,0,0,55.0,0,1,1,5
NCT01611363,COMPLETED,2011-10-27,2012-02-03,2012-02-03,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","ASP1941, Placebo",Astellas Pharma Europe B.V.,INDUSTRY,False,0,0,0,0,0,3.0,0,2,1,3
NCT01106287,COMPLETED,2009-10-15,2010-03-15,2010-01-15,PHASE1,13.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","MK-0941, Comparator: Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,2,2,0,0,0,3.0,1,55,1,5
NCT01976858,COMPLETED,2011-06-15,2011-12-15,2011-09-15,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes,DRUG,PEX168,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,3.0,0,15,0,4
NCT02910518,COMPLETED,2017-02-17,2017-05-03,2017-05-03,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type1 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Insulin glulisine (U300), Insulin glulisine, Insulin aspart, NPH insulin, Glucagon, Glucose, Heparin",Sanofi,INDUSTRY,False,0,0,0,0,0,2.0,1,25,0,3
NCT06063109,COMPLETED,2023-10-09,2023-11-09,2023-11-09,PHASE1,51.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Hypertension, Diabetes Mellitus, Type 2","DRUG, DRUG","THP-00101 (Dapagliflozin) 10mg, THP-00102 (Telmisartan) 80mg",THPharm Corp.,INDUSTRY,False,0,0,0,0,0,1.0,0,1,0,3
NCT01490658,COMPLETED,2006-06-15,2006-08-15,2006-08-15,PHASE1,93.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","repaglinide, metformin, repaglinide and metformin combination tablet",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,2.0,1,126,0,2
NCT03973515,COMPLETED,2019-08-27,2019-12-19,2019-12-19,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Type2 Diabetes Mellitus,"DRUG, DRUG","glucokinase activator, Placebo","PegBio Co., Ltd.",OTHER,False,0,0,0,0,0,4.0,0,2,1,4
NCT02020616,TERMINATED,2013-12-15,2015-02-15,2015-02-15,PHASE1,60.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","LY3053102, Exenatide ER, Placebo, Metformin",Eli Lilly and Company,INDUSTRY,True,12,1,11,0,0,14.0,1,64,1,5
NCT05596747,COMPLETED,2022-11-30,2023-10-10,2023-10-10,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3209590, Insulin Glargine",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,10.0,1,64,0,2
NCT04407234,COMPLETED,2020-09-15,2021-01-07,2021-01-07,PHASE1,36.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,"Overweight, Obesity, Diabetes Mellitus, Type 2","DRUG, DRUG","Tirzepatide, Acetaminophen",Eli Lilly and Company,INDUSTRY,True,7,2,5,0,0,4.0,1,64,0,0
NCT03864432,COMPLETED,2019-07-02,2020-02-28,2019-10-03,PHASE1,48.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Gemigliptin 25mg, Gemigliptin 50mg, Gemigliptin 100mg, Gemiglptin 50mg multiple dose",LG Chem,INDUSTRY,False,0,0,0,0,0,3.0,0,3,0,1
NCT06879132,COMPLETED,2024-11-05,2024-12-07,2024-12-07,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG","BR3409, BR3409-1, BR3409-2","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0,1.0,0,9,0,2
NCT01662999,COMPLETED,2012-08-15,2012-11-15,2012-11-15,PHASE1,42.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Saxagliptin, Dapagliflozin",AstraZeneca,INDUSTRY,True,26,6,20,0,0,3.0,1,79,0,2
NCT01856595,COMPLETED,2013-05-13,2014-03-01,2014-01-10,PHASE1,117.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","PF-06291874, Placebo",Pfizer,INDUSTRY,True,55,37,18,9,0,8.0,1,42,1,4
NCT01272804,COMPLETED,2011-02-15,2011-07-15,2011-07-15,PHASE1,61.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2, NIDDM","DRUG, DRUG","PF-04937319, Placebo",Pfizer,INDUSTRY,True,27,18,9,0,0,5.0,1,42,1,5
NCT06642584,COMPLETED,2024-10-15,2025-08-13,2025-07-10,PHASE1,90.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Healthy Volunteers Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG","Semaglutide B, Semaglutide J, Semaglutide L, Semaglutide M, Semaglutide N",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,9.0,1,126,0,2
NCT01221545,COMPLETED,2010-10-15,2011-01-15,2011-01-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,BASIC_SCIENCE,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","AZD1656, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,3.0,1,79,1,2
NCT01488877,TERMINATED,2012-01-15,2012-07-15,2012-07-15,PHASE1,6.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Type 2 Diabetic Nephropathy,"DRUG, DRUG, DRUG, DRUG, OTHER","PF-03882845, PF-03882845, PF-03882845, Spironolactone, placebo",Pfizer,INDUSTRY,True,6,3,3,0,0,6.0,1,42,1,4
NCT04907019,COMPLETED,2021-07-06,2021-08-17,2021-08-17,PHASE1,24.0,INTERVENTIONAL,UNKNOWN,SEQUENTIAL,TREATMENT,NONE,Type 2 Diabetes,DRUG,rifampicin，SY-004,"Suzhou Yabao Pharmaceutical R&D Co., Ltd.",INDUSTRY,False,0,0,0,0,0,1.0,0,4,0,1
NCT01474083,COMPLETED,2011-11-15,2012-09-15,2012-08-15,PHASE1,248.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","GK1-399 (formerly TTP399), GK1-399 (formerly TTP399), GK1-399 (formerly TTP399), Placebo",vTv Therapeutics,INDUSTRY,False,0,0,0,0,0,9.0,0,1,1,4
NCT03322631,COMPLETED,2017-11-15,2018-11-28,2018-05-29,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Tirzepatide, Placebo",Eli Lilly and Company,INDUSTRY,True,4,1,3,0,0,6.0,1,64,1,4
NCT01751399,COMPLETED,2012-12-15,2013-09-15,2013-09-15,PHASE1,35.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Healthy Volunteers, Hepatic Insufficiency, Diabetes Mellitus, Type 2",DRUG,LY2605541,Eli Lilly and Company,INDUSTRY,True,2,2,0,0,0,9.0,1,64,0,2
NCT02000700,COMPLETED,2014-03-15,2016-04-15,2016-04-15,PHASE1,17.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Canagliflozin 100 mg, Canagliflozin 50 mg, Canagliflozin 300 mg, Placebo","Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0,25.0,1,10,1,3
NCT00882882,COMPLETED,2001-06-15,2001-06-15,2001-06-15,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes,"DRUG, DRUG, DRUG, DRUG","Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC, Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC, GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb, GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb",Sandoz,INDUSTRY,False,0,0,0,0,0,0.0,0,4,0,2
NCT02146079,COMPLETED,2014-05-21,2014-10-20,2014-10-20,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG","semaglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,5.0,1,126,1,5
NCT01537120,COMPLETED,2011-12-15,2012-10-15,2012-10-15,PHASE1,25.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,DIAGNOSTIC,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Vildagliptin, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,3,1,2,0,0,10.0,1,55,1,1
NCT03058289,COMPLETED,2017-02-09,2023-02-22,2023-02-22,PHASE1,111.0,INTERVENTIONAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,"Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma","DRUG, BIOLOGICAL, BIOLOGICAL","INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody","Intensity Therapeutics, Inc.",INDUSTRY,True,8,1,4,0,0,72.0,0,1,0,1
NCT01068717,COMPLETED,2010-03-15,2010-03-15,2010-03-15,PHASE1,27.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state), Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)",AstraZeneca,INDUSTRY,True,12,8,4,0,0,0.0,1,79,0,2
NCT00947024,COMPLETED,1993-11-15,1993-11-15,1993-11-15,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG","10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast., 10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast., 10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.",Sandoz,INDUSTRY,False,0,0,0,0,0,0.0,0,4,0,2
NCT01154348,COMPLETED,2010-06-15,2010-12-15,2010-11-15,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","S-707106, Placebo, Metformin, S-707106 plus metformin, Metformin, placebo plus metformin",Shionogi,INDUSTRY,False,0,0,0,0,0,5.0,0,1,1,5
NCT03816488,WITHDRAWN,2023-12-01,2024-12-01,2024-06-01,PHASE1,0.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,"Diabetes Mellitus, Type 2, Hyperglycemia, Perioperative/Postoperative Complications","DRUG, DRUG","Metformin, Salsalate",McMaster University,OTHER,False,0,0,0,0,0,6.0,0,1,0,3
NCT03392961,COMPLETED,2014-03-27,2014-07-01,2014-07-01,PHASE1,51.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, OTHER","IN-105 (Insulin Tregopil), Placebo comparator",Biocon Limited,INDUSTRY,False,0,0,0,0,0,3.0,0,1,1,3
NCT00770302,COMPLETED,2008-10-15,2008-10-15,2008-10-15,PHASE1,34.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,Type 2 Diabetes,DRUG,Saxagliptin,AstraZeneca,INDUSTRY,False,0,0,0,0,0,0.0,1,79,0,0
NCT06051565,COMPLETED,2021-11-06,2022-09-15,2022-06-13,PHASE1,12.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,DIAGNOSTIC,NONE,"Diabetes, Magnetic Resonance Imaging",DRUG,Polysaccharide superparamagnetic iron oxide injection,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",INDUSTRY,False,0,0,0,0,0,7.0,0,2,0,0
NCT02754219,COMPLETED,2016-09-22,2018-01-19,2018-01-19,PHASE1,24.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Liver Dysfunction,DRUG,Evogliptin,"Dong-A ST Co., Ltd.",INDUSTRY,False,0,0,0,0,0,16.0,0,6,0,1
NCT03095651,COMPLETED,2017-04-12,2018-01-30,2018-01-30,PHASE1,33.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, DRUG, BIOLOGICAL","MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg, Glargine 0.4 U/kg, Placebo to Glargine, Placebo to MK-5160, Dextrose, Glargine 0.6 U/kg",Merck Sharp & Dohme LLC,INDUSTRY,True,14,3,11,0,0,10.0,1,55,1,5
NCT01105429,COMPLETED,2010-05-15,2010-10-15,2010-10-15,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Non-Insulin-Dependent","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","BMS-820132, BMS-820132, BMS-820132, BMS-820132, BMS-820132, BMS-820132, BMS-820132, BMS-820132, BMS-820132, Placebo, Placebo",Bristol-Myers Squibb,INDUSTRY,False,0,0,0,0,0,5.0,1,7,1,5
NCT01087645,COMPLETED,2010-03-12,2010-09-16,2010-09-16,PHASE1,70.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG, DRUG","NN9925 (oral), NN9925 (i.v.), placebo, NN9925 (oral), placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,6.0,1,126,1,5
NCT02016911,COMPLETED,2013-12-12,2015-01-12,2015-01-12,PHASE1,56.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2, Healthy",DRUG,semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,13.0,1,126,0,2
NCT02528396,COMPLETED,2015-08-15,2015-12-15,2015-12-15,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Type 1 Diabetes Mellitus,"DRUG, DRUG","BioChaperone insulin lispro, Humalog®",Adocia,INDUSTRY,False,0,0,0,0,0,4.0,0,9,0,3
NCT02148861,COMPLETED,2014-05-26,2015-06-01,2015-06-01,PHASE1,49.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Type 2 Diabetes Mellitus","DRUG, DRUG, DRUG","Insulin icodec, insulin degludec, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,12.0,1,126,1,5
NCT02058641,COMPLETED,2014-02-26,2014-08-18,2014-08-18,PHASE1,9.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,BASIC_SCIENCE,NONE,Atherosclerosis,DRUG,Darapladib,GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,6.0,1,35,0,0
NCT06654960,COMPLETED,2024-11-05,2024-12-26,2024-12-26,PHASE1,20.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","HRS9531 injection, Metformin Hydrochloride tablets","Fujian Shengdi Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0,2.0,0,7,0,1
NCT04324424,COMPLETED,2019-04-23,2019-09-30,2019-09-30,PHASE1,17.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,HMS5552,Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0,5.0,0,10,0,2
NCT02167061,COMPLETED,2014-07-15,2014-11-15,2014-11-15,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","DA-1229_01, E+M, DA-1229_01 fast, DA-1229_01 fed","Dong-A ST Co., Ltd.",INDUSTRY,False,0,0,0,0,0,4.0,0,6,0,2
NCT04001231,WITHDRAWN,2020-06-30,2021-07-02,2021-07-02,PHASE1,0.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,OTHER,NONE,Type 2 Diabetes,DRUG,Exenatide Once-Weekly Suspension,AstraZeneca,INDUSTRY,False,0,0,0,0,0,12.0,1,79,0,0
NCT01497561,COMPLETED,2003-03-15,2003-06-15,2003-06-15,PHASE1,15.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","insulin detemir, insulin NPH",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,3.0,1,126,0,3
NCT00767260,COMPLETED,2008-03-15,2015-03-15,2012-03-15,PHASE1,82.0,INTERVENTIONAL,RANDOMIZED,FACTORIAL,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DEVICE, DRUG","BM-MNC+HOT, BM-MNC, HOT, SMT",Fuzhou General Hospital,OTHER,False,0,0,0,0,0,48.0,0,2,0,2
NCT02113163,COMPLETED,2014-03-15,2014-07-15,2014-06-15,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia","DRUG, DRUG","Metformin Eicosapentaenoate, Metformin HCl and Vascepa",Thetis Pharmaceuticals LLC,INDUSTRY,False,0,0,0,0,0,3.0,0,1,0,3
NCT02502253,COMPLETED,2015-06-15,2022-06-01,2022-06-01,PHASE1,14.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,"Mild Cognitive Impairment, Alzheimer's Disease",DRUG,"grape seed polyphenolic extract, resveratrol",Johns Hopkins University,OTHER,False,0,0,0,0,0,84.0,0,1,0,3
NCT00790153,COMPLETED,2008-11-15,2009-02-15,2009-02-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Insulin, AZD1656",AstraZeneca,INDUSTRY,False,0,0,0,0,0,3.0,1,79,0,2
NCT02637037,COMPLETED,2015-12-21,2016-04-07,2016-04-07,PHASE1,80.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects","DRUG, DRUG, DRUG, DRUG","dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)",AstraZeneca,INDUSTRY,True,7,3,4,0,0,4.0,1,79,0,1
NCT00558571,COMPLETED,2008-01-15,2008-04-15,2008-04-15,PHASE1,78.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","BI 10773 low dose, placebo to BI 10773, BI 10773 medium dose, BI 10773 high dose",Boehringer Ingelheim,INDUSTRY,True,19,2,17,0,0,3.0,1,19,1,5
NCT00961857,COMPLETED,2005-12-01,2006-01-01,2005-12-01,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","sitagliptin phosphate (+) metformin hydrochloride, Comparator: metformin 500 mg, Comparator: sitagliptin, Comparator: FMI sitagliptin/metformin 50 mg/500 mg FDC tablet, Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet, Comparator: metformin 1000 mg",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0,0.0,1,55,0,2
NCT00055042,COMPLETED,2003-02-15,2004-01-15,2004-01-15,PHASE1,40.0,INTERVENTIONAL,UNKNOWN,UNKNOWN,TREATMENT,NONE,"Macular Edema, Diabetes Mellitus",DRUG,Vitamin E,National Eye Institute (NEI),NIH,False,0,0,0,0,0,11.0,0,2,0,1
NCT05890950,COMPLETED,2023-03-13,2023-07-12,2023-07-12,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Obesity, Type 2 Diabetes Mellitus in Obese","DRUG, DRUG","K-757 and K-833, Matching placebo to K-757 and K-833",Kallyope Inc.,INDUSTRY,False,0,0,0,0,0,4.0,0,2,1,5
NCT00310297,COMPLETED,2004-11-15,2004-12-15,2004-12-15,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,Insulin Glulisine,Sanofi,INDUSTRY,False,0,0,0,0,1,1.0,1,25,0,2
NCT05498610,COMPLETED,2022-08-11,2022-10-12,2022-10-12,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","NNC0480 0389, Semaglutide",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,2.0,1,126,0,3
NCT02163278,COMPLETED,2014-06-15,2015-01-15,2015-01-15,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","DBPR108, matching placebo","National Health Research Institutes, Taiwan",OTHER,False,0,0,0,0,0,7.0,0,2,1,4
NCT06141590,COMPLETED,2023-03-11,2023-08-29,2023-08-29,PHASE1,35.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","administration of UI068, administration of UIC202205, UIC202206",Korea United Pharm. Inc.,INDUSTRY,False,0,0,0,0,0,6.0,0,1,0,2
NCT01965496,COMPLETED,2012-03-15,2013-04-15,2013-03-15,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes,DRUG,PEX168,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,12.0,0,15,0,4
NCT02588950,TERMINATED,2016-01-12,2017-05-25,2017-05-25,PHASE1,11.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2",DRUG,U-500R,Eli Lilly and Company,INDUSTRY,True,9,4,5,0,0,16.0,1,64,0,1
NCT01069926,COMPLETED,2010-03-15,2010-10-15,2010-10-15,PHASE1,21.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Glucose Lowering,DRUG,AZD1656,AstraZeneca,INDUSTRY,False,0,0,0,0,0,7.0,1,79,0,1
NCT00370084,COMPLETED,2005-03-15,2006-07-15,2006-05-15,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Gastroparesis,"DRUG, OTHER","Itopride, Placebo",Forest Laboratories,INDUSTRY,False,0,0,0,0,0,14.0,0,1,1,4
NCT02250222,COMPLETED,2014-10-15,2015-06-15,2015-05-15,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","LGD-6972, Placebo (Captisol ®)",Ligand Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,7.0,0,3,1,5
NCT04373265,COMPLETED,2020-09-30,2024-01-12,2023-10-17,PHASE1,15.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Adrenocortical Carcinoma,"DRUG, DRUG","Relacorilant, Pembrolizumab",Corcept Therapeutics,INDUSTRY,False,0,0,0,0,0,37.0,0,1,0,1
NCT00924105,COMPLETED,2009-06-15,2011-11-15,2011-11-15,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","CYT013-IL1bQb, Placebo",Cytos Biotechnology AG,INDUSTRY,False,0,0,0,0,0,29.0,0,1,1,5
NCT01434901,COMPLETED,2011-08-15,2014-07-07,2014-07-07,PHASE1,50.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Placebo, Bethanechol (25 mg), Bethanechol (50 mg), Bethanechol (100 mg)",Washington University School of Medicine,OTHER,False,0,0,0,0,0,35.0,0,3,1,1
NCT00946972,TERMINATED,2009-07-15,2009-11-15,2009-11-15,PHASE1,33.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2",DRUG,JNJ-38431055; Placebo,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0,4.0,0,9,1,4
NCT06823856,COMPLETED,2025-05-11,2025-05-21,2025-05-21,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Diabetes Mellitus Type 2,"DRUG, DRUG","Empagliflozin + Metformin hydrochloride 12.5 mg/1000 mg combination film-coated tablets, Synjardy 12.5 mg/1000 mg film-coated tablets",Gedeon Richter Plc.,INDUSTRY,False,0,0,0,0,0,0.0,0,3,0,2
NCT02461914,COMPLETED,2015-08-01,2016-07-13,2015-12-12,PHASE1,16.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,OTHER,NONE,Healthy,"DRUG, DRUG","PEX168, Warfarin","Jiangsu Hansoh Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0,4.0,0,3,0,0
NCT01085292,COMPLETED,2010-07-15,2012-02-15,2012-02-15,PHASE1,47.0,INTERVENTIONAL,RANDOMIZED,FACTORIAL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","NOX-E36, NOX-E36",TME Pharma AG,INDUSTRY,False,0,0,0,0,0,19.0,0,2,0,3
NCT00690287,COMPLETED,2008-02-15,2008-06-15,2008-06-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Type 2 Diabetes,"DRUG, DRUG, DRUG","AZD6370, AZD6370, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,4.0,1,79,1,3
NCT05415644,COMPLETED,2022-07-05,2022-08-08,2022-08-08,PHASE1,78.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","hrx0701 tablets、Metformin hydrochloride tablets、Retagliptin phosphate tablets, hrx0701 tablets","Shandong Suncadia Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,1.0,0,5,0,3
NCT01489644,COMPLETED,2006-06-15,2006-07-15,2006-07-15,PHASE1,62.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","repaglinide, metformin, repaglinide and metformin combination tablet",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,1.0,1,126,0,2
NCT01676233,COMPLETED,2012-09-15,2013-08-15,2013-08-15,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 1 Diabetes Mellitus,"DRUG, DRUG","insulin glargine (HOE901), insulin glargine- new formulation (HOE901)",Sanofi,INDUSTRY,False,0,0,0,0,0,11.0,1,25,0,2
NCT04869800,COMPLETED,2021-05-27,2021-06-15,2021-06-07,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","CKD-398, CKD-501, D745",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,0.0,0,32,0,2
NCT00982254,COMPLETED,2001-10-15,2001-11-15,2001-11-15,PHASE1,10.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Oral insulin, regular human insulin",Profil Institut für Stoffwechselforschung GmbH,INDUSTRY,False,0,0,0,0,0,1.0,0,2,0,2
NCT01406262,COMPLETED,2011-07-06,2011-12-29,2011-12-29,PHASE1,94.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","BIOLOGICAL, DRUG","Albiglutide, Moxifloxacin",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,6.0,1,35,0,3
NCT05407961,COMPLETED,2022-06-07,2024-01-12,2024-01-12,PHASE1,90.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","LY3532226, Placebo, Dulaglutide",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,19.0,1,64,1,4
NCT00554450,COMPLETED,2006-03-15,2008-10-15,2008-10-15,PHASE1,40.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Dapagliflozin,AstraZeneca,INDUSTRY,False,0,0,0,0,0,31.0,1,79,0,2
NCT04345120,COMPLETED,2020-06-15,2021-12-15,2021-12-15,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","SY-008, SY-008 matching placebo","Suzhou Yabao Pharmaceutical R&D Co., Ltd.",INDUSTRY,False,0,0,0,0,0,18.0,0,4,1,4
NCT00924053,COMPLETED,2009-06-15,2009-07-15,2009-07-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetes Mellitus Type 2,"DRUG, DRUG","EGT0001474, Placebo",Theracos,INDUSTRY,True,10,10,0,0,0,1.0,0,5,1,5
NCT01324505,COMPLETED,2011-03-15,2012-01-15,2012-01-15,PHASE1,43.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","semaglutide, placebo, Microgyn®",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,10.0,1,126,1,2
NCT01386541,COMPLETED,2011-06-15,2011-11-15,2011-09-15,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,DRUG,BYK324677,Nycomed,INDUSTRY,False,0,0,0,0,0,3.0,0,1,0,3
NCT01316341,COMPLETED,2011-03-15,2012-01-15,2012-01-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG","BI10773, Placebo, Placebo, Placebo, BI10773",Boehringer Ingelheim,INDUSTRY,True,29,28,1,0,0,10.0,1,19,1,5
NCT01305551,WITHDRAWN,2011-03-15,2011-03-15,2011-03-15,PHASE1,0.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG","Saxagliptin, Metformin XR, Saxagliptin/Metformin XR FDC",AstraZeneca,INDUSTRY,False,0,0,0,0,0,0.0,1,79,0,2
NCT01874483,COMPLETED,2013-06-15,2013-12-15,2013-12-15,PHASE1,71.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Placebo, BI 187004, BI 187004, BI 187004, BI 187004, BI 187004, BI 187004, BI 187004",Boehringer Ingelheim,INDUSTRY,False,0,0,0,0,0,6.0,1,19,1,5
NCT03138356,COMPLETED,2017-05-25,2017-11-28,2017-11-28,PHASE1,126.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet, 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet, 5 mg dapagliflozin / 850 mg metformin XR FDC, 5 mg dapagliflozin / 1000 mg metformin XR FDC, 2.5 mg ONGLYZA® (saxagliptin) tablet, 5 mg Forxiga® (dapagliflozin) tablet, 500 mg Glucophage XR®",AstraZeneca,INDUSTRY,False,0,0,0,0,0,6.0,1,79,0,2
NCT01358929,COMPLETED,2011-04-15,2011-09-15,2011-09-15,PHASE1,45.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG","Placebo, RO6807952",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0,5.0,1,15,1,5
NCT01381887,COMPLETED,2011-06-15,2011-11-15,2011-11-15,PHASE1,37.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Placebo, Canagliflozin 300mg/Placebo, Canagliflozin 300mg/Canagliflozin 150mg, Canagliflozin 300mg","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0,5.0,0,9,1,4
NCT05897216,COMPLETED,2023-07-14,2023-08-08,2023-07-23,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","CKD-383, CKD-501, D745, D150, D029",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,0.0,0,32,0,2
NCT00566865,COMPLETED,2007-11-15,2007-12-15,2007-12-15,PHASE1,14.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","placebo for gemfibrozil, gemfibrozil",Elixir Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,1.0,0,1,1,4
NCT02206607,COMPLETED,2014-09-15,2015-01-15,2015-01-15,PHASE1,39.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","PF-04937319 IR MST, PF-04937319 MR 1, PF-04937319 MR 2, PF-04937319 MR 3",Pfizer,INDUSTRY,True,11,2,9,3,0,4.0,1,42,0,1
NCT03802487,COMPLETED,2019-01-14,2019-03-28,2019-03-28,PHASE1,6.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Healthy Subjects","DRUG, DRUG, DRUG","Sotagliflozin (SAR439954), 14C-microtracer, Charcoal",Sanofi,INDUSTRY,False,0,0,0,0,0,2.0,1,25,0,1
NCT03616392,COMPLETED,2018-07-25,2018-11-13,2018-09-17,PHASE1,41.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type II",DRUG,"D308, CKD-501",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,2.0,0,32,0,2
NCT01748552,COMPLETED,2012-12-15,2013-08-15,2013-08-15,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Placebo, LY2922083",Eli Lilly and Company,INDUSTRY,True,5,1,4,0,0,8.0,1,64,1,2
NCT01535677,COMPLETED,2013-04-15,2013-07-15,2013-07-15,PHASE1,71.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Dapagliflozin + Glucophage tablet fasted, Dapagliflozin/metformin IR FDC tablet fasted, Dapagliflozin + Glucophage tablet fed, Dapagliflozin/metformin IR FDC tablet fed",AstraZeneca,INDUSTRY,False,0,0,0,0,0,3.0,1,79,0,1
NCT00817271,COMPLETED,2009-02-15,2009-04-15,2009-04-15,PHASE1,8.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","AZD1656, Glucagon",AstraZeneca,INDUSTRY,False,0,0,0,0,0,2.0,1,79,0,2
NCT02039258,COMPLETED,2014-01-15,2014-03-15,2014-03-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Healthy Volunteers,DRUG,CANA/MET XR FDC,"Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0,2.0,1,10,0,2
NCT00943501,COMPLETED,2009-11-15,2011-09-15,2011-09-15,PHASE1,21.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","liraglutide, placebo, liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,22.0,1,126,1,5
NCT03414892,COMPLETED,2018-01-03,2019-12-01,2019-01-04,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Hyperglycaemia (Diabetic), Type 2 Diabetes Mellitus","DRUG, DRUG","Globalagliatin Hydrochloride, Placebo",Yabao Pharmaceutical Group,INDUSTRY,False,0,0,0,0,0,12.0,0,1,1,4
NCT06086912,COMPLETED,2023-11-07,2023-12-12,2023-12-12,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG","HR17031, HR17031, HR17031","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,1.0,0,15,0,2
NCT05411965,COMPLETED,2022-04-28,2022-07-03,2022-07-03,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","BR3003(T), BR3003B(R1), BR3003C(R2)","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0,2.0,0,9,0,2
NCT00239187,COMPLETED,2005-09-15,2007-01-15,2007-01-15,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Type 2 Diabetes,DRUG,E1 and G1,"OPKO Health, Inc.",INDUSTRY,False,0,0,0,0,0,16.0,0,1,0,3
NCT05086445,COMPLETED,2021-11-12,2022-09-05,2022-09-05,PHASE1,62.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3502970, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,10.0,1,64,1,4
NCT01017302,COMPLETED,2009-12-15,2011-08-15,2011-08-15,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG, DRUG, DRUG","Placebo, Placebo, RO5095932, RO5095932",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0,20.0,1,15,1,4
NCT01755494,COMPLETED,2013-02-15,2013-04-15,2013-04-15,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus(T2DM),"DRUG, DRUG, DRUG, DRUG, DRUG","Saxagliptin 5 mg, Metformin XR 500 mg, Mertformin XR 2 x 500 mg, Komboglyze XR 5/500 mg, Komboglyze XR 5/1000 mg",AstraZeneca,INDUSTRY,False,0,0,0,0,0,2.0,1,79,0,1
NCT00422357,COMPLETED,2007-01-15,2007-04-15,2007-04-15,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,FACTORIAL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,DRUG,Urtica Dioica (Tea bag),Shahid Beheshti University of Medical Sciences,OTHER,False,0,0,0,0,0,3.0,0,1,0,3
NCT06084156,COMPLETED,2019-08-10,2019-12-09,2019-12-09,PHASE1,22.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","HSK7653, Metformin","Haisco Pharmaceutical Group Co., Ltd.",INDUSTRY,False,0,0,0,0,0,4.0,0,2,0,1
NCT04878406,COMPLETED,2021-05-18,2021-07-20,2021-07-20,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Healthy Volunteers Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG","NNC0480-0389, Placebo (NNC0480-0389), Semaglutide, Placebo (Semaglutide)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,2.0,1,126,1,5
NCT01869621,COMPLETED,2013-04-15,2014-10-15,2014-03-15,PHASE1,34.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,Type 2 Diabetes,DRUG,Metformin,University of Southern Denmark,OTHER,False,0,0,0,0,0,11.0,0,3,0,0
NCT06268145,COMPLETED,2024-02-06,2024-03-29,2024-03-29,PHASE1,14.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,ECC5004,Eccogene,INDUSTRY,False,0,0,0,0,0,2.0,0,3,0,2
NCT01405261,COMPLETED,2011-08-15,2012-05-15,2012-05-15,PHASE1,101.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG","oral NNC 0113-0987, oral NNC 0113-0987, I.v. NNC 0113-0987, oral placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,9.0,1,126,1,4
NCT02648854,COMPLETED,2015-10-15,2015-11-15,2015-10-15,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type II","DRUG, DRUG","CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T, CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,0.0,0,32,0,2
NCT00774553,COMPLETED,2008-10-15,2010-01-15,2010-01-15,PHASE1,70.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","AZD1656, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,15.0,1,79,1,5
NCT01956305,COMPLETED,2013-09-15,2014-06-15,2014-06-15,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","DS-7309, placebo, Metformin",Daiichi Sankyo,INDUSTRY,False,0,0,0,0,0,9.0,0,3,1,3
NCT01202266,TERMINATED,2010-08-15,2010-12-15,2010-12-15,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","PF-05161704 or Placebo, PF-05161704 or Placebo, PF-05161704 or Placebo, PF-05161704 or Placebo, PF-05161704 or Placebo, PF-05161704 or Placebo, PF-05161704 or Placebo, PF-05161704 or Placebo",Pfizer,INDUSTRY,False,0,0,0,0,0,4.0,1,42,1,4
NCT00894322,COMPLETED,2009-04-15,2009-08-15,2009-08-15,PHASE1,65.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, OTHER","exenatide once weekly, exenatide once weekly, Placebo",AstraZeneca,INDUSTRY,True,19,13,6,0,0,4.0,1,79,1,4
NCT06169982,COMPLETED,2023-12-07,2024-07-18,2024-07-18,PHASE1,56.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2",DRUG,LY3209590,Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,7.0,1,64,0,0
NCT00798915,COMPLETED,2008-12-15,2012-12-15,2012-12-15,PHASE1,40.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Diabetes,"DRUG, DRUG, DRUG, DRUG","Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25",Washington University School of Medicine,OTHER,False,0,0,0,0,0,48.0,0,3,1,2
NCT00464776,COMPLETED,2005-10-15,2008-04-15,2008-04-15,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Aliskiren, Aliskiren, Aliskiren, Aliskiren",Novartis,INDUSTRY,False,0,0,0,0,0,30.0,1,5,0,3
NCT02197520,COMPLETED,2014-07-15,2015-06-15,2015-06-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Insulin Peglispro, Insulin Glargine, Insulin Lispro",Eli Lilly and Company,INDUSTRY,True,6,1,5,0,0,11.0,1,64,0,1
NCT00935220,COMPLETED,2009-06-15,2010-08-15,2010-08-15,PHASE1,41.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,linagliptin QD (once daily) for 7 days,Boehringer Ingelheim,INDUSTRY,True,9,3,6,0,0,14.0,1,19,0,1
NCT03723785,COMPLETED,2018-11-09,2019-09-06,2019-09-06,PHASE1,58.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Insulin icodec,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,10.0,1,126,0,2
NCT00727896,COMPLETED,2008-08-15,2010-04-15,2010-04-15,PHASE1,200.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Type 2 Diabetes,"BEHAVIORAL, DRUG","Pre-coded messages, Diabetes Treatment",India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals,OTHER,False,0,0,0,0,0,20.0,0,1,0,2
NCT00904176,COMPLETED,2009-06-15,2009-08-15,2009-08-15,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Dapagliflozin, Warfarin, Digoxin",AstraZeneca,INDUSTRY,False,0,0,0,0,0,2.0,1,79,0,2
NCT02744820,TERMINATED,2016-04-15,2017-09-15,2017-09-15,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Healthy, Type 2 Diabetes Mellitus","DRUG, OTHER","GMC-252-L-Lysine Salt, Placebo",Genmedica Therapeutics S.L.,INDUSTRY,False,0,0,0,0,0,17.0,0,2,1,5
NCT01907113,COMPLETED,2009-07-15,2009-12-15,2009-12-15,PHASE1,40.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG","BI 10773, BI 10773, BI 10773, BI 10773, BI 10773",Boehringer Ingelheim,INDUSTRY,True,16,2,14,0,0,5.0,1,19,0,2
NCT03350191,COMPLETED,2017-12-20,2018-06-07,2018-06-07,PHASE1,13.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","SAR425899, [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer), [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)",Sanofi,INDUSTRY,False,0,0,0,0,0,6.0,1,25,0,1
NCT01211197,COMPLETED,2010-10-15,2010-12-15,2010-12-15,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","C: BI 10773 / metformin tablet, B: BI 10773 tablet and metformin tablet, A: BI 10773 / metformin tablet",Boehringer Ingelheim,INDUSTRY,True,13,4,9,0,0,2.0,1,19,0,2
NCT02548585,COMPLETED,2015-12-09,2017-02-24,2017-02-24,PHASE1,113.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","MEDI0382, Placebo",MedImmune LLC,INDUSTRY,True,26,2,24,2,0,15.0,0,3,1,5
NCT01095991,COMPLETED,2010-03-15,2010-05-15,2010-05-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","AZD1656, Sitagliptin",AstraZeneca,INDUSTRY,False,0,0,0,0,0,2.0,1,79,0,2
NCT00873821,COMPLETED,2008-12-15,2009-05-15,2009-05-15,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","MK-0941, Comparator: Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,3,3,0,1,0,5.0,1,55,1,5
NCT01597713,COMPLETED,2012-05-15,2012-10-15,2012-10-15,PHASE1,83.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","NNC 0148-0000-0362, insulin glargine, placebo, NNC 0148-0000-0362, NNC 0148-0000-0362, NNC 0148-0000-0362",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,5.0,1,126,1,5
NCT01606397,COMPLETED,2008-03-15,2008-11-15,2008-11-15,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Placebo, LY2409021",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,8.0,1,64,1,4
NCT05129891,COMPLETED,2021-11-03,2023-05-04,2023-02-26,PHASE1,384.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Healthy Volunteers, High Blood Cholesterol Levels, Type 2 Diabetes","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Semaglutide D, Semaglutide G, Semaglutide H, Semaglutide I, NNC0385-0434 B, NNC0385-0434 C, NNC0385-0434 D, NNC0385-0434 E",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,16.0,1,126,0,3
NCT01460368,COMPLETED,2011-10-15,2012-03-15,2012-03-15,PHASE1,67.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","LY2409021, Placebo, Moxifloxacin",Eli Lilly and Company,INDUSTRY,True,2,1,1,0,0,5.0,1,64,1,3
NCT02753803,COMPLETED,2016-07-27,2017-03-10,2016-10-19,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,HEALTH_SERVICES_RESEARCH,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Evogliptin, Pioglitazone, Evogliptin+Pioglitazone, Pioglitazone, Evogliptin, Evogliptin+Pioglitazone, Evogliptin, Evogliptin+Pioglitazone, Pioglitazone, Pioglitazone, Evogliptin+Pioglitazone, Evogliptin, Evogliptin+Pioglitazone, Evogliptin, Pioglitazone, Evogliptin+Pioglitazone, Pioglitazone, Evogliptin","Dong-A ST Co., Ltd.",INDUSTRY,False,0,0,0,0,0,3.0,0,6,0,1
NCT05497674,COMPLETED,2022-02-21,2023-02-24,2022-07-22,PHASE1,28.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Rongliflozin, Rifampin, Rongliflozin, Probenecid","Sunshine Lake Pharma Co., Ltd.",INDUSTRY,False,0,0,0,0,0,5.0,0,2,0,1
NCT06305351,COMPLETED,2023-12-07,2024-06-21,2024-05-15,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Obesity, Type 2 Diabetes Mellitus (T2DM)","DRUG, DRUG, DRUG, DRUG","K-757 and K-833 QD, K-757 and K-833 BID, Matching placebo to K-757 and K-833 QD, Matching placebo to K-757 and K-833 BID",Kallyope Inc.,INDUSTRY,False,0,0,0,0,0,5.0,0,2,1,5
NCT00388986,COMPLETED,2006-10-15,2007-07-15,2007-07-15,PHASE1,18.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,Diabetes Mellitus Type 2,"DRUG, DRUG","GK Activator (2), Glyburide",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0,9.0,1,15,0,1
NCT05248841,COMPLETED,2022-03-08,2022-08-31,2022-08-31,PHASE1,104.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","DRUG, DRUG","HEC-Glargine, US-Lantus","Lannett Company, Inc.",INDUSTRY,False,0,0,0,0,0,6.0,0,1,0,3
NCT03199261,COMPLETED,2016-12-23,2017-01-21,2017-01-21,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","rE-4 Injection, rE-4 Freeze-dried Powder","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",INDUSTRY,False,0,0,0,0,0,1.0,0,2,0,2
NCT01546558,COMPLETED,2012-02-15,2012-03-15,2012-03-15,PHASE1,25.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Metformin, Ranolazine",Gilead Sciences,INDUSTRY,False,0,0,0,0,0,1.0,0,3,0,1
NCT02161276,COMPLETED,2014-04-15,2014-09-15,2014-08-15,PHASE1,110.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,DOUBLE,Accidental Exposure While Preparing Drug for Administration,"DRUG, DRUG","TNTL capsule, Placebo",Guizhou Bailing Group Pharmaceutical Co Ltd,INDUSTRY,False,0,0,0,0,0,4.0,0,1,1,3
NCT02055547,COMPLETED,2013-05-10,2013-09-17,2013-09-17,PHASE1,61.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","MK-8521 35μg, MK-8521 100μg, MK-8521 125μg, MK-8521 150μg, MK-8521 175μg, MK-8521 200μg, MK-8521 300μg, MK-8521 50/72μg, MK-8521 72/125μg, MK-8521 100/150μg, MK-8521 125/150μg, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,39,21,18,0,0,4.0,1,55,1,5
NCT04152915,COMPLETED,2019-11-25,2020-05-25,2020-05-25,PHASE1,68.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Healthy Volunteers, Diabetes Mellitus, Type 2",DRUG,Semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,6.0,1,126,0,3
NCT01273558,COMPLETED,2011-01-15,2011-07-15,2011-07-15,PHASE1,28.0,INTERVENTIONAL,UNKNOWN,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Canagliflozin,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0,6.0,0,9,0,2
NCT00946504,COMPLETED,1992-10-15,1992-10-15,1992-10-15,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.), Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)",Sandoz,INDUSTRY,False,0,0,0,0,0,0.0,0,4,0,2
NCT01588366,COMPLETED,2012-04-15,2013-09-15,2013-09-15,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Placebo, LY2409021",Eli Lilly and Company,INDUSTRY,True,6,2,4,0,0,17.0,1,64,1,3
NCT01650324,COMPLETED,2012-07-15,2012-12-15,2012-12-15,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","DBPR108, matching placebo","National Health Research Institutes, Taiwan",OTHER,True,5,1,4,0,0,5.0,0,2,1,4
NCT05521256,COMPLETED,2022-08-26,2023-03-27,2023-03-27,PHASE1,70.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,"Healthy Volunteers, Type 2 Diabetes","DRUG, DRUG","NNC0113-6856, Placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,7.0,1,126,1,4
NCT01919684,COMPLETED,2013-11-15,2014-03-15,2014-02-15,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","LGD-6972, Placebo (Captisol®)",Ligand Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,3.0,0,3,1,5
NCT02824874,COMPLETED,2016-04-15,2016-05-15,2016-04-15,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type II","DRUG, DRUG","Duvie Tab. 0.5mg, Duvie Tab. 0.5mg + Januvia Tab. 100mg",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,0.0,0,32,0,2
NCT04208620,COMPLETED,2020-01-21,2020-07-08,2020-07-08,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","Placebo, Cotadutide",AstraZeneca,INDUSTRY,False,0,0,0,0,0,6.0,1,79,1,5
NCT01571661,COMPLETED,2004-09-15,2005-01-15,2005-01-15,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, OTHER","GSK189075A, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,4.0,1,35,1,4
NCT00873223,COMPLETED,2009-03-15,2009-09-15,2009-09-15,PHASE1,33.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","liraglutide, insulin detemir",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,6.0,1,126,0,1
NCT00519480,COMPLETED,2007-09-11,2008-04-01,2008-04-01,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","GSK189075, Metformin, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,7.0,1,35,1,5
NCT03611322,COMPLETED,2018-08-08,2019-01-07,2019-01-07,PHASE1,54.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DEVICE, DEVICE","Semaglutide, 0.25 mg, Semaglutide, 0.5 mg, Semaglutide, 1.0 mg, DV3372, PDS290 pen-injector",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,5.0,1,126,0,4
NCT04768673,COMPLETED,2021-03-26,2021-04-27,2021-04-22,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes,"DRUG, DRUG, DRUG","CKD-393 formulation I, CKD-393 formulation II, D501, D759, H053",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,1.0,0,32,0,2
NCT00541229,COMPLETED,2007-08-24,2008-07-01,2008-06-17,PHASE1,103.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG, DRUG","sitagliptin phosphate, sitagliptin phosphate, Comparator: Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,1,1,0,2,0,10.0,1,55,1,4
NCT06370819,COMPLETED,2024-04-15,2024-11-27,2024-11-27,PHASE1,36.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,NNC0519-0130,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,7.0,1,126,0,1
NCT04389775,COMPLETED,2020-03-29,2021-09-29,2021-09-29,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,"Type 2 Diabetes Mellitus, Obesity, Nonalcoholic Steatohepatitis","DRUG, DRUG, DRUG, DRUG","Cohort A, Placebo A, Cohort B, Placebo B",Sciwind Biosciences APAC CO Pty. Ltd.,INDUSTRY,False,0,0,0,0,0,18.0,0,2,1,4
NCT01492465,TERMINATED,2011-11-15,2012-10-15,2012-07-15,PHASE1,47.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetes Mellitus,DRUG,AMG 876,Amgen,INDUSTRY,False,0,0,0,0,0,8.0,1,3,0,4
NCT02886884,COMPLETED,2017-10-20,2020-09-03,2019-08-26,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","20 million Allogeneic Mesenchymal Human Stem Cells, 100 million Allogeneic Mesenchymal Human Stem Cells",Joshua M Hare,OTHER,True,7,1,6,0,0,22.0,0,1,0,4
NCT06703658,COMPLETED,2024-11-02,2025-03-13,2025-03-13,PHASE1,35.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,"Healthy Participants, Type 2 Diabetes","DRUG, DRUG, DRUG, DRUG","AZD5004(Part A), Placebo(Part A), AZD5004(Part B), Placebo(Part B)",AstraZeneca,INDUSTRY,False,0,0,0,0,0,4.0,1,79,1,4
NCT02565368,COMPLETED,2015-07-15,2015-08-15,2015-08-15,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type II","DRUG, DRUG","Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg, CKD-395 0.5/1000mg",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,1.0,0,32,0,2
NCT01724814,COMPLETED,2012-12-20,2014-07-01,2014-07-01,PHASE1,86.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Healthy, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","DRUG, DRUG","HM12460A, Placebo",Hanmi Pharmaceutical Company Limited,INDUSTRY,False,0,0,0,0,0,18.0,0,1,1,5
NCT04513704,COMPLETED,2020-08-28,2021-05-26,2021-04-20,PHASE1,156.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Healthy Volunteers Type 2 Diabetes,DRUG,Oral Semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,8.0,1,126,0,3
NCT02356224,COMPLETED,2013-06-15,2013-12-15,2013-12-15,PHASE1,84.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes,"DRUG, DRUG","SHR3824, Placebo","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,6.0,0,15,1,5
NCT00971659,COMPLETED,2008-01-15,2008-11-15,2008-09-15,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG","insulin glargine + exenatide + preexisting metformin, insulin glargine + sitagliptin + preexisting metformin, insulin glargine + preexisting metformin",Profil Institut für Stoffwechselforschung GmbH,INDUSTRY,False,0,0,0,0,0,8.0,0,2,0,3
NCT04575181,COMPLETED,2020-10-21,2021-12-24,2021-12-10,PHASE1,86.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","NNC0268-0965, Insulin glargine, Placebo (NNC0268-0965), Placebo (insulin glargine)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,14.0,1,126,1,5
NCT01221519,COMPLETED,2010-09-15,2011-01-15,2011-01-15,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Type 2 Diabetes Mellitus, High Blood Sugar",DRUG,AZD1656,AstraZeneca,INDUSTRY,False,0,0,0,0,0,4.0,1,79,0,1
NCT01096940,COMPLETED,2010-03-15,2010-08-15,2010-08-15,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","AZD1656, simvastatin",AstraZeneca,INDUSTRY,False,0,0,0,0,0,5.0,1,79,0,2
NCT04880291,COMPLETED,2021-05-05,2022-02-08,2022-02-08,PHASE1,39.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,"Kidney Diseases, Diabetic Nephropathies, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases","DRUG, DRUG","GFB-024, Placebo","Goldfinch Bio, Inc.",INDUSTRY,False,0,0,0,0,0,9.0,0,1,1,4
NCT04032197,COMPLETED,2019-08-12,2023-06-06,2022-12-16,PHASE1,101.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Semaglutide, Placebo (semaglutide)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,40.0,1,126,1,5
NCT04097600,COMPLETED,2019-09-30,2021-01-20,2020-12-16,PHASE1,274.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Healthy Volunteers, Type 2 Diabetes",DRUG,Oral semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,15.0,1,126,0,2
NCT01606371,COMPLETED,2007-05-15,2007-10-15,2007-10-15,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Placebo, LY2409021",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,5.0,1,64,1,3
NCT05754424,COMPLETED,2023-02-27,2024-02-12,2024-01-18,PHASE1,41.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","AT278, NovoRapid, Humulin R 500 UNT/ML Injectable Solution",Arecor Limited,INDUSTRY,False,0,0,0,0,0,11.0,0,2,0,3
NCT05881213,COMPLETED,2023-06-01,2023-07-10,2023-06-28,PHASE1,23.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes,DRUG,CKD-378 (low-dose),Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,1.0,0,32,0,2
NCT02014259,COMPLETED,2013-12-11,2014-10-24,2014-10-24,PHASE1,71.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2, Healthy",DRUG,semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,10.0,1,126,0,2
NCT01369277,COMPLETED,2011-06-15,2011-09-15,2011-09-15,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders","DRUG, DRUG, DRUG","PF-04991532, Placebo, PF-04991532",Pfizer,INDUSTRY,False,0,0,0,0,0,3.0,1,42,1,5
NCT02862431,TERMINATED,2016-07-12,2016-12-05,2016-11-29,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","JNJ-64565111, Placebo","Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0,5.0,1,10,1,5
NCT06386328,COMPLETED,2024-05-03,2024-06-13,2024-06-03,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes Mellitus,DRUG,"CKD-378, QD, PO",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,1.0,0,32,0,2
NCT01340911,COMPLETED,2011-06-03,2011-11-24,2011-11-24,PHASE1,78.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","SRT3025, Placebo","Sirtris, a GSK Company",INDUSTRY,False,0,0,0,0,0,6.0,1,5,1,3
NCT03903016,COMPLETED,2019-03-26,2019-08-19,2019-08-19,PHASE1,90.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Type 1 Diabetes,"DRUG, DRUG","Insulin Lispro SAR342434, Insulin Lispro SAR342434",Sanofi,INDUSTRY,False,0,0,0,0,0,5.0,1,25,0,3
NCT03417076,WITHDRAWN,2018-08-01,2018-09-16,2018-09-16,PHASE1,0.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,Bexagliflozin,Theracos,INDUSTRY,False,0,0,0,0,0,2.0,0,5,0,1
NCT07020949,COMPLETED,2024-06-13,2024-11-27,2024-11-27,PHASE1,49.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG","THDBH120 injection, Placebo of THDBH120 injection","Tonghua Dongbao Pharmaceutical Co.,Ltd",INDUSTRY,False,0,0,0,0,0,5.0,0,1,1,5
NCT06948747,COMPLETED,2025-05-06,2025-10-03,2025-10-03,PHASE1,49.0,INTERVENTIONAL,NON_RANDOMIZED,FACTORIAL,TREATMENT,NONE,Healthy Participants,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","AZD5004, Rosuvastatin, Erythromycin, Atorvastatin, Simvastatin, Repaglinide",AstraZeneca,INDUSTRY,False,0,0,0,0,0,5.0,1,79,0,1
NCT04426708,COMPLETED,2019-02-18,2020-07-03,2020-07-03,PHASE1,25.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,HMS5552,Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0,16.0,0,10,0,2
NCT04142424,COMPLETED,2019-10-28,2021-11-12,2021-11-12,PHASE1,73.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Metabolic Disorders, Non-alcoholic Steatohepatitis","DRUG, DRUG","AZD2693, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,25.0,1,79,1,5
NCT00961480,COMPLETED,2007-10-15,2007-11-15,2007-11-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","sitagliptin phosphate (+) metformin hydrochloride, Comparator: metformin 500mg, Comparator: sitagliptin, Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet, Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet, Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet, Comparator: metformin 1000 mg, Comparator: metformin 850 mg",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0,1.0,1,55,0,2
NCT05029076,COMPLETED,2019-05-21,2019-07-01,2019-06-01,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Liraglutide injection, Victoza","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",INDUSTRY,False,0,0,0,0,0,0.0,0,2,0,2
NCT01083212,COMPLETED,2010-03-15,2010-06-15,2010-06-15,PHASE1,19.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","AZD1656, Gemfibrozil, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,3.0,1,79,1,3
NCT01043965,COMPLETED,2005-08-15,2009-08-15,2009-08-15,PHASE1,61.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,DIAGNOSTIC,SINGLE,Type 2 Diabetes,DRUG,Metformin,University of Sao Paulo General Hospital,OTHER,False,0,0,0,0,0,48.0,0,1,0,0
NCT00790556,COMPLETED,2008-10-15,2009-09-15,2009-09-15,PHASE1,14.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","MK8245, Comparator: Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,3,2,0,0,0,11.0,1,55,1,4
NCT01500798,TERMINATED,2012-01-31,2013-10-01,2012-11-01,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Chronic Kidney Disease, Type 2 Diabetes","DRUG, DRUG","20 mg bardoxolone methyl, Placebo",Biogen,INDUSTRY,False,0,0,0,0,0,9.0,0,3,1,5
NCT04050553,COMPLETED,2020-02-24,2022-01-25,2022-01-25,PHASE1,42.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2, Hypoglycemia","DRUG, DRUG","Tirzepatide, Placebo",Eli Lilly and Company,INDUSTRY,True,7,1,6,1,0,23.0,1,64,1,3
NCT01798264,COMPLETED,2009-02-15,2009-05-15,2009-05-15,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,DRUG,ITCA 650 (exenatide in DUROS),Intarcia Therapeutics,INDUSTRY,True,4,1,3,0,0,3.0,0,1,0,3
NCT00943371,TERMINATED,2007-08-15,2009-05-15,2007-09-15,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","MK6349, Comparator: Placebo to MK6349",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0,1.0,1,55,1,5
NCT00254800,COMPLETED,2005-11-15,2006-08-15,2006-08-15,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","ethinyl estradiol and levonorgestrel; exenatide, ethinyl estradiol and levonorgestrel; exenatide, ethinyl estradiol and levonorgestrel; exenatide",AstraZeneca,INDUSTRY,False,0,0,0,0,0,9.0,1,79,0,2
NCT02815787,COMPLETED,2014-03-15,2014-07-15,2014-07-15,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","SP2086, Glyburide","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,4.0,0,15,0,2
NCT06634927,COMPLETED,2024-09-22,2025-02-12,2024-11-14,PHASE1,68.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Ozempic®, HDG1901","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0,2.0,0,1,0,3
NCT01804842,COMPLETED,2012-12-15,2013-04-15,2013-04-15,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,DRUG,Met DR,"Elcelyx Therapeutics, Inc.",INDUSTRY,True,4,4,0,12,0,4.0,0,2,0,1
NCT05549570,COMPLETED,2017-10-22,2017-11-01,2017-11-01,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,"Bioequivalence, Diabetes Mellitus, Type 2",DRUG,Sitagliptin/Metformin HCl 50/850 mg film-coated tablet,Galenicum Health,INDUSTRY,False,0,0,0,0,0,0.0,0,6,0,1
NCT01809184,COMPLETED,2013-03-04,2013-09-06,2013-09-06,PHASE1,84.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","insulin 287, insulin glargine, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,6.0,1,126,1,5
NCT02815748,COMPLETED,2015-08-15,2015-10-15,2015-10-15,PHASE1,8.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,DRUG,SP2086,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,2.0,0,15,0,1
NCT01068743,COMPLETED,2010-02-15,2010-03-15,2010-03-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","saxagliptin, metformin, saxagliptin + metformin (FDC tablet)",AstraZeneca,INDUSTRY,True,17,4,7,0,0,1.0,1,79,0,2
NCT02942914,COMPLETED,2016-12-20,2017-10-18,2017-10-18,PHASE1,80.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","LY3209590, Placebo, Insulin Glargine",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,10.0,1,64,1,4
NCT00562250,COMPLETED,2008-05-15,2008-08-15,2008-08-15,PHASE1,11.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Dapagliflozin, Glimepiride, Dapagliflozin + Glimepiride",AstraZeneca,INDUSTRY,False,0,0,0,0,0,3.0,1,79,0,2
NCT01183715,COMPLETED,2010-07-15,2010-09-15,2010-09-15,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","PF-05161704 or placebo, PF-05161704 or placebo",Pfizer,INDUSTRY,False,0,0,0,0,0,2.0,1,42,1,3
NCT01511692,COMPLETED,2005-11-15,2007-09-15,2007-09-15,PHASE1,43.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","liraglutide, placebo, placebo, glimepiride",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,22.0,1,126,1,4
NCT01253304,COMPLETED,2010-11-15,2011-11-15,2011-11-15,PHASE1,26.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,LY2189265,Eli Lilly and Company,INDUSTRY,True,7,7,0,0,0,12.0,1,64,0,1
NCT02627287,COMPLETED,2015-12-01,2016-02-25,2016-02-25,PHASE1,150.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","DEVICE, DEVICE, DRUG","FlexPen®, DV3316 pen-injector, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,3.0,1,126,1,3
NCT00975052,COMPLETED,2006-01-15,2006-03-15,2006-03-15,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG","sitagliptin phosphate, Comparator: metformin, Comparator: sitagliptin and metformin, Comparator: placebo",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0,2.0,1,55,1,4
NCT02324309,COMPLETED,2014-05-15,2014-11-15,2014-11-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","BIOD-531, Humalog Mix 75/25, Humulin R U-500, BIOD-531",Biodel,INDUSTRY,False,0,0,0,0,0,6.0,0,2,0,2
NCT02735239,COMPLETED,2016-06-24,2022-06-16,2022-06-16,PHASE1,73.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Esophageal Cancer,"DRUG, DRUG, DRUG, DRUG, RADIATION, DRUG, DRUG, DRUG, DRUG, DRUG","Durvalumab, Tremelimumab, Oxaliplatin, Capecitabine, Radiotherapy, Paclitaxel, Carboplatin, 5-fluorouracil (5-FU), Leucovorin, Docetaxel",Ludwig Institute for Cancer Research,OTHER,True,7,2,5,0,0,72.0,0,1,0,2
NCT01865292,COMPLETED,2006-08-15,2006-11-15,2006-11-15,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","DRUG, DRUG","insulin degludec, insulin glargine",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,3.0,1,126,0,3
NCT02749032,COMPLETED,2011-11-15,2014-03-15,2014-03-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Type 2 Diabetes,"OTHER, DRUG, DRUG, DRUG, DRUG, OTHER","Mixed meal test, Vildagliptin, Sitagliptin, Placebo, Metformin, Diet and exercise",Michael A. Nauck,OTHER,False,0,0,0,0,0,28.0,0,1,1,4
NCT02212067,COMPLETED,2014-08-11,2015-05-11,2015-05-11,PHASE1,87.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","semaglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,9.0,1,126,1,5
NCT00912002,COMPLETED,2008-10-15,2009-01-15,2008-11-15,PHASE1,6.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,DRUG,MK-0941,Merck Sharp & Dohme LLC,INDUSTRY,True,3,1,2,0,0,1.0,1,55,0,1
NCT01755442,TERMINATED,2012-11-15,2013-01-15,2013-01-15,PHASE1,5.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Diabetes Mellitus,"OTHER, DRUG","Placebo, AMG 151",Amgen,INDUSTRY,False,0,0,0,0,0,2.0,1,3,1,4
NCT03310749,COMPLETED,2016-01-15,2016-05-03,2016-05-03,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Gemigliptin, Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day, Metformin","Stendhal Americas, S.A.",INDUSTRY,False,0,0,0,0,0,4.0,0,1,0,2
NCT06247748,COMPLETED,2023-10-19,2024-04-15,2024-04-15,PHASE1,28.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2, Overweight","DRUG, DRUG, DRUG, DRUG","Exendin-4 Fc fusion protein (JY09) injection, Metformin Hydrochloride tablet, Rosuvastatin calcium tablets, Digoxin tablet","Beijing Dongfang Biotech Co., Ltd.",INDUSTRY,False,0,0,0,0,0,6.0,0,2,0,1
NCT04540016,COMPLETED,2020-11-15,2021-01-21,2021-01-14,PHASE1,6.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type II Diabetes,DRUG,[14C]HSK7653,"Sichuan Haisco Pharmaceutical Group Co., Ltd",INDUSTRY,False,0,0,0,0,0,2.0,0,1,0,1
NCT01511185,COMPLETED,2001-02-15,2001-10-15,2001-10-15,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,8.0,1,126,1,4
NCT04016974,COMPLETED,2019-10-08,2021-02-26,2021-01-23,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Healthy Volunteers, Diabetes Mellitus, Type 2","DRUG, DRUG","Oral semaglutide, Placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,16.0,1,126,1,5
NCT01952535,COMPLETED,2013-09-15,2013-12-15,2013-12-15,PHASE1,60.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type II Diabetes Mellitus,"DRUG, DRUG","HMS5552, Placebo",Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0,3.0,0,10,1,5
NCT02029924,COMPLETED,2013-12-15,2014-08-15,2014-03-15,PHASE1,37.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Diabetes Mellitus Type 1,"DRUG, DRUG","BioChaperone insulin lispro, Humalog®",Adocia,INDUSTRY,False,0,0,0,0,0,3.0,0,9,0,3
NCT00418366,COMPLETED,2003-01-15,2003-03-15,2003-03-15,PHASE1,24.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Renal Insufficiency, Hemodialysis",DRUG,"MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0,2.0,1,55,0,2
NCT01843127,COMPLETED,2013-04-15,2013-09-15,2013-09-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Ranolazine, Placebo, Exenatide",Gilead Sciences,INDUSTRY,False,0,0,0,0,0,5.0,0,3,1,3
NCT00964262,COMPLETED,2009-08-15,2010-10-15,2010-10-15,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","SR Exenatide (PT302), Placebo","Peptron, Inc.",INDUSTRY,False,0,0,0,0,0,14.0,0,1,1,4
NCT00377442,COMPLETED,2006-08-15,2007-04-15,2007-04-15,PHASE1,33.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Diabetes Mellitus Type 2,"DRUG, DRUG","GK Activator (2), Simvastatin",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0,8.0,1,15,0,2
NCT02210871,COMPLETED,2014-08-07,2015-06-03,2015-06-03,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2, Hepatic Impaired",DRUG,semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,10.0,1,126,0,3
NCT03859934,COMPLETED,2019-09-26,2021-08-18,2021-05-03,PHASE1,17.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,"Metabolic Disease, Insulin Sensitivity, Glucose Metabolism Disorders (Including Diabetes Mellitus), Type 2 Diabetes Mellitus, Blood Pressure, Inflammation","DRUG, DRUG","Melatonin, Placebo Oral Tablet",University of Aarhus,OTHER,False,0,0,0,0,0,19.0,0,1,1,4
NCT03790787,COMPLETED,2019-04-18,2020-03-15,2020-03-15,PHASE1,16.0,INTERVENTIONAL,UNKNOWN,SEQUENTIAL,TREATMENT,NONE,Patients,"DRUG, DRUG","Empagliflozin, Dorzagliatin",Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0,11.0,0,10,0,1
NCT01366287,COMPLETED,2011-01-15,2011-02-15,2011-02-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","PF-03882845, PF-03882845, PF-03882845",Pfizer,INDUSTRY,False,0,0,0,0,0,1.0,1,42,0,1
NCT00970593,COMPLETED,2009-09-02,2011-07-25,2011-07-25,PHASE1,92.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Diabetes Mellitus,"DRUG, DRUG","OAP-189, placebo comparator",Pfizer,INDUSTRY,True,14,10,0,0,0,23.0,1,42,1,5
NCT00806338,COMPLETED,2008-11-15,2009-04-15,2009-04-15,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Obesity","DRUG, DRUG","Trodusquemine (MSI-1436), Placebo",Genaera Corporation,INDUSTRY,False,0,0,0,0,0,5.0,0,2,1,4
NCT00332085,TERMINATED,2006-01-15,2007-03-15,2007-03-15,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Type 2 Diabetes,DRUG,Chromium Picolinate,Bastyr University,OTHER,False,0,0,0,0,0,14.0,0,1,0,3
NCT05266404,COMPLETED,2022-03-21,2022-05-31,2022-05-31,PHASE1,46.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus),"DRUG, DRUG, DRUG","Dapagliflozin/sitagliptin FDC, Sitagliptin, Dapagliflozin",AstraZeneca,INDUSTRY,False,0,0,0,0,0,2.0,1,79,0,2
NCT00504816,COMPLETED,2007-04-15,2008-04-15,2008-01-15,PHASE1,22.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2","DRUG, DRUG","GSK189075, Brevicon",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,9.0,1,35,0,1
NCT02077452,COMPLETED,2014-03-15,2014-10-15,2014-09-15,PHASE1,53.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","HMS5552, Placebo",Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0,6.0,0,10,1,4
NCT00930865,COMPLETED,2009-07-15,2009-09-15,2009-09-15,PHASE1,42.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Bumetanide, Dapagliflozin",AstraZeneca,INDUSTRY,False,0,0,0,0,0,2.0,1,79,0,3
NCT03296800,COMPLETED,2017-09-27,2017-12-06,2017-12-06,PHASE1,48.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Bexagliflozin, Probenecid, Rifampin, Verapamil",Theracos,INDUSTRY,True,5,4,1,0,0,2.0,0,5,0,1
NCT06615700,COMPLETED,2024-05-06,2024-09-20,2024-08-12,PHASE1,74.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Overweight or Obesity, Type 2 Diabetes","DRUG, DRUG","NA-931, Placebo","Biomed Industries, Inc.",INDUSTRY,False,0,0,0,0,0,3.0,0,1,1,5
NCT00495014,COMPLETED,2007-06-15,2007-12-15,2007-12-15,PHASE1,70.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,DIAGNOSTIC,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","GSK376501, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,6.0,1,35,1,3
NCT01441232,COMPLETED,2011-10-15,2011-11-15,2011-11-15,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","LX4211, Januvia®",Lexicon Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,1.0,0,4,0,2
NCT01077505,COMPLETED,2010-03-15,2010-11-24,2010-11-24,PHASE1,16.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,OTHER,NONE,"Diabetes Mellitus, Type 2","BIOLOGICAL, DRUG","albiglutide, Oral contraceptive (Brevicon)",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,8.0,1,35,0,0
NCT00306072,COMPLETED,2005-06-15,2005-09-15,2005-09-15,PHASE1,82.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Diabetes Mellitus,DRUG,nutritional herbal extract from Salacia oblonga,Ross Products,INDUSTRY,False,0,0,0,0,0,3.0,0,1,0,3
NCT01225939,COMPLETED,2010-11-15,2010-12-15,2010-12-15,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","AZD8329, AZD8329",AstraZeneca,INDUSTRY,False,0,0,0,0,0,1.0,1,79,0,2
NCT00302224,COMPLETED,2005-02-15,2006-08-15,2006-08-15,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,DRUG,"2S, 4R Ketoconazole (DIO-902)",DiObex,INDUSTRY,False,0,0,0,0,0,18.0,0,1,0,4
NCT01054118,COMPLETED,2009-12-15,2010-02-15,2010-02-15,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","JNJ-38431055, Sitagliptin 100 mg, JNJ-38431055 + Sitagliptin 100 mg, Placebo","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0,2.0,0,9,1,4
NCT01546597,COMPLETED,2012-02-15,2012-03-15,2012-03-15,PHASE1,24.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Metformin, Ranolazine",Gilead Sciences,INDUSTRY,False,0,0,0,0,0,1.0,0,3,0,1
NCT05274880,COMPLETED,2022-06-21,2022-07-26,2022-07-15,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes Mellitus,DRUG,CKD-393,Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,1.0,0,32,0,2
NCT03776227,COMPLETED,2019-01-25,2019-04-22,2019-04-22,PHASE1,66.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Healthy Subjects",DRUG,sotagliflozin (SAR439954),Sanofi,INDUSTRY,False,0,0,0,0,0,3.0,1,25,0,2
NCT06996886,COMPLETED,2025-05-22,2025-07-25,2025-07-15,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Healthy Participants,DRUG,AZD5004,AstraZeneca,INDUSTRY,False,0,0,0,0,0,2.0,1,79,0,2
NCT01103622,COMPLETED,2010-06-15,2010-12-15,2010-12-15,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","AZD1656, Digoxin, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,6.0,1,79,1,3
NCT05184322,COMPLETED,2022-04-12,2025-03-25,2024-07-13,PHASE1,87.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Obesity, Type 2 Diabetes Mellitus","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","T2026, Placebo, Oral ecnoglutide tablet, Oral ecnoglutide tablet, Oral ecnoglutide tablet, Oral ecnoglutide tablet, Oral ecnoglutide tablet, Oral ecnoglutide tablet, T2026, Placebo, T2026, Placebo",Sciwind Biosciences APAC CO Pty. Ltd.,INDUSTRY,False,0,0,0,0,0,27.0,0,2,1,5
NCT02009527,COMPLETED,2012-01-15,2013-09-15,2013-04-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Coronary Artery Disease, Type 2 Diabetes Mellitus","DRUG, DRUG","N-hydroxy-nor-arginine, NaCl",Karolinska Institutet,OTHER,False,0,0,0,0,0,15.0,0,1,0,1
NCT01247896,COMPLETED,2010-12-15,2011-06-15,2011-06-15,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type II","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","PF-05190457, PF-05190457, PF-05190457, PF-05190457, PF-05190457, PF-05190457, PF-05190457, PF-05190457, Placebo",Pfizer,INDUSTRY,False,0,0,0,0,0,6.0,1,42,1,5
NCT04262661,COMPLETED,2020-03-02,2020-09-25,2020-09-25,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Healthy Volunteers, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","NNC0472-0147, insulin glargine, Placebo (NNC0472-0147)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,7.0,1,126,1,5
NCT02022254,COMPLETED,2013-12-17,2014-08-28,2014-08-28,PHASE1,24.0,INTERVENTIONAL,UNKNOWN,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG","semaglutide, placebo, metformin, warfarin",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,8.0,1,126,1,2
NCT00938275,COMPLETED,2009-01-20,2009-03-27,2009-03-27,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2",DRUG,0.5g SRT2104,"Sirtris, a GSK Company",INDUSTRY,False,0,0,0,0,0,2.0,1,5,0,1
NCT00935467,COMPLETED,2009-07-15,2009-08-15,2009-08-15,PHASE1,12.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,Saxagliptin,AstraZeneca,INDUSTRY,False,0,0,0,0,0,1.0,1,79,0,1
NCT02002611,COMPLETED,2013-12-15,2014-05-15,2014-02-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Lobeglitazone, Warfarin",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,2.0,0,32,0,2
NCT01726764,COMPLETED,2013-01-15,2014-05-15,2013-06-15,PHASE1,20.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Type 2 Diabetes, Depression","OTHER, DRUG","St John's Wort, Metformin",University of Southern Denmark,OTHER,False,0,0,0,0,0,5.0,0,3,0,1
NCT01236404,COMPLETED,2010-11-15,2011-11-15,2011-11-15,PHASE1,80.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl), Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)",PhaseBio Pharmaceuticals Inc.,INDUSTRY,False,0,0,0,0,0,12.0,0,4,1,5
NCT00964964,COMPLETED,2009-08-15,2009-09-15,2009-09-15,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1","DRUG, DRUG, DRUG","insulin degludec, insulin degludec, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,1.0,1,126,1,4
NCT01042106,COMPLETED,2009-11-15,2010-07-15,2010-07-15,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","DSP-8658, Placebo","Sumitomo Pharma America, Inc.",INDUSTRY,False,0,0,0,0,0,8.0,0,1,1,5
NCT01508806,COMPLETED,2005-08-15,2006-03-15,2006-03-15,PHASE1,30.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2",DRUG,liraglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,7.0,1,126,0,2
NCT01511900,COMPLETED,2011-12-15,2012-04-15,2012-04-15,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","CAT 1004, Placebo, CAT 1004, CAT 1004, CAT 1004, CAT 1004",Catabasis Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,4.0,0,1,1,5
NCT00916604,COMPLETED,2009-05-15,2009-10-15,2009-10-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Type 2 Diabetes,"DRUG, DRUG","AZD1656, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,5.0,1,79,1,4
NCT01433380,COMPLETED,2011-07-15,2012-05-15,2012-05-15,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","PF-05175157, Placebo",Pfizer,INDUSTRY,False,0,0,0,0,0,10.0,1,42,1,3
NCT00819884,COMPLETED,2009-01-15,2009-05-15,2009-05-15,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Type II Diabetes,DRUG,AZD1656,AstraZeneca,INDUSTRY,False,0,0,0,0,0,4.0,1,79,0,2
NCT01620424,COMPLETED,2001-02-15,2001-04-15,2001-04-15,PHASE1,10.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","biphasic insulin aspart 30, biphasic insulin aspart 50",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,2.0,1,126,0,3
NCT01517555,COMPLETED,2006-10-15,2007-05-15,2007-05-15,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","liraglutide, placebo, paracetamol",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,7.0,1,126,1,4
NCT05046873,COMPLETED,2021-09-06,2022-01-05,2022-01-05,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL, semaglutide 1.34 mg/mL (placebo), Semaglutide 1.34 mg/mL, NNC0480-0389 A 10 mg/mL",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,4.0,1,126,1,4
NCT02960659,COMPLETED,2017-05-09,2022-05-20,2022-05-20,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Type 2 Diabetes,"DRUG, DRUG","Liraglutide, Metformin",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,True,9,1,8,0,0,60.0,0,3,0,2
NCT00400283,COMPLETED,2001-01-19,2001-05-03,2001-05-03,PHASE1,23.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2",DRUG,NNC 55-0414,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,3.0,1,126,0,4
NCT01703286,COMPLETED,2012-10-15,2014-01-15,2014-01-15,PHASE1,42.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Placebo, Linagliptin, Placebo, Placebo, Placebo, Glimepiride",Boehringer Ingelheim,INDUSTRY,True,4,1,3,3,0,15.0,1,19,1,4
NCT01549769,TERMINATED,2012-04-30,2013-10-31,2012-11-30,PHASE1,24.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2",DRUG,Bardoxolone Methyl,Biogen,INDUSTRY,False,0,0,0,0,0,7.0,0,3,0,1
NCT04586907,COMPLETED,2020-11-23,2021-11-30,2021-11-30,PHASE1,85.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Healthy, Type 2 Diabetes Mellitus","DRUG, DRUG","LY3537021, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,12.0,1,64,1,4
NCT01300260,COMPLETED,2011-02-15,2011-08-15,2011-08-15,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","BIOLOGICAL, DRUG, DRUG, DRUG, DRUG","LY2189265, Placebo, Insulin, Glucose, Glucagon",Eli Lilly and Company,INDUSTRY,True,6,4,1,8,0,6.0,1,64,1,4
NCT01018628,COMPLETED,2009-12-07,2010-08-06,2010-08-06,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","SRT2379, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,8.0,1,35,1,3
NCT01845064,COMPLETED,2013-04-15,2014-11-15,2014-09-15,PHASE1,98.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetes Type 2,"DRUG, DRUG","DM199, Placebo",DiaMedica Therapeutics Inc,INDUSTRY,False,0,0,0,0,0,17.0,0,1,1,5
NCT02538848,COMPLETED,2015-10-15,2016-03-15,2016-03-15,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,FACTORIAL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,DRUG,HTD4010,HighTide Biopharma Pty Ltd,INDUSTRY,False,0,0,0,0,0,5.0,0,1,0,3
NCT02065752,COMPLETED,2014-02-15,2014-04-15,2014-04-15,PHASE1,2.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Healthy Volunteers,"DRUG, DRUG, DRUG, DRUG","Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/500 mg, CANA/MET XR FDC, Formulation 2, 50 mg/500 mg","Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0,2.0,1,10,0,2
NCT03060538,COMPLETED,2017-03-05,2019-12-13,2019-12-13,PHASE1,154.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2, Non-Alcoholic Fatty Liver Disease","DRUG, OTHER","BFKB8488A, Placebo","Genentech, Inc.",INDUSTRY,False,0,0,0,0,0,33.0,0,1,1,5
NCT01867216,COMPLETED,2013-06-15,2014-01-15,2014-01-15,PHASE1,66.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Placebo, LY2922470",Eli Lilly and Company,INDUSTRY,True,7,1,6,0,0,7.0,1,64,1,4
NCT05814107,COMPLETED,2023-05-09,2025-11-07,2025-11-07,PHASE1,94.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,"Type 2 Diabetes, Overweight or Obesity","DRUG, DRUG","CT-996, Placebo",Carmot Australia First Pty Ltd,INDUSTRY,False,0,0,0,0,0,30.0,0,1,1,4
NCT00871507,COMPLETED,2009-04-15,2009-07-15,2009-07-15,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","JNJ-38431055 Dose 1, Sitagliptin 100 mg, Placebo, JNJ-38431055 Dose 2","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0,3.0,0,9,1,4
NCT04065581,COMPLETED,2019-10-14,2020-03-06,2019-11-25,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Acarbose/Metformin FDC(BAY81-9783), Glucobay, Glucophage",Bayer,INDUSTRY,False,0,0,0,0,0,1.0,1,4,0,1
NCT02218099,COMPLETED,2013-09-16,2014-09-09,2014-09-09,PHASE1,55.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,"Healthy Subjects, Pharmacokinetics of ASP8232, Pharmacodynamics of ASP8232, Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM)","DRUG, DRUG","ASP8232, Placebo",Astellas Pharma Europe B.V.,INDUSTRY,False,0,0,0,0,0,12.0,0,2,1,4
NCT02036528,TERMINATED,2014-01-15,2014-12-15,2014-12-15,PHASE1,9.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetic Foot Ulcers,"DRUG, DRUG, DRUG","Gentamicin Topical Gel, Ciprofloxacin, Doxycycline","Royer Biomedical, Inc.",INDUSTRY,False,0,0,0,0,0,11.0,0,1,0,3
NCT06288412,COMPLETED,2024-02-26,2025-04-14,2025-03-10,PHASE1,30.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Insulin icodec, Insulin degludec",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,12.0,1,126,0,1
NCT02724566,COMPLETED,2016-05-15,2017-04-15,2017-04-15,PHASE1,9.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,Diabetes,"DRUG, DRUG","apelin, placebo","University Hospital, Toulouse",OTHER,False,0,0,0,0,0,11.0,0,1,1,3
NCT03945656,COMPLETED,2019-05-07,2021-09-27,2021-09-27,PHASE1,43.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","insulin icodec, Insulin glargine",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,29.0,1,126,0,2
NCT00707954,COMPLETED,2008-06-15,2009-02-15,2009-02-15,PHASE1,61.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","TA-7284, Placebo of TA-7284",Mitsubishi Tanabe Pharma Corporation,INDUSTRY,True,3,1,2,0,0,8.0,0,2,1,5
NCT05682495,COMPLETED,2023-01-31,2023-04-04,2023-04-04,PHASE1,96.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","ARM A, ARM B, ARM C, ARM D, ARM E, ARM F","Shandong Suncadia Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,2.0,0,5,0,2
NCT01068756,TERMINATED,2010-03-15,2010-04-15,2010-04-15,PHASE1,14.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Dapagliflozin, Rifampin",AstraZeneca,INDUSTRY,False,0,0,0,0,0,1.0,1,79,0,1
NCT00931372,COMPLETED,2009-06-15,2009-08-15,2009-08-15,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Lixisenatide (AVE0010), Placebo",Sanofi,INDUSTRY,False,0,0,0,0,0,2.0,1,25,1,4
NCT01869959,COMPLETED,2009-04-15,2009-12-15,2009-06-15,PHASE1,47.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY2405319, Placebo",Eli Lilly and Company,INDUSTRY,True,16,1,15,0,0,2.0,1,64,1,4
NCT01865305,COMPLETED,2006-09-15,2007-02-15,2007-02-15,PHASE1,59.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","insulin degludec/insulin aspart 30, insulin degludec/insulin aspart 40, insulin degludec/insulin aspart 50, insulin degludec, insulin aspart, biphasic insulin aspart 30, insulin degludec/insulin aspart 40, insulin degludec/insulin aspart 50, biphasic insulin aspart 30",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,5.0,1,126,0,3
NCT01274663,COMPLETED,2010-11-15,2011-05-15,2011-05-15,PHASE1,63.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","PF-05175157 or Placebo, PF-05175157 or Placebo, PF-05175157 or Placebo, PF-05175157 or Placebo, PF-05175157 or Placebo, PF-05175157 or Placebo, PF-05175157 or Placebo",Pfizer,INDUSTRY,False,0,0,0,0,0,6.0,1,42,1,4
NCT05544214,COMPLETED,2022-10-21,2022-11-17,2022-11-14,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes Mellitus,DRUG,CKD-371,Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,1.0,0,32,0,2
NCT00279240,COMPLETED,2001-03-15,2004-12-15,2004-12-15,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,UNKNOWN,PREVENTION,NONE,Diabetes,DRUG,Metformin,M.V. Hospital for Diabetes,OTHER,False,0,0,0,0,1,45.0,0,1,0,1
NCT01055652,COMPLETED,2010-01-15,2010-04-15,2010-04-15,PHASE1,28.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,Dapagliflozin,AstraZeneca,INDUSTRY,False,0,0,0,0,0,3.0,1,79,0,1
NCT00707590,TERMINATED,2008-08-15,2008-11-15,2008-11-15,PHASE1,120.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,DRUG,BMS-767778 or Placebo,Bristol-Myers Squibb,INDUSTRY,False,0,0,0,0,0,3.0,1,7,1,5
NCT00836225,COMPLETED,2009-01-15,2012-01-15,2011-10-15,PHASE1,103.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,DRUG,ISIS 388626,"Ionis Pharmaceuticals, Inc.",INDUSTRY,False,0,0,0,0,0,33.0,0,3,0,4
NCT06124560,COMPLETED,2022-10-28,2022-11-07,2022-11-07,PHASE1,58.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,"Bioequivalence, Diabetes Mellitus, Type 2",DRUG,Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet,Galenicum Health,INDUSTRY,False,0,0,0,0,0,0.0,0,6,0,1
NCT02106585,COMPLETED,2014-03-15,2014-08-15,2014-08-15,PHASE1,94.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Diabetes Mellitus,DRUG,JTT-251 or Placebo,Akros Pharma Inc.,INDUSTRY,False,0,0,0,0,0,5.0,0,3,1,4
NCT01215968,COMPLETED,2010-09-15,2011-07-15,2011-07-15,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","BIOLOGICAL, DRUG","LY2189265, Placebo",Eli Lilly and Company,INDUSTRY,True,5,1,4,0,0,10.0,1,64,1,4
NCT00682097,COMPLETED,2008-05-15,2009-03-15,2009-03-15,PHASE1,55.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG","RO4998452, placebo",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0,10.0,1,15,1,5
NCT05294458,COMPLETED,2022-03-28,2022-09-12,2022-09-12,PHASE1,10.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease",DRUG,cotadutide solution for injection,AstraZeneca,INDUSTRY,False,0,0,0,0,0,6.0,1,79,0,2
NCT00859755,COMPLETED,2009-03-15,2009-07-15,2009-07-15,PHASE1,41.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,TRIPLE,Type 2 Diabetes,"DRUG, DRUG","ARRY-403, glucokinase activator; oral, Placebo; oral",Array BioPharma,INDUSTRY,False,0,0,0,0,0,4.0,0,1,1,4
NCT02078440,COMPLETED,2014-01-15,2016-06-15,2016-06-15,PHASE1,18.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,DRUG,Bromocriptine mesylate,VeroScience,INDUSTRY,False,0,0,0,0,0,29.0,0,1,0,1
NCT00979368,COMPLETED,2009-11-15,2010-02-15,2010-02-15,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Non-Insulin-Dependent, Dyslipidemia","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","BMS-816336, BMS-816336, BMS-816336, BMS-816336, BMS-816336, Placebo",Bristol-Myers Squibb,INDUSTRY,False,0,0,0,0,0,3.0,1,7,1,5
NCT00976261,COMPLETED,2009-10-17,2010-09-05,2010-09-05,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, OTHER","GSK1614235, Sitagliptin, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,11.0,1,35,1,5
NCT06439056,COMPLETED,2024-05-27,2025-07-18,2025-07-18,PHASE1,12.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,DRUG,"NEX-22A, a prolonged release formulation of liraglutide",Nanexa AB,INDUSTRY,False,0,0,0,0,0,14.0,0,1,0,1
NCT05409027,COMPLETED,2021-07-23,2024-02-07,2022-03-10,PHASE1,12.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,"Type 2 Diabetes Mellitus in Obese, Obesity, Type2Diabetes","DRUG, DRUG","SPI-62, Cortisone-d8",Sparrow Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,8.0,0,1,0,0
NCT01093794,COMPLETED,2010-04-15,2010-06-15,2010-06-15,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG","Co-administration of 50 mg sitagliptin and 500 mg metformin, sitagliptin/metformin 50 mg/500 mg tablet, Co-administration of 50 mg sitagliptin and 850 mg metformin, sitagliptin/metformin 50 mg/850 mg tablet",Merck Sharp & Dohme LLC,INDUSTRY,True,2,2,0,0,0,2.0,1,55,0,2
NCT04305587,COMPLETED,2020-03-16,2021-07-14,2021-07-14,PHASE1,66.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Diabetes Mellitus Type 2,"DRUG, OTHER, DRUG","PF-07081532, Placebo, Clopidogrel",Pfizer,INDUSTRY,True,11,4,7,0,0,16.0,1,42,1,4
NCT01156246,COMPLETED,2010-06-15,2010-08-15,2010-08-15,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Healthy,DRUG,Dapagliflozin/Metformin,AstraZeneca,INDUSTRY,False,0,0,0,0,0,2.0,1,79,0,1
NCT06695572,COMPLETED,2024-11-06,2024-12-13,2024-12-07,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus (T2DM),DRUG,CKD-383,Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,1.0,0,32,0,2
NCT01933672,COMPLETED,2013-10-15,2014-03-15,2014-03-15,PHASE1,33.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","PF-04937319 once-daily, PF-04937319 split-dose, Sitagliptin once-daily",Pfizer,INDUSTRY,True,15,1,14,0,0,5.0,1,42,0,2
NCT00365781,COMPLETED,2006-08-15,2006-09-15,2006-09-15,PHASE1,10.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,ISIS 113715,"Ionis Pharmaceuticals, Inc.",INDUSTRY,False,0,0,0,0,0,1.0,0,3,0,1
NCT01686945,COMPLETED,2012-09-19,2013-04-08,2013-04-08,PHASE1,107.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG, DRUG","semaglutide, semaglutide, semaglutide, placebo, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,7.0,1,126,1,5
NCT01667900,COMPLETED,2012-08-15,2014-06-15,2014-06-15,PHASE1,58.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2, Healthy Volunteers","DRUG, DRUG","Dulaglutide, Placebo",Eli Lilly and Company,INDUSTRY,True,5,4,1,0,0,22.0,1,64,1,5
NCT02265809,COMPLETED,2014-10-03,2016-05-26,2016-05-26,PHASE1,41.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,BASIC_SCIENCE,NONE,Type 1 Diabetes,DRUG,Aldesleukin,Cambridge University Hospitals NHS Foundation Trust,OTHER,False,0,0,0,0,0,20.0,0,2,0,0
NCT00607906,COMPLETED,2007-11-16,2008-03-10,2008-03-10,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","SB-756050 immediate release capsule, SB-756050 modified release capsule, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,4.0,1,35,1,4
NCT01972893,COMPLETED,2011-02-15,2012-06-15,2012-03-15,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","ZYD1, Placebo",Zydus Lifesciences Limited,INDUSTRY,False,0,0,0,0,0,13.0,0,1,1,5
NCT02820298,COMPLETED,2016-06-20,2016-08-29,2016-08-29,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,Bexagliflozin,Theracos,INDUSTRY,True,5,5,0,0,0,2.0,0,5,0,2
NCT01177163,COMPLETED,2008-05-15,2009-03-15,2009-03-15,PHASE1,29.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Placebo, JNJ 28431754 300 mg/placebo, JNJ 28431754 100 mg/placebo","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0,10.0,0,9,1,5
NCT01524809,COMPLETED,2001-01-15,2001-06-15,2001-06-15,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1","DRUG, DRUG","biphasic insulin aspart 30, biphasic insulin aspart 70",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,5.0,1,126,0,3
NCT00475371,COMPLETED,2007-04-15,2007-06-15,2007-06-15,PHASE1,26.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2, Healthy Males",DRUG,MKC253 Inhalation Powder,Mannkind Corporation,INDUSTRY,False,0,0,0,0,0,2.0,0,3,0,1
NCT01542450,COMPLETED,2002-08-15,2003-02-15,2003-02-15,PHASE1,23.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 1","DRUG, DRUG","insulin detemir, insulin NPH",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,6.0,1,126,0,2
NCT02004678,COMPLETED,2013-09-15,2013-10-15,2013-09-15,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, OTHER","DS-1150b, Placebo",Daiichi Sankyo,INDUSTRY,False,0,0,0,0,0,0.0,0,3,1,4
NCT00513214,COMPLETED,2007-07-15,2010-02-15,2009-06-15,PHASE1,68.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","XOMA 052, Placebo",XOMA (US) LLC,INDUSTRY,False,0,0,0,0,0,23.0,0,2,1,5
NCT02440061,WITHDRAWN,2018-05-15,2019-06-15,2019-06-15,PHASE1,0.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Synthetic human AG, Arginine, 0.9% saline solution","Jenny Tong, MD, MPH",OTHER,False,0,0,0,0,0,13.0,0,2,0,1
NCT03603704,COMPLETED,2018-08-17,2019-05-27,2019-05-27,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3209590, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,9.0,1,64,1,4
NCT02292433,COMPLETED,2015-01-15,2015-03-15,2015-03-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","PF-04937319 high dose, PF-04937319 low dose, Placebo",Pfizer,INDUSTRY,True,30,14,16,0,0,2.0,1,42,1,3
NCT03598621,COMPLETED,2018-07-23,2019-01-17,2019-01-17,PHASE1,68.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DEVICE, DEVICE, DEVICE, DEVICE","Semaglutide, 0.5 mg/mL, Semaglutide, 1.0 mg/mL, Semaglutide, 1.34 mg/mL, Semaglutide, 2.0 mg/mL, DV3372, 0.5 mg/mL, DV3372, 1.0 mg/mL, PDS290, NovoPen®4",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,6.0,1,126,0,3
NCT00558909,COMPLETED,2007-06-15,2007-11-15,2007-11-15,PHASE1,80.0,INTERVENTIONAL,UNKNOWN,UNKNOWN,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","BI 44847, placebo for BI 44847",Boehringer Ingelheim,INDUSTRY,False,0,0,0,0,0,5.0,1,19,1,2
NCT02147431,COMPLETED,2014-05-21,2015-05-20,2015-05-20,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","semaglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,12.0,1,126,1,4
NCT01176097,COMPLETED,2010-07-15,2011-02-15,2011-02-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,Type 2 Diabetes,"DRUG, DRUG","AZD5658, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,7.0,1,79,1,3
NCT01159353,COMPLETED,2007-09-15,2008-04-15,2008-04-15,PHASE1,37.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Insulin glulisine, Insulin aspart",Sanofi,INDUSTRY,False,0,0,0,0,0,7.0,1,25,0,3
NCT03657537,COMPLETED,2018-09-17,2019-02-14,2019-02-14,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Type2 Diabetes, Ketonemia, Cognitive Change","DRUG, DRUG","Ketone infusion, Saline infusion",Bispebjerg Hospital,OTHER,False,0,0,0,0,0,5.0,0,1,0,2
NCT00368368,COMPLETED,2006-01-15,2007-08-15,2007-08-15,PHASE1,5.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetes Mellitus Type 2,DRUG,GK Activator (2),Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0,19.0,1,15,0,2
NCT01253278,COMPLETED,2010-03-15,2011-05-15,2011-05-15,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY2393910, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,14.0,1,64,1,5
NCT01129258,COMPLETED,2010-06-15,2010-12-15,2010-12-15,PHASE1,110.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders","DRUG, DRUG","PF-04991532, Placebo",Pfizer,INDUSTRY,False,0,0,0,0,0,6.0,1,42,1,5
NCT01515202,COMPLETED,2012-03-15,2012-09-15,2012-09-15,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","BMS-823778, BMS-823778, BMS-823778, BMS-823778, Placebo matching with BMS-823778",Bristol-Myers Squibb,INDUSTRY,False,0,0,0,0,0,6.0,1,7,1,5
NCT01862939,COMPLETED,2011-04-15,2011-09-15,2011-09-15,PHASE1,52.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","DS-7309, placebo",Daiichi Sankyo,INDUSTRY,False,0,0,0,0,0,5.0,0,3,1,4
NCT00757601,COMPLETED,2008-04-15,2008-12-15,2008-12-15,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","MK1006, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,7,2,5,0,0,8.0,1,55,1,4
NCT02073227,COMPLETED,2014-02-15,2014-06-15,2014-06-15,PHASE1,52.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Healthy Volunteers,"DRUG, DRUG, DRUG, DRUG","Canagliflozin, 300 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg, CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg","Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0,4.0,1,10,0,2
NCT04426474,COMPLETED,2020-10-08,2021-07-12,2021-07-12,PHASE1,68.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3502970, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,9.0,1,64,1,3
NCT00823940,COMPLETED,2009-01-13,2009-04-27,2009-04-27,PHASE1,42.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","GSK1362885, GSK1362885, Glucagon, Glucagon + GSK1362885",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,3.0,1,35,0,4
NCT01746017,COMPLETED,2012-12-15,2013-03-15,2013-03-15,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Placebo, LY2922470",Eli Lilly and Company,INDUSTRY,True,5,1,4,0,0,3.0,1,64,1,2
NCT05790681,COMPLETED,2023-04-25,2024-02-08,2024-02-08,PHASE1,18.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Insulin icodec,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,9.0,1,126,0,1
NCT01054300,COMPLETED,2010-02-17,2010-04-07,2010-04-07,PHASE1,52.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,DOUBLE,"Diabetes Mellitus, Type 2, Adult","DRUG, DRUG, DRUG, DRUG, DRUG","Ertugliflozin 2 mg single dose, Ertugliflozin 2 mg split into twice daily, Ertugliflozin 4 mg single dose, Ertugliflozin 4 mg split into twice daily, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,11,11,0,0,0,2.0,1,55,1,3
NCT00908271,COMPLETED,2009-07-15,2009-08-15,2009-08-15,PHASE1,7.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,Dapagliflozin,AstraZeneca,INDUSTRY,False,0,0,0,0,0,1.0,1,79,0,1
NCT01473953,COMPLETED,2011-10-15,2012-03-15,2012-03-15,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG","liraglutide-depot, placebo",Novo Nordisk A/S,INDUSTRY,True,7,1,6,0,0,5.0,1,126,1,5
NCT05870670,COMPLETED,2023-05-15,2023-10-16,2023-10-07,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","NNC0519-0130, Placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,5.0,1,126,1,5
NCT04136067,COMPLETED,2019-10-29,2020-08-23,2020-08-23,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","NNC0268-0965, insulin glargine",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,10.0,1,126,0,4
NCT02703337,COMPLETED,2016-03-15,2016-08-15,2016-08-15,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY900014, Insulin Lispro",Eli Lilly and Company,INDUSTRY,True,4,2,2,0,0,5.0,1,64,0,2
NCT01710371,COMPLETED,2012-12-15,2015-09-15,2015-09-15,PHASE1,40.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,DIAGNOSTIC,NONE,Type 2 Diabetes,"DRUG, DRUG","18F-AV-133, 10% Arginine Hydrochloride-R-Gene 10",Avid Radiopharmaceuticals,INDUSTRY,False,0,0,0,0,0,33.0,0,2,0,0
NCT00615212,COMPLETED,2008-01-02,2008-02-15,2008-02-15,PHASE1,23.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","GSK376501, Midazolam, Rosiglitazone, Flurbiprofen",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,1.0,1,35,0,1
NCT00995787,COMPLETED,2009-10-15,2010-02-15,2010-02-15,PHASE1,75.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,Type II Diabetes Mellitus,"DRUG, DRUG","AZD1656, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,4.0,1,79,1,3
NCT00754130,COMPLETED,2008-09-15,2008-10-15,2008-10-15,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Non-Insulin-Dependent","DRUG, DRUG","Placebo, MK-0941",Merck Sharp & Dohme LLC,INDUSTRY,True,8,2,6,0,0,1.0,1,55,1,5
NCT00436475,COMPLETED,2007-09-15,2009-11-15,2009-11-15,PHASE1,92.0,INTERVENTIONAL,RANDOMIZED,FACTORIAL,PREVENTION,QUADRUPLE,"Glucose Intolerance, Type 2 Diabetes Mellitus, Metabolic Syndrome","DRUG, DRUG, DRUG, DRUG","Vitamin D3 2,000 IU orally once daily, Calcium Carbonate 400 mg orally twice daily, Vitamin D3-Placebo, Calcium-Placebo",Tufts Medical Center,OTHER,True,2,1,1,0,0,26.0,0,1,1,3
NCT00517465,COMPLETED,2007-09-15,2009-03-15,2009-03-15,PHASE1,41.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG","Placebo, RG1511",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0,18.0,1,15,1,5
NCT04973111,COMPLETED,2021-07-16,2022-04-22,2022-04-22,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Diabetes,"DRUG, DRUG, DRUG","CT-868 as SC Injection, Placebo as SC Injection, Active Comparator as SC Injection","Carmot Therapeutics, Inc.",INDUSTRY,False,0,0,0,0,0,9.0,0,2,1,4
NCT01103609,COMPLETED,2010-04-15,2010-08-15,2010-08-15,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Warfarin, Placebo, AZD1656",AstraZeneca,INDUSTRY,False,0,0,0,0,0,4.0,1,79,1,3
NCT02361138,COMPLETED,2013-12-15,2014-05-15,2014-05-15,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes,"DRUG, DRUG","SHR3824, Placebo","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,5.0,0,15,1,5
NCT02759107,COMPLETED,2016-05-11,2017-06-26,2017-06-26,PHASE1,142.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Healthy, Type 2 Diabetes Mellitus (T2DM)","DRUG, DRUG, DRUG","Tirzepatide, Placebo, Dulaglutide",Eli Lilly and Company,INDUSTRY,True,6,1,5,0,0,14.0,1,64,1,4
NCT00605449,COMPLETED,2008-01-15,2008-03-15,2008-03-15,PHASE1,39.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,GSK376501,GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,2.0,1,35,0,2
NCT02472236,COMPLETED,2015-06-08,2016-01-18,2015-09-24,PHASE1,16.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,OTHER,NONE,Healthy,"DRUG, DRUG","PEX168, Digoxin","Jiangsu Hansoh Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0,4.0,0,3,0,0
NCT01028404,COMPLETED,2009-11-15,2010-06-15,2010-06-15,PHASE1,84.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","NN1952, insulin aspart, placebo, NN1952, insulin aspart, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,7.0,1,126,1,5
NCT01469065,COMPLETED,2011-12-15,2012-05-15,2012-05-15,PHASE1,82.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG","PF-04991532, PF-04991532, PF-04991532, PF-0499132, Placebo",Pfizer,INDUSTRY,True,19,1,18,0,0,5.0,1,42,1,4
NCT03991299,TERMINATED,2021-04-29,2022-02-11,2022-02-11,PHASE1,4.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Obese, Diabetes Mellitus, Type 2",DRUG,Botox 200 UNT Injection,Vanderbilt University Medical Center,OTHER,True,3,3,0,0,0,9.0,0,3,0,1
NCT04662164,WITHDRAWN,2025-12-15,2025-12-15,2025-12-15,PHASE1,0.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,SINGLE,Type 2 Diabetes Patients,DRUG,hepalatide,"Shanghai HEP Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0,0.0,0,1,0,2
NCT02060201,COMPLETED,2014-02-15,2014-05-15,2014-05-15,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Saxagliptin, Dapagliflozin, Saxagliptin/Dapagliflozin FDC",AstraZeneca,INDUSTRY,False,0,0,0,0,0,3.0,1,79,0,2
NCT03235219,COMPLETED,2017-08-01,2018-02-19,2018-02-19,PHASE1,39.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","JNJ-64565111, Placebo","Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0,7.0,1,10,1,5
NCT00862433,COMPLETED,2014-10-10,2022-05-03,2016-10-21,PHASE1,50.0,INTERVENTIONAL,NON_RANDOMIZED,FACTORIAL,PREVENTION,NONE,"Diabetes, Fatty Liver, Obesity, Healthy Volunteers","DRUG, OTHER, OTHER","Alpha tocopherol, Vitamin E, Vitamin C",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,False,0,0,0,0,0,24.0,0,3,0,0
NCT01508858,COMPLETED,2006-11-15,2007-04-15,2007-04-15,PHASE1,21.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","liraglutide, placebo, levonorgestrel / ethinylestradiol",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,5.0,1,126,1,4
NCT05153564,COMPLETED,2021-12-13,2022-09-01,2022-08-13,PHASE1,27.0,INTERVENTIONAL,UNKNOWN,SEQUENTIAL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG","Semaglutide 1.34 mg/mL, Semaglutide 3.0 mg/mL, NNC0480-0389 10 mg/mL, NNC0480-0389 30 mg/mL, Microgynon®",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,8.0,1,126,0,1
NCT01394055,COMPLETED,2011-07-15,2012-12-15,2012-11-15,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications, Gastroparesis, Gastrointestinal Motility Disorder","DRUG, DRUG","RM-131, Placebo","Motus Therapeutics, Inc.",INDUSTRY,False,0,0,0,0,0,16.0,0,1,1,4
NCT05579314,COMPLETED,2022-09-26,2024-11-16,2024-11-16,PHASE1,127.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","XW014, Placebo, XW014, Placebo","Sciwind Biosciences USA Co., Ltd.",INDUSTRY,False,0,0,0,0,0,26.0,0,1,1,4
NCT02211963,COMPLETED,2007-02-15,2007-06-15,2007-06-15,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","BI 44847, Placebo",Boehringer Ingelheim,INDUSTRY,False,0,0,0,0,0,4.0,1,19,1,5
NCT04109508,COMPLETED,2019-10-02,2021-01-27,2020-12-24,PHASE1,278.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Healthy Volunteers, Type 2 Diabetes",DRUG,Oral semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,15.0,1,126,0,2
NCT04582448,COMPLETED,2020-10-01,2021-09-27,2021-09-27,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Insulin icodec,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,12.0,1,126,0,2
NCT06553248,COMPLETED,2023-03-22,2023-11-01,2023-11-01,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetes,"DRUG, DRUG","GZR4, Insulin Degludec","Gan and Lee Pharmaceuticals, USA",INDUSTRY,False,0,0,0,0,0,7.0,0,5,0,3
NCT00813020,COMPLETED,2009-01-15,2009-04-15,2009-04-15,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","semaglutide, semaglutide, semaglutide",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,3.0,1,126,0,3
NCT02120976,TERMINATED,2014-04-15,2015-03-15,2015-02-15,PHASE1,85.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Diabetes Mellitus,"DRUG, DRUG","JTT-252 or Placebo, JTT-252",Akros Pharma Inc.,INDUSTRY,False,0,0,0,0,0,10.0,0,3,1,4
NCT06435676,COMPLETED,2024-06-04,2024-10-08,2024-10-08,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Overweight or Obesity; Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG","HRS9531, Placebo, HRS9531, Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0,4.0,0,7,1,5
NCT00882726,COMPLETED,2009-02-15,2010-04-15,2010-04-15,PHASE1,133.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients), Placebo","Centocor, Inc.",INDUSTRY,False,0,0,0,0,0,14.0,0,1,1,4
NCT01432938,COMPLETED,2011-09-15,2011-12-15,2011-12-15,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","BIOLOGICAL, DRUG","dulaglutide, Warfarin",Eli Lilly and Company,INDUSTRY,True,5,3,2,0,0,3.0,1,64,0,2
NCT04524832,COMPLETED,2020-09-29,2022-02-25,2022-02-25,PHASE1,290.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Oral semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,17.0,1,126,0,3
NCT00618995,COMPLETED,2007-08-15,2007-12-15,2007-12-15,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Comparator: ER niacin (+) laropiprant, Comparator: ER niacin, Comparator: laropiprant, Comparator: placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,2,1,1,0,0,4.0,1,55,1,4
NCT02722239,COMPLETED,2016-03-30,2016-05-05,2016-05-05,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Xigduo XR, Metformin ER (Glucophage® long), Dapagliflozin (Forxiga)",AstraZeneca,INDUSTRY,True,5,5,0,0,0,1.0,1,79,0,2
NCT02375139,COMPLETED,2015-04-15,2015-06-15,2015-06-15,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","DA-1229_01, E+M","Dong-A ST Co., Ltd.",INDUSTRY,False,0,0,0,0,0,2.0,0,6,0,2
NCT03115099,COMPLETED,2017-05-31,2018-04-05,2018-04-05,PHASE1,80.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","LY3325656, Placebo, Liraglutide, Sitagliptin",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,10.0,1,64,1,3
NCT00865033,COMPLETED,2005-11-15,2005-11-15,2005-11-15,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Metformin HCL Tablets, 1000 mg Sandoz, Glucophage 1000 mg",Sandoz,INDUSTRY,False,0,0,0,0,0,0.0,0,4,0,2
NCT01436201,COMPLETED,2011-09-15,2011-11-15,2011-11-15,PHASE1,24.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, BIOLOGICAL","Digoxin, Dulaglutide",Eli Lilly and Company,INDUSTRY,True,3,3,0,0,0,2.0,1,64,0,1
NCT01396187,COMPLETED,2011-07-15,2012-05-15,2012-05-15,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, OTHER","PF-05231023, PF-05231023, PF-05231023, PF-05231023, Placebo",Pfizer,INDUSTRY,True,20,6,14,0,0,10.0,1,42,1,5
NCT01677611,COMPLETED,2008-12-15,2012-03-15,2010-09-15,PHASE1,10.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,QUADRUPLE,Type 2 Diabetes,"DRUG, DRUG","Trans-resveratrol extract from Polygonum Cuspidatum, Placebo",Khoo Teck Puat Hospital,OTHER,False,0,0,0,0,0,21.0,0,1,1,4
NCT01515592,COMPLETED,2006-01-15,2006-04-15,2006-04-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","liraglutide, liraglutide, liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,3.0,1,126,1,4
NCT01478399,COMPLETED,2011-12-15,2012-10-15,2012-10-15,PHASE1,16.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,PB1023 Injection,PhaseBio Pharmaceuticals Inc.,INDUSTRY,False,0,0,0,0,0,10.0,0,4,0,2
NCT02935712,COMPLETED,2016-12-16,2018-01-08,2017-08-04,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Male Subjects With Type II Diabetes (T2DM),"DRUG, DRUG, DRUG","AZD8601+Placebo (SAD), AZD8601+Placebo, Placebo+Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,8.0,1,79,1,4
NCT01527630,COMPLETED,2002-11-16,2003-01-08,2003-01-08,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2",DRUG,biphasic insulin aspart 50,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,2.0,1,126,0,3
NCT01188863,COMPLETED,2010-09-15,2010-10-15,2010-10-15,PHASE1,15.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","300 mg LX4211 (150 mg tablets), 300 mg LX4211 (50 mg tablets), 300 mg LX4211 (liquid)",Lexicon Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,1.0,0,4,0,2
NCT03033433,COMPLETED,2016-10-15,2018-08-15,2017-12-15,PHASE1,28.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type2 Diabetes,DRUG,DCB-DM101,"VitNovo, Inc.",INDUSTRY,False,0,0,0,0,0,14.0,0,1,0,1
NCT01838083,COMPLETED,2013-04-15,2013-08-15,2013-08-15,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type1 Diabetes,DRUG,Insulin glargine new formulation HOE901,Sanofi,INDUSTRY,False,0,0,0,0,0,4.0,1,25,0,3
NCT00609154,TERMINATED,2010-08-12,2014-05-13,2014-05-13,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Type 2 Diabetes,"DRUG, DIETARY_SUPPLEMENT","glucagon like peptide-1, glucose control",Albert Einstein College of Medicine,OTHER,True,1,1,0,0,0,45.0,0,1,0,2
NCT02845219,COMPLETED,2016-07-15,2016-12-15,2016-12-15,PHASE1,25.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","semaglutide, SNAC, Microgynon®",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,5.0,1,126,0,1
NCT01223339,COMPLETED,2010-10-15,2011-02-15,2011-02-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Ertugliflozin, Placebo, Ertugliflozin, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0,4.0,1,55,1,5
NCT00537719,COMPLETED,2007-12-07,2008-04-04,2008-04-04,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","GSK716155, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,4.0,1,35,1,4
NCT01582308,COMPLETED,2012-06-21,2012-12-14,2012-12-04,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","Sitagliptin 100 mg, Saxagliptin 5 mg, Vildagliptin 50 mg, Vildagliptin 50 mg BID, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,5,1,4,10,0,5.0,1,55,1,3
NCT05409924,COMPLETED,2022-04-11,2023-10-04,2023-10-04,PHASE1,71.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","ATR-258, ATR-258, ATR-258",Atrogi AB,INDUSTRY,False,0,0,0,0,0,18.0,0,1,0,3
NCT01821079,COMPLETED,2013-03-15,2013-04-15,2013-04-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Healthy,"DRUG, DRUG, DRUG, DRUG","PF-05175157, PF-05175157, PF-05175157, PF-05175157",Pfizer,INDUSTRY,False,0,0,0,0,0,1.0,1,42,0,1
NCT02500979,COMPLETED,2015-08-17,2016-08-05,2016-08-05,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Type 1 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Pramlintide acetate, Placebo, Lispro insulin U-100, Regular insulin U-100",AstraZeneca,INDUSTRY,True,15,1,14,1,0,12.0,1,79,1,3
NCT04235959,COMPLETED,2020-10-21,2021-08-17,2021-08-17,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Tirzepatide, Placebo",Eli Lilly and Company,INDUSTRY,True,5,1,4,0,0,10.0,1,64,1,4
NCT01121276,COMPLETED,2010-04-15,2010-09-15,2010-09-15,PHASE1,82.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG","Faster-acting insulin aspart, insulin aspart, Faster-acting insulin aspart, Faster-acting insulin aspart, Faster-acting insulin aspart",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,5.0,1,126,0,3
NCT06289920,COMPLETED,2024-03-02,2024-03-28,2024-03-28,PHASE1,47.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","BR3005, BR3005-1, BR3005-2","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0,1.0,0,9,0,2
NCT01131091,COMPLETED,2010-05-15,2010-11-15,2010-11-15,PHASE1,30.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,SK-0403,"Kowa Research Institute, Inc.",INDUSTRY,False,0,0,0,0,0,6.0,0,1,0,2
NCT05761301,TERMINATED,2023-03-10,2025-04-03,2025-04-03,PHASE1,49.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG","ALN-KHK, Placebo",Alnylam Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,25.0,0,1,1,4
NCT01154881,COMPLETED,2010-06-15,2010-11-15,2010-11-15,PHASE1,49.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2",DRUG,insulin degludec,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,5.0,1,126,0,3
NCT01398267,COMPLETED,2011-08-15,2012-10-15,2012-10-15,PHASE1,55.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG, DRUG","aleglitazar, lisinopril, placebo",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0,14.0,1,15,1,5
NCT00961909,COMPLETED,2009-06-15,2010-10-15,2010-10-15,PHASE1,122.0,INTERVENTIONAL,UNKNOWN,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG, DRUG, DRUG","RO5095932, RO5095932, metformin, placebo",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0,16.0,1,15,1,4
NCT02346175,COMPLETED,2014-06-15,2014-12-15,2014-09-15,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","SHR3824, Placebo","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,3.0,0,15,1,5
NCT06204107,COMPLETED,2023-11-21,2023-12-06,2023-12-06,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","CKD-379(Empagliflozin+sitagliptin+metformin) Test drug, CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,0.0,0,32,0,2
NCT00813228,COMPLETED,2009-01-06,2019-11-26,2019-11-26,PHASE1,76.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus Type 1, Diabetes Mellitus Type 2",DRUG,Sitagliptin (Januvia),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,False,0,0,0,0,0,131.0,0,3,0,3
NCT06423872,COMPLETED,2023-06-19,2023-12-08,2023-10-20,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, OTHER","ZT002, Placebo","Beijing QL Biopharmaceutical Co.,Ltd",INDUSTRY,False,0,0,0,0,0,4.0,0,2,1,5
NCT00937872,COMPLETED,2008-11-22,2008-12-22,2008-12-22,PHASE1,9.0,INTERVENTIONAL,UNKNOWN,CROSSOVER,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","250 mg SRT2104 Suspension, Carbon-14 radio-labeled SRT2104","Sirtris, a GSK Company",INDUSTRY,False,0,0,0,0,0,1.0,1,5,0,0
NCT02660736,COMPLETED,2016-02-15,2016-08-15,2016-08-15,PHASE1,59.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Albiglutide Liquid Auto-injector, Albiglutide Lyophilized DCC Pen Injector, Placebo Liquid Auto-injector, Placebo Lyophilized DCC Pen injector",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,6.0,1,35,1,4
NCT01332071,COMPLETED,2009-11-24,2009-12-06,2009-12-06,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg, Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg",GlaxoSmithKline,INDUSTRY,True,6,6,0,0,0,0.0,1,35,0,1
NCT01135446,COMPLETED,2010-05-15,2010-06-15,2010-06-15,PHASE1,35.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","dapagliflozin, dapagliflozin, dapagliflozin, dapagliflozin, dapagliflozin, dapagliflozin",AstraZeneca,INDUSTRY,False,0,0,0,0,0,1.0,1,79,0,3
NCT03916601,COMPLETED,2017-12-13,2018-03-22,2018-03-22,PHASE1,52.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 1 Diabetes,"DRUG, DRUG, DRUG, DRUG","SAR341402, Insulin Aspart, Insulin Aspart, SAR341402",Sanofi,INDUSTRY,False,0,0,0,0,0,3.0,1,25,0,3
NCT01807377,COMPLETED,2013-04-15,2013-08-15,2013-08-15,PHASE1,15.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG, OTHER, DRUG","PF-05175157, Midazolam, Placebo, Midazolam",Pfizer,INDUSTRY,False,0,0,0,0,0,4.0,1,42,1,4
NCT01640873,COMPLETED,2012-09-19,2012-12-20,2012-12-20,PHASE1,33.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","MK-8655, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,6,3,3,1,0,3.0,1,55,1,5
NCT01538511,COMPLETED,2006-06-05,2007-03-13,2007-03-13,PHASE1,59.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","biphasic insulin aspart 70, biphasic insulin aspart 30",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,9.0,1,126,0,3
NCT01088711,COMPLETED,2010-03-11,2010-05-11,2010-05-11,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes (T2D),"DRUG, DRUG","Omarigliptin, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,7,2,5,0,0,2.0,1,55,1,5
NCT02131948,COMPLETED,2013-11-15,2014-07-15,2014-07-15,PHASE1,8.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Insulin Resistance, Diabetes","DRUG, DRUG","Intranasal insulin, Intranasal placebo","University Health Network, Toronto",OTHER,False,0,0,0,0,0,8.0,0,1,1,2
NCT00842556,COMPLETED,2009-03-15,2009-05-15,2009-05-15,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Dapagliflozin, Glimepiride, Sitagliptin",AstraZeneca,INDUSTRY,False,0,0,0,0,0,2.0,1,79,0,2
NCT03414736,COMPLETED,2018-01-19,2018-10-05,2018-10-05,PHASE1,60.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,SAR425899,Sanofi,INDUSTRY,False,0,0,0,0,0,9.0,1,25,0,3
NCT02713477,COMPLETED,2016-04-15,2016-06-15,2016-06-15,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010, Insulin glargine HOE901, Placebo",Sanofi,INDUSTRY,False,0,0,0,0,0,2.0,1,25,1,3
NCT05294536,COMPLETED,2020-06-22,2020-11-27,2020-07-20,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Liraglutide injection,RD12014, Liraglutide injection,Victoza","Sunshine Lake Pharma Co., Ltd.",INDUSTRY,False,0,0,0,0,0,1.0,0,2,0,2
NCT01995656,COMPLETED,2013-12-15,2014-04-15,2014-04-15,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Placebo - Capsule, LY3108743 - Capsule, Placebo - Solution, LY3108743 - Solution",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,4.0,1,64,1,3
NCT04641312,COMPLETED,2020-11-25,2021-12-21,2021-12-21,PHASE1,67.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Healthy, Type 2 Diabetes","DRUG, DRUG, DRUG","LY3457263, Dulaglutide, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,13.0,1,64,1,4
NCT01581736,TERMINATED,2012-04-15,2016-04-15,2016-04-15,PHASE1,48.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,"Obesity, Type 2 Diabetes Mellitus","DRUG, OTHER","U100 Humulin, Exercise",Mayo Clinic,OTHER,False,0,0,0,0,0,48.0,0,2,0,0
NCT01464320,COMPLETED,2011-11-15,2012-04-15,2012-04-15,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,"Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine","DRUG, DRUG","ABT-614, Placebo Comparator",Abbott,INDUSTRY,False,0,0,0,0,0,5.0,0,1,1,4
NCT07039890,COMPLETED,2025-03-08,2025-06-05,2025-05-14,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG","Empagliflozin + Linagliptin filmcoated tablets, Glyxambi film-coated tablets",Humanis Saglık Anonim Sirketi,INDUSTRY,False,0,0,0,0,0,2.0,0,3,0,1
NCT01407003,COMPLETED,2011-06-15,2013-02-15,2013-02-15,PHASE1,138.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,OTHER,DOUBLE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG","LIK066, Placebo",Novartis Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,20.0,1,4,1,4
NCT00902161,COMPLETED,2009-05-15,2009-11-15,2009-10-15,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","MK0893, MK0893-matched Placebo, Propranolol Hydrochloride (HCL)",Merck Sharp & Dohme LLC,INDUSTRY,True,5,1,4,1,0,5.0,1,55,1,4
NCT01509742,COMPLETED,2001-04-15,2001-11-15,2001-11-15,PHASE1,19.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,7.0,1,126,1,4
NCT01416324,COMPLETED,2011-06-15,2011-09-09,2011-09-09,PHASE1,17.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","placebo, 0.1 mg GSK2330672, 0.3 mg GSK2330672, 1 mg GSK2330672, 3 mg GSK2330672, 10 mg GSK2330672, 30 mg GSK2330672, 60 mg GSK2330672",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,3.0,1,35,1,2
NCT00642798,COMPLETED,2008-03-15,2008-03-15,2008-03-15,PHASE1,16.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Diabetes Mellitus Non-insulin-dependent,DRUG,sitagliptin phosphate,Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0,0.0,1,55,0,1
NCT02877355,COMPLETED,2016-08-22,2017-11-24,2017-11-24,PHASE1,55.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2",DRUG,semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,15.0,1,126,0,1
NCT02672839,COMPLETED,2016-02-15,2016-05-15,2016-05-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG","LGD-6972 Solution, LGD-6972 Capsules",Ligand Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,3.0,0,3,0,2
NCT05977465,COMPLETED,2022-01-20,2023-08-03,2023-08-01,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetic Neuropathy Peripheral,DRUG,Empagliflozin 25 MG,Tanta University,OTHER,False,0,0,0,0,0,18.0,0,1,0,3
NCT01217905,COMPLETED,2010-11-15,2011-07-15,2011-07-15,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,BASIC_SCIENCE,DOUBLE,"Type 2 Diabetes, Obesity",DRUG,AZD7687,AstraZeneca,INDUSTRY,False,0,0,0,0,0,8.0,1,79,0,2
NCT01686828,COMPLETED,2013-06-15,2017-12-15,2015-05-15,PHASE1,53.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency, Metabolic Disease","DRUG, DRUG, DRUG, DRUG, DRUG","Acyline, Testosterone 1.62% gel, Letrozole, Placebo gel (for Testosterone 1.62% gel), Placebo pill (for Letrozole)",University of Washington,OTHER,True,3,1,2,1,0,23.0,0,1,1,5
NCT01290575,COMPLETED,2011-02-15,2011-11-15,2011-11-15,PHASE1,67.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Placebo, Placebo, BMS-820132, BMS-820132, BMS-820132, BMS-820132, BMS-820132, BMS-820132, BMS-820132",Bristol-Myers Squibb,INDUSTRY,False,0,0,0,0,0,9.0,1,7,1,5
NCT01537497,COMPLETED,2012-03-15,2012-05-15,2012-05-15,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","PF-05175157, PF-05175157, PF-05175157, Placebo",Pfizer,INDUSTRY,False,0,0,0,0,0,2.0,1,42,1,4
NCT06636877,COMPLETED,2024-10-23,2024-12-11,2024-12-11,PHASE1,52.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Essential Hypertension, Type 2 Diabetes","DRUG, DRUG, DRUG","BR1019, BR1019-2, BR1019-3","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0,2.0,0,9,0,2
NCT02479022,COMPLETED,2015-06-15,2015-12-15,2015-12-15,PHASE1,84.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG","Insulin 320, insulin glargine, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,6.0,1,126,1,4
NCT01971554,COMPLETED,2013-10-14,2014-04-26,2014-04-26,PHASE1,63.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","MK-8666, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,7,3,4,0,0,6.0,1,55,1,5
NCT02971202,COMPLETED,2016-12-15,2019-02-15,2019-02-15,PHASE1,33.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance","DRUG, DRUG","Hyperinsulinemic, euglycemic clamp, 20% dextrose",Vanderbilt University,OTHER,True,3,1,2,0,0,26.0,0,1,0,1
NCT01690169,COMPLETED,2012-09-14,2012-12-11,2012-12-11,PHASE1,45.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG","NNC0113-0987, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,3.0,1,126,1,5
NCT01819922,COMPLETED,2013-04-15,2013-10-15,2013-10-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,Healthy,"DRUG, DRUG","PF-05175157, Placebo",Pfizer,INDUSTRY,True,40,4,36,0,0,6.0,1,42,1,3
NCT03305822,COMPLETED,2017-10-11,2017-12-14,2017-12-14,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY900014, Insulin Lispro",Eli Lilly and Company,INDUSTRY,True,2,1,1,0,0,2.0,1,64,0,2
NCT04552470,COMPLETED,2020-10-26,2021-03-25,2021-03-25,PHASE1,37.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Placebo, PF-06882961",Pfizer,INDUSTRY,True,8,4,4,0,0,5.0,1,42,1,4
NCT05015894,COMPLETED,2021-08-30,2022-08-02,2022-08-02,PHASE1,42.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,NNC0480-0389,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,11.0,1,126,0,1
NCT01614769,COMPLETED,2012-07-18,2013-01-23,2013-01-09,PHASE1,10.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, PROCEDURE","Placebo, Glimepiride 2 mg, Glimepiride 4 mg, Hypoglycemic Clamp",Merck Sharp & Dohme LLC,INDUSTRY,True,3,3,0,0,0,6.0,1,55,1,4
NCT03951753,COMPLETED,2019-06-28,2021-04-08,2021-04-08,PHASE1,117.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Tirzepatide, Semaglutide, Placebo",Eli Lilly and Company,INDUSTRY,True,9,1,8,3,0,21.0,1,64,1,4
NCT00552227,COMPLETED,2002-09-15,2005-07-15,2005-07-15,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus,"DRUG, OTHER","ruboxistaurin, placebo","Chromaderm, Inc.",INDUSTRY,False,0,0,0,0,0,34.0,0,1,1,5
NCT00551590,COMPLETED,2007-12-15,2011-09-15,2008-12-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,DIAGNOSTIC,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Placebo tablet, Sitagliptin tablet, Saline infusion, Exendin(9-39) infusion",Ludwig-Maximilians - University of Munich,OTHER,False,0,0,0,0,0,12.0,0,2,1,3
NCT00791661,COMPLETED,2008-11-15,2009-03-15,2009-03-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Non-Insulin-Dependent","DRUG, DRUG","MK-1006, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,8,2,6,0,0,4.0,1,55,1,5
NCT01082120,COMPLETED,2010-02-15,2010-05-15,2010-05-15,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","AZD1656, Pioglitazone",AstraZeneca,INDUSTRY,False,0,0,0,0,0,3.0,1,79,0,2
NCT02039245,COMPLETED,2014-01-15,2014-03-15,2014-02-15,PHASE1,12.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Healthy Volunteers,DRUG,CANA/MET XR FDC,"Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0,1.0,1,10,0,1
NCT00801164,COMPLETED,2008-12-15,2010-06-15,2010-04-15,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,PREVENTION,QUADRUPLE,"Diabetes Type 2, Periodontitis","DRUG, DRUG","Frio Mouth Rinse Placebo, Frio Mouth Rinse",Biomedical Development Corporation,INDUSTRY,False,0,0,0,0,0,16.0,0,1,1,3
NCT01247363,COMPLETED,2010-11-15,2011-03-15,2011-03-15,PHASE1,20.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,OTHER,NONE,"Diabetes Mellitus, Type 2",DRUG,LY2608204,Eli Lilly and Company,INDUSTRY,True,5,1,4,0,0,4.0,1,64,0,0
NCT01786707,COMPLETED,2009-07-15,2013-03-15,2011-03-15,PHASE1,2.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Type 2 Diabetes Mellitus,"BIOLOGICAL, OTHER, DRUG, DRUG","Autologous stem cells, Hyperbaric oxygen therapy, Insulin, Metformin",Rodolfo Alejandro,OTHER,True,2,1,1,0,0,20.0,0,1,0,2
NCT00730275,COMPLETED,2008-07-18,2011-02-14,2010-12-30,PHASE1,35.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","Sitagliptin phosphate, Comparator: matching placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,6,2,4,0,0,29.0,1,55,1,5
NCT00673465,COMPLETED,2008-04-17,2008-12-11,2008-12-11,PHASE1,17.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","SCH 497079, Placebo, Metformin",Merck Sharp & Dohme LLC,INDUSTRY,True,14,2,12,2,0,8.0,1,55,1,4
NCT01493934,COMPLETED,2010-04-15,2013-03-15,2013-03-15,PHASE1,12.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,DIAGNOSTIC,NONE,Type 2 Diabetes Mellitus,DRUG,injection of 6-DIG,"Institut National de la Santé Et de la Recherche Médicale, France",OTHER_GOV,False,0,0,0,0,0,35.0,0,1,0,1
NCT04504045,TERMINATED,2020-09-01,2022-05-10,2022-05-10,PHASE1,10.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,OTHER,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Metformin, Caffeine, Efavirenz, Losartan, Omeprazol, Metoprolol, Midazolam",University of Southern Denmark,OTHER,False,0,0,0,0,0,20.0,0,3,0,0
NCT02773381,COMPLETED,2016-06-02,2018-10-19,2018-10-19,PHASE1,15.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","semaglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,29.0,1,126,1,4
NCT04744636,COMPLETED,2017-04-03,2018-09-15,2018-09-15,PHASE1,100.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,OTHER,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Other, Other",Institut de Recherches Internationales Servier,OTHER,False,0,0,0,0,0,17.0,0,1,0,1
NCT02506647,COMPLETED,2015-12-15,2016-09-15,2016-09-15,PHASE1,41.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 1","DRUG, DRUG","Gan & Lee insulin glargine followed by Lantus, Lantus followed by Gan & Lee insulin glargine","Gan and Lee Pharmaceuticals, USA",INDUSTRY,False,0,0,0,0,0,9.0,0,5,0,2
NCT01515384,TERMINATED,2010-06-15,2013-02-15,2013-02-15,PHASE1,19.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,DIAGNOSTIC,NONE,"Type 1 Diabetes, Type 2 Diabetes",DRUG,18F-AV-133,Avid Radiopharmaceuticals,INDUSTRY,False,0,0,0,0,0,32.0,0,2,0,1
NCT01941199,COMPLETED,2013-07-15,2013-11-15,2013-11-15,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","DA-1229, metformin, DA-1229 + metformin","Dong-A Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0,4.0,0,1,0,2
NCT01673178,COMPLETED,2012-10-15,2013-09-15,2013-08-15,PHASE1,107.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Melliuts, Type 2","OTHER, DRUG, DRUG, DRUG, DRUG","Placebo, 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023, 150 mg PF-05231023",Pfizer,INDUSTRY,True,49,37,12,0,0,10.0,1,42,1,5
NCT01581658,COMPLETED,2012-04-01,2012-11-01,2012-11-01,PHASE1,32.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","BI10773, BI10773, BI10773, BI10773",Boehringer Ingelheim,INDUSTRY,True,3,3,0,0,0,7.0,1,19,0,2
NCT00993304,COMPLETED,2009-10-15,2010-12-15,2010-12-15,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,14.0,1,126,1,4
NCT06879158,COMPLETED,2024-11-10,2025-01-26,2025-01-26,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG","BR3409, BR3409-1, BR3409-2","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0,3.0,0,9,0,2
NCT02377362,TERMINATED,2015-03-15,2016-11-09,2016-11-09,PHASE1,74.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","GLWL-01, Part A, Placebo, Part A, GLWL-01, Part B, Placebo, Part B, GLWL-01, Part C, Placebo, Part C",GLWL Research Inc.,OTHER,True,32,2,30,0,0,20.0,0,1,1,5
NCT06819488,COMPLETED,2025-02-27,2025-04-16,2025-04-16,PHASE1,6.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Weight Loss",DRUG,[14C]HRS-7535,"Shandong Suncadia Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,2.0,0,5,0,1
NCT04616027,COMPLETED,2021-01-13,2022-02-18,2022-02-18,PHASE1,42.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2, Renal Impairment, Healthy",DRUG,PF-06882961 20 mg,Pfizer,INDUSTRY,True,17,4,13,0,0,13.0,1,42,0,2
NCT05210504,COMPLETED,2022-03-09,2023-01-27,2023-01-27,PHASE1,23.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","L-Lysine, Normal Saline",Vanderbilt University Medical Center,OTHER,True,2,2,0,0,0,11.0,0,3,0,0
NCT04431687,COMPLETED,2020-06-15,2020-10-26,2020-07-24,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","CKD 501, D759, D150, CKD-501, D759, D150",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,1.0,0,32,0,2
NCT01866748,COMPLETED,2013-05-15,2014-04-15,2014-04-15,PHASE1,170.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG","semaglutide, semaglutide, placebo, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,11.0,1,126,1,5
NCT00841048,COMPLETED,2009-02-15,2009-05-15,2009-05-15,PHASE1,107.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,Diabetes Mellitus Type 2,"DRUG, DRUG","AZD4017, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,3.0,1,79,1,3
NCT02224118,COMPLETED,2009-07-15,2010-03-15,2010-03-15,PHASE1,64.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Healthy, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG","CNTO 3649 10 mcg/kg, CNT0 3649 30 mcg/kg, CNTO 3649 100 mcg/kg, CNTO 3649 300 mcg/kg, Placebo",Janssen Pharmaceutical K.K.,INDUSTRY,False,0,0,0,0,0,8.0,1,1,1,3
NCT00979459,COMPLETED,2009-09-15,2009-12-15,2009-11-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","MK-1006 DFC, MK-1006 FCT",Merck Sharp & Dohme LLC,INDUSTRY,True,4,2,2,0,0,2.0,1,55,0,2
NCT02562326,COMPLETED,2015-09-15,2016-01-15,2016-01-15,PHASE1,51.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","BioChaperone insulin lispro, Humalog®",Adocia,INDUSTRY,False,0,0,0,0,0,4.0,0,9,0,3
NCT04260438,COMPLETED,2020-04-08,2020-06-24,2020-06-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T, CKD-393 0.5/100/1000mg formulation 1 Tab. 1T, CKD-393 0.5/100/1000mg formulation 2 Tab. 1T",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,2.0,0,32,0,2
NCT03538743,COMPLETED,2018-06-25,2019-06-10,2019-05-23,PHASE1,98.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Placebo, PF-06882961, PF-06882961, PF-06882961, PF-06882961, PF-06882961, PF-06882961, PF-06882961, PF-06882961",Pfizer,INDUSTRY,True,11,4,7,0,0,11.0,1,42,1,3
NCT05158244,COMPLETED,2021-12-22,2022-06-15,2022-06-15,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","PF-07081532, Placebo",Pfizer,INDUSTRY,True,9,5,4,0,0,6.0,1,42,1,4
NCT01285518,COMPLETED,2011-02-15,2011-07-15,2011-07-15,PHASE1,84.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, OTHER","PF-05231023, PF-05231023, PF-05231023, PF-05231023, PF-05231023, PF-05231023, PF-05231023, Placebo",Pfizer,INDUSTRY,True,34,25,9,0,0,5.0,1,42,1,5
NCT01002807,COMPLETED,2009-11-15,2010-01-15,2009-12-15,PHASE1,15.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG, DRUG","Dapagliflozin, Metformin XR, Glucophage",AstraZeneca,INDUSTRY,False,0,0,0,0,0,1.0,1,79,0,2
NCT02964104,COMPLETED,2016-11-15,2017-12-12,2017-12-12,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Insulin icodec, placebo, insulin degludec, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,13.0,1,126,1,5
NCT01554631,COMPLETED,2012-03-15,2012-05-15,2012-05-15,PHASE1,34.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Acarbose (Glucobay ODT, BAYG5421), Acarbose (Glucobay, BAYG5421)",Bayer,INDUSTRY,False,0,0,0,0,0,2.0,1,4,0,1
NCT04155645,COMPLETED,2019-11-21,2021-06-07,2021-06-07,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Dyslipidemia,"DRUG, DRUG","AZD8233 subcutaneous injection, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,19.0,1,79,1,4
NCT02597400,COMPLETED,2015-10-15,2015-10-15,2015-10-15,PHASE1,12.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Metformin, HMS5552",Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0,0.0,0,10,0,1
NCT03310944,COMPLETED,2017-10-18,2017-12-08,2017-12-08,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,HEALTH_SERVICES_RESEARCH,NONE,"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus",DRUG,sotagliflozin (SAR439954),Sanofi,INDUSTRY,False,0,0,0,0,0,2.0,1,25,0,1
NCT03907202,TERMINATED,2018-04-17,2019-12-03,2019-12-03,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Type II Diabetes Mellitus,DRUG,Daily injection of KBP/placebo for up to 28 days,KeyBioscience AG,INDUSTRY,False,0,0,0,0,0,20.0,0,1,1,5
NCT00574912,COMPLETED,2007-03-15,2010-01-15,2009-09-15,PHASE1,20.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG","Placebo, Insulin Glargine 0.5 u/kg body wt SC, Insulin Glargine 1.0 u/kg body wt SC, Insulin Glargine 1.5 u/kg body wt SC, Insulin Glargine 2.0 u/kg body wt SC",Vanderbilt University Medical Center,OTHER,True,1,1,0,1,0,30.0,0,3,1,2
NCT05831644,COMPLETED,2023-03-31,2023-06-20,2023-06-16,PHASE1,11.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Type2diabetes, Endothelial Dysfunction",DRUG,C21,Vicore Pharma AB,INDUSTRY,True,2,1,1,1,0,3.0,0,1,0,2
NCT06279234,COMPLETED,2024-02-20,2025-04-11,2025-04-11,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Type 2 Diabetes Mellitus (T2DM), Obesity","DRUG, DRUG, DRUG, DRUG, DRUG","Placebo, Rosuvastatin, Midazolam, Omeprazole, PF-06954522",Pfizer,INDUSTRY,False,0,0,0,0,0,14.0,1,42,1,3
NCT00425009,COMPLETED,2004-01-15,2004-12-15,2004-12-15,PHASE1,70.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Berberine, Metformin",Shanghai Jiao Tong University School of Medicine,OTHER,False,0,0,0,0,0,11.0,0,1,0,3
NCT01313286,COMPLETED,2011-03-15,2011-04-15,2011-04-15,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Healthy Volunteers,"DRUG, DRUG","LY2608204 Reference, LY2608204 Test",Eli Lilly and Company,INDUSTRY,True,2,2,0,0,0,1.0,1,64,0,1
NCT00115973,COMPLETED,2005-06-15,2006-01-15,2006-01-15,PHASE1,71.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2, Delivery Systems","DEVICE, DRUG","pump, insulin aspart",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,7.0,1,126,0,2
NCT01747083,COMPLETED,2013-01-15,2013-04-15,2013-03-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,DRUG,FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets)),LG Life Sciences,INDUSTRY,False,0,0,0,0,0,2.0,0,1,0,2
NCT03286751,COMPLETED,2017-10-13,2018-02-06,2018-02-06,PHASE1,42.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY900014, Insulin Lispro",Eli Lilly and Company,INDUSTRY,True,2,1,1,3,0,4.0,1,64,0,2
NCT01013766,COMPLETED,2009-08-13,2009-11-20,2009-11-20,PHASE1,23.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","GSK1362885, GSK1362885",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,3.0,1,35,0,3
NCT01037582,COMPLETED,2009-12-17,2010-05-07,2010-05-07,PHASE1,155.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","NN9924 (oral), placebo, NN9924 (oral), placebo, NN9924 (s.c.), NN9924 (i.v.)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,5.0,1,126,1,5
NCT06559527,COMPLETED,2024-08-20,2025-03-05,2025-02-24,PHASE1,42.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2, Obesity, Overweight",DRUG,NNC0487-0111,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,6.0,1,126,0,2
NCT07158346,COMPLETED,2025-08-18,2025-10-23,2025-10-03,PHASE1,49.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG, DRUG","L03RD1, L03RD2, CT-L03",Celltrion,INDUSTRY,False,0,0,0,0,0,2.0,0,1,0,2
NCT00957268,COMPLETED,2009-09-15,2013-11-15,2013-11-15,PHASE1,46.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Alogliptin,Takeda,INDUSTRY,True,11,3,8,0,0,50.0,1,4,0,2
NCT00854113,COMPLETED,2009-02-15,2009-07-15,2009-07-15,PHASE1,78.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Safety and Tolerability of EGT0001474 in Healthy Volunteers,"DRUG, DRUG","EGT0001474, Placebo",Theracos,INDUSTRY,True,8,8,0,0,0,5.0,0,5,1,5
NCT05741437,COMPLETED,2023-04-11,2023-09-05,2023-08-31,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes,DRUG,"CKD-378, QD, PO Drug: D745, D150, QD, PO",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,5.0,0,32,0,2
NCT04972539,COMPLETED,2020-08-01,2021-03-09,2020-11-30,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","AJU-A51 Tab., A51R1 Tab. and A51R2 Tab.","AJU Pharm Co., Ltd.",INDUSTRY,False,0,0,0,0,0,4.0,0,2,0,2
NCT05373212,COMPLETED,2022-05-12,2023-01-02,2023-01-02,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","Euglycemic clamp with BC Combo THDB0207, Euglycemic clamp with Humalog® Mix25",Adocia,INDUSTRY,False,0,0,0,0,0,8.0,0,9,0,3
NCT06766500,COMPLETED,2025-01-20,2025-02-28,2025-02-28,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Diabetes Mellitus Type 2,"DRUG, DRUG","Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablets, Synjardy® 5 mg/850 mg film-coated tablets",Gedeon Richter Plc.,INDUSTRY,False,0,0,0,0,0,1.0,0,3,0,2
NCT01681693,COMPLETED,2010-02-15,2013-07-15,2013-07-15,PHASE1,33.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,DIAGNOSTIC,NONE,"Healthy, Type 2 Diabetes Mellitus",DRUG,Metformin,"University of California, San Francisco",OTHER,False,0,0,0,0,0,41.0,0,1,0,0
NCT06855147,COMPLETED,2025-04-21,2025-06-17,2025-06-17,PHASE1,7.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Weight Loss",DRUG,[14C]HRS9531,"Fujian Shengdi Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0,2.0,0,7,0,1
NCT03466567,COMPLETED,2018-03-15,2018-07-10,2018-07-10,PHASE1,21.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Semaglutide, Probenecid, Ciclosporin",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,4.0,1,126,0,2
NCT02650206,COMPLETED,2015-01-15,2019-09-27,2019-09-27,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,"Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset, Inflammation","DRUG, OTHER","Victoza (liraglutide) with dietician monitoring, Placebo with dietician monitoring",Stanford University,OTHER,False,0,0,0,0,0,56.0,0,1,1,4
NCT00747175,COMPLETED,2008-08-15,2009-04-15,2009-04-15,PHASE1,52.0,INTERVENTIONAL,RANDOMIZED,FACTORIAL,TREATMENT,SINGLE,Type 2 Diabetes,"DRUG, DRUG","AZD1656, AZD1656",AstraZeneca,INDUSTRY,False,0,0,0,0,0,8.0,1,79,0,2
NCT02623465,WITHDRAWN,2018-01-15,2018-04-15,2018-04-15,PHASE1,0.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2",DRUG,Insulin Lispro,Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,3.0,1,64,0,2
NCT04676906,COMPLETED,2020-11-26,2021-04-28,2021-04-28,PHASE1,18.0,INTERVENTIONAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,"Healthy Volunteers, Type 2 Diabetes","DRUG, DRUG, DRUG","NNC0113-6861, NNC0113-6860, NNC0113-6891",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,5.0,1,126,0,1
NCT03144271,COMPLETED,2007-06-11,2007-10-08,2007-10-08,PHASE1,58.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG","semaglutide, Placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,4.0,1,126,1,5
NCT01365091,COMPLETED,2011-06-15,2011-11-15,2011-11-15,PHASE1,112.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","Saxagliptin/metformin fixed-dose combination (FDC), Saxagliptin, Metformin extended-release (XR), Saxagliptin/Metformin FDC, Metformin",AstraZeneca,INDUSTRY,True,4,3,1,0,0,5.0,1,79,0,2
NCT01043510,COMPLETED,2010-01-15,2010-10-15,2010-10-15,PHASE1,63.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","insulin degludec, insulin detemir",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,9.0,1,126,0,3
NCT05875259,COMPLETED,2023-05-13,2023-06-29,2023-06-29,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Hypertension, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","BR1019-1, BR1019-2, BR1019-1 + BR1019-2","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0,2.0,0,9,0,2
NCT04597697,COMPLETED,2020-12-22,2022-03-24,2022-03-24,PHASE1,25.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Insulin icodec,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,15.0,1,126,0,2
NCT01467414,TERMINATED,2011-10-15,2011-12-15,2011-12-15,PHASE1,1.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2",DRUG,insulin degludec,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,2.0,1,126,0,1
NCT01677299,COMPLETED,2012-05-15,2012-09-15,2012-09-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release)","Elcelyx Therapeutics, Inc.",INDUSTRY,True,4,4,0,12,0,4.0,0,2,0,2
NCT01572649,COMPLETED,2012-05-15,2014-03-15,2014-03-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Lixisenatide (AVE0010), Placebo",Sanofi,INDUSTRY,False,0,0,0,0,0,22.0,1,25,1,4
NCT01282970,COMPLETED,2011-02-15,2011-07-15,2011-07-15,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","BI 135585, Placebo to BI 135585",Boehringer Ingelheim,INDUSTRY,False,0,0,0,0,0,5.0,1,19,1,5
NCT02012166,COMPLETED,2005-07-15,2005-12-15,2005-12-15,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL","MK-0893 10 mg, MK-0893 40 mg, MK-0893 200 mg, MK-0893 1000 mg, Placebo, Sandostatine®, Insulin, Glucagon",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0,5.0,1,55,1,4
NCT01725672,TERMINATED,2012-09-27,2013-08-21,2013-08-21,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Metformin, 500 mg extended release tablet, Metformin, 1000 mg extended release tablet, Glimepiride, 1 mg immediate release tablet, Glimepiride, 2 mg immediate release tablet, Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers, Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers, Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers, Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,11.0,1,35,0,2
NCT02815657,COMPLETED,2013-04-15,2014-01-15,2014-01-15,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","SP2086, Valsartan","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,9.0,0,15,0,2
NCT03235362,COMPLETED,2017-08-07,2017-09-19,2017-09-19,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Dyslipidemia, Type 2 Diabetes Mellitus","DRUG, DRUG, DRUG","YHR1705, YHR1706, YHR1705+YHR1706",Yuhan Corporation,INDUSTRY,False,0,0,0,0,0,1.0,0,1,0,2
NCT04930679,COMPLETED,2018-11-24,2019-02-22,2019-02-22,PHASE1,14.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Andiabet,"Centre of Clinical Pharmacology, Hanoi Medical University",OTHER,False,0,0,0,0,0,3.0,0,1,0,3
NCT00924430,COMPLETED,2009-06-15,2009-07-15,2009-07-15,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin, Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin",Solvay Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,1.0,0,2,0,2
NCT01796366,COMPLETED,2013-02-21,2013-08-19,2013-08-19,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","insulin 338 (GIPET I), placebo, insulin glargine, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,6.0,1,126,1,5
NCT01358981,COMPLETED,2011-05-24,2011-08-17,2011-08-17,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY2881835, Placebo",Eli Lilly and Company,INDUSTRY,True,7,1,6,0,0,3.0,1,64,1,2
NCT04817644,COMPLETED,2021-09-10,2023-07-03,2023-05-26,PHASE1,14.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Oral semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,20.0,1,126,0,1
NCT00733577,COMPLETED,2008-08-11,2009-03-03,2009-03-03,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Diabetes Mellitus, Type 2",DRUG,SB756050,GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0,7.0,1,35,0,3
NCT02673554,COMPLETED,2004-05-15,2008-12-15,2008-12-15,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, PROCEDURE, PROCEDURE","GIP Bolus, GIP Clamp, Oral glucose tolerance test (OGTT), hyperglycemic clamp",Diabeteszentrum Bad Lauterberg im Harz,OTHER,False,0,0,0,0,0,55.0,0,1,0,2
NCT04143802,COMPLETED,2019-12-18,2020-12-28,2020-12-28,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","LY3437943, Dulaglutide, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,12.0,1,64,1,4
NCT07213895,COMPLETED,2025-05-21,2025-09-18,2025-09-15,PHASE1,14.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG","Empagliflozin/Linagliptin/Metformin HCL, Trijardy® XR Extended release film coated tablets",Humanis Saglık Anonim Sirketi,INDUSTRY,False,0,0,0,0,0,4.0,0,3,0,1
NCT06555822,COMPLETED,2024-08-15,2025-03-06,2025-03-06,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Healthy Participants,"DRUG, DRUG","AZD5004, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,7.0,1,79,1,4
NCT01767688,COMPLETED,2013-01-16,2013-03-07,2013-03-01,PHASE1,16.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,MK-3102,Merck Sharp & Dohme LLC,INDUSTRY,True,8,1,7,0,0,1.0,1,55,0,2
NCT01145534,COMPLETED,2009-01-15,2009-10-15,2009-08-15,PHASE1,15.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetes,"DRUG, OTHER","glibenclamide, medicinal plant infusion",Federal University of Paraíba,OTHER,False,0,0,0,0,0,7.0,0,1,0,2
NCT05692934,COMPLETED,2023-01-31,2023-03-11,2023-03-11,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG","HR20031 FDC, HR20031 FDC, HR20031 FDC, HR20031 FDC","Shandong Suncadia Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,1.0,0,5,0,2
NCT00567112,COMPLETED,2007-11-15,2008-04-15,2008-02-15,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","10 mg MK-0941 DFC (fasted), 10 mg MK-0941 OCT (after meal), 10 mg MK-0941 OCT (before meal), 10 mg MK-0941 OCT (fasted)",Merck Sharp & Dohme LLC,INDUSTRY,True,8,4,4,4,0,3.0,1,55,0,2
NCT02627027,COMPLETED,2015-08-15,2015-09-15,2015-09-15,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type II","DRUG, DRUG","Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg, CKD-395 0.25/750mg",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,1.0,0,32,0,2
NCT05272059,WITHDRAWN,2023-09-01,2025-04-14,2025-04-14,PHASE1,0.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Type 1 Diabetes Mellitus,"DRUG, DRUG","MHS552, Placebo",Novartis Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,19.0,1,4,1,4
NCT05031871,COMPLETED,2021-09-02,2021-11-19,2021-11-19,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","HR17031 injection ；INS068 injection；SHR20004 injection, HR17031 injection ；INS068 injection；SHR20004 injection, HR17031 injection ；INS068 injection；SHR20004 injection, HR17031 injection ；INS068 injection；SHR20004 injection","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,3.0,0,15,0,2
NCT01349855,COMPLETED,2011-03-15,2011-05-15,2011-05-15,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 1 Diabetes Mellitus,DRUG,Insulin glargine HOE901,Sanofi,INDUSTRY,False,0,0,0,0,0,2.0,1,25,0,3
NCT01292993,COMPLETED,2011-02-15,2011-03-15,2011-03-15,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","400 mg LX4211, 1000 mg metformin",Lexicon Pharmaceuticals,INDUSTRY,False,0,0,0,0,0,1.0,0,4,0,2
NCT05689099,COMPLETED,2023-01-17,2023-05-30,2023-05-30,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2, Healthy Participants","DRUG, DRUG","Semaglutide B, 1.34 mg/mL, Semaglutide B, 0.68 mg/mL",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,4.0,1,126,0,2
NCT06132126,COMPLETED,2023-11-17,2024-06-28,2024-06-28,PHASE1,66.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,BASIC_SCIENCE,DOUBLE,"Healthy, Type 2 Diabetes Mellitus","DRUG, DRUG, DRUG","LY3938577, Placebo, Insulin degludec",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,7.0,1,64,1,3
NCT00888238,COMPLETED,2009-05-12,2009-07-21,2009-06-10,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,DIAGNOSTIC,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","sitagliptin, Comparator: Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,2,1,1,1,0,1.0,1,55,1,3
NCT05328726,COMPLETED,2022-03-08,2023-03-09,2023-02-09,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, OTHER","GZR-18, Placebo","Gan and Lee Pharmaceuticals, USA",INDUSTRY,False,0,0,0,0,0,11.0,0,5,1,5
NCT05719155,COMPLETED,2023-02-27,2023-04-10,2023-03-23,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes Mellitus,"DRUG, DRUG","CKD-379, D759+D745+D150",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,1.0,0,32,0,2
NCT01031108,COMPLETED,2010-05-28,2011-10-12,2011-10-12,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Placebo, SRT2104","Sirtris, a GSK Company",INDUSTRY,False,0,0,0,0,0,16.0,1,5,1,3
NCT02535078,WITHDRAWN,2015-11-15,2023-09-06,2023-06-19,PHASE1,0.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Malignant Melanoma,DRUG,Tebentafusp (IMCgp100),Immunocore Ltd,INDUSTRY,False,0,0,0,0,0,91.0,0,1,0,1
NCT01396161,COMPLETED,2011-07-15,2012-02-15,2012-02-15,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,UNKNOWN,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG","PF-05175157 or Placebo, PF-05175157 or Placebo, PF-05175157 or Placebo, PF-05175157 or Placebo, PF-05175157 or Placebo",Pfizer,INDUSTRY,True,8,1,7,0,0,7.0,1,42,1,3
NCT01408888,COMPLETED,2011-08-15,2012-04-15,2012-04-15,PHASE1,29.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","BIOLOGICAL, DRUG","LY2189265, Sitagliptin",Eli Lilly and Company,INDUSTRY,True,6,2,4,0,0,8.0,1,64,0,2
NCT02803918,COMPLETED,2017-05-17,2020-01-27,2020-01-27,PHASE1,23.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Lixisenatide (AVE0010), Placebo, Basal Insulin, Metformin",Sanofi,INDUSTRY,False,0,0,0,0,0,32.0,1,25,1,4
NCT02827890,COMPLETED,2016-04-15,2016-05-15,2016-04-15,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Diabetes Mellitus Type 2,"DRUG, DRUG","Januvia Tab. 100mg, Januvia Tab. 100mg + Duvie Tab. 0.5mg",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,0.0,0,32,0,2
NCT02685774,COMPLETED,2016-02-15,2016-04-15,2016-03-15,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type II","DRUG, DRUG","Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg, CKD-395 0.25/500mg",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,1.0,0,32,0,2
NCT02806960,TERMINATED,2014-06-15,2014-08-15,2014-06-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2",DRUG,Nasal Glucagon,Eli Lilly and Company,INDUSTRY,True,7,7,0,0,0,0.0,1,64,0,1
NCT03027960,COMPLETED,2017-06-27,2019-06-01,2019-05-14,PHASE1,21.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Heart Failure, Type II; Diabetes","DRUG, DRUG","Empagliflozin, Placebo Oral Capsule",Yale University,OTHER,False,0,0,0,0,0,23.0,0,1,1,4
NCT02212925,TERMINATED,2006-11-15,2007-03-15,2007-03-15,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","BI 14332 CL, Placebo",Boehringer Ingelheim,INDUSTRY,False,0,0,0,0,0,4.0,1,19,1,5
NCT00824668,COMPLETED,2007-08-15,2007-10-15,2007-10-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","biphasic insulin aspart 30, insulin glargine, insulin glulisine",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,2.0,1,126,0,2
NCT01507389,COMPLETED,2006-03-15,2006-06-15,2006-06-15,PHASE1,24.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2",DRUG,liraglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,3.0,1,126,0,2
NCT01870297,COMPLETED,2013-06-15,2014-12-15,2014-12-15,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","LY3025876, Placebo, Liraglutide",Eli Lilly and Company,INDUSTRY,True,5,1,4,0,0,18.0,1,64,1,4
NCT02386982,COMPLETED,2015-03-15,2015-05-15,2015-05-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,DRUG,HMS5552,Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0,2.0,0,10,0,3
NCT00633997,TERMINATED,2008-02-15,2008-12-15,2008-12-15,PHASE1,22.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Vildagliptin, Vildagliptin",Novartis,INDUSTRY,False,0,0,0,0,0,10.0,1,5,0,1
NCT00102297,COMPLETED,2005-01-15,2007-06-15,2007-06-15,PHASE1,20.0,INTERVENTIONAL,NON_RANDOMIZED,UNKNOWN,TREATMENT,NONE,Diabetes Mellitus,DRUG,FG-3019,FibroGen,INDUSTRY,False,0,0,0,0,0,29.0,0,2,0,1
NCT00481117,COMPLETED,2008-08-15,2008-12-15,2008-12-15,PHASE1,37.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","LY2405319, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0,4.0,1,64,1,4
NCT02183350,COMPLETED,2005-04-15,2005-08-15,2005-08-15,PHASE1,47.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","BI 1356 BS - single rising dose, Placebo",Boehringer Ingelheim,INDUSTRY,False,0,0,0,0,0,4.0,1,19,1,4
NCT01516255,COMPLETED,2006-07-15,2006-11-15,2006-11-15,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, PROCEDURE, PROCEDURE","liraglutide, placebo, moxifloxacin, placebo, electrocardiogram (ECG), electrocardiogram (ECG)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,4.0,1,126,1,4
NCT04317703,COMPLETED,2020-08-19,2020-09-05,2020-09-05,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Gemigliptin tartrate sesquihydrate and metformin, gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release",LG Chem,INDUSTRY,False,0,0,0,0,0,1.0,0,3,0,2
NCT00830791,TERMINATED,2009-01-15,2009-09-15,2009-09-15,PHASE1,32.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","MK-0941 20 mg, MK-0941 5 mg",Merck Sharp & Dohme LLC,INDUSTRY,True,21,3,18,2,0,8.0,1,55,0,1
NCT00517283,COMPLETED,2005-01-15,2005-06-15,2005-06-15,PHASE1,17.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","exenatide and placebo, Exenatide and placebo, Exenatide and placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,5.0,1,79,1,3
NCT03288740,COMPLETED,2017-09-21,2018-08-07,2018-07-10,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Semaglutide 0.5 mg, Placebo (semaglutide 0.5 mg), Semaglutide 1.0 mg, Placebo (semaglutide 1.0 mg)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,10.0,1,126,1,5
NCT01373450,COMPLETED,2011-06-15,2011-07-15,2011-07-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","Oxyntomodulin, Liraglutide 0.6 mg, Liraglutide 1.2 mg, Placebo for Oxyntomodulin, Placebo for Liraglutide",Merck Sharp & Dohme LLC,INDUSTRY,True,6,3,3,3,0,1.0,1,55,1,4
NCT00572650,COMPLETED,2007-10-15,2007-11-15,2007-11-15,PHASE1,29.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,vildagliptin,Novartis,INDUSTRY,False,0,0,0,0,0,1.0,1,5,0,1
NCT06137469,COMPLETED,2023-12-26,2024-03-16,2024-03-16,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,BASIC_SCIENCE,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Acetaminophen/SHR20004, Acetaminophen/Placebo","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,3.0,0,15,1,3
NCT03376802,COMPLETED,2018-04-18,2018-12-27,2018-12-27,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","SAR425899, Placebo",Sanofi,INDUSTRY,False,0,0,0,0,0,8.0,1,25,1,4
NCT01982630,COMPLETED,2013-11-07,2014-10-03,2014-10-03,PHASE1,87.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus,"DRUG, DRUG, DRUG","MK-8521, Liraglutide, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,51,34,17,0,0,11.0,1,55,1,5
NCT01880827,COMPLETED,2013-01-15,2016-01-15,2015-11-15,PHASE1,36.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Type 2 Diabetes, Obesity","PROCEDURE, DRUG, DRUG, DRUG, PROCEDURE","Roux-en-Y, GIP-infusion, GLP-1, MMS, Sleeve gastrectomy",Turku University Hospital,OTHER_GOV,False,0,0,0,0,0,34.0,0,1,0,1
NCT03341013,COMPLETED,2017-11-30,2018-01-29,2018-01-29,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","MEDI0382 Formulation 2, MEDI0382 Formulation 3",MedImmune LLC,INDUSTRY,False,0,0,0,0,0,2.0,0,3,0,1
NCT02084251,COMPLETED,2014-02-15,2014-11-15,2014-11-15,PHASE1,70.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,DOUBLE,Type II Diabetes,DRUG,PB-119,"PegBio Co., Ltd.",OTHER,False,0,0,0,0,0,9.0,0,2,0,2
NCT06932159,COMPLETED,2024-12-23,2025-04-08,2025-03-07,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG","Empagliflozin + Linagliptin film-coated tablets, Glyxambi film-coated tablets",Humanis Saglık Anonim Sirketi,INDUSTRY,False,0,0,0,0,0,2.0,0,3,0,1
NCT01134224,COMPLETED,2010-05-15,2010-11-15,2010-11-15,PHASE1,39.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","insulin degludec/insulin aspart, insulin degludec/insulin aspart, insulin degludec/insulin aspart, biphasic insulin aspart 30, biphasic insulin aspart 30, biphasic insulin aspart 30",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,6.0,1,126,0,3
NCT02815722,COMPLETED,2013-07-15,2014-05-15,2014-05-15,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","SP2086, Simvastatin","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,10.0,0,15,0,2
NCT01023945,COMPLETED,2009-11-07,2010-03-26,2010-03-26,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","ASP1941, Placebo",Astellas Pharma Inc,INDUSTRY,False,0,0,0,0,0,5.0,0,4,1,5
NCT03560323,COMPLETED,2019-01-07,2024-12-30,2024-08-30,PHASE1,41.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,BASIC_SCIENCE,NONE,"Heart Failure, Type 2 Diabetes Mellitus",DRUG,Beta-hydroxy-butyrate,The University of Texas Health Science Center at San Antonio,OTHER,True,5,3,2,0,0,68.0,0,1,0,0
NCT06883656,COMPLETED,2022-03-15,2022-11-01,2022-11-01,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Type 2 Diabetes Mellitus (T2DM), Renal Insuficiency",DRUG,SAL067,"Shenzhen Salubris Pharmaceuticals Co., Ltd.",INDUSTRY,False,0,0,0,0,0,8.0,0,1,0,3
NCT01044537,COMPLETED,2010-02-15,2010-05-15,2010-05-15,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,OTHER,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Placebo, PF-04937319",Pfizer,INDUSTRY,True,15,8,7,0,0,3.0,1,42,1,4
NCT02447601,COMPLETED,2015-03-30,2015-08-11,2015-05-14,PHASE1,16.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,OTHER,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","PEX168, Simvastatin","Jiangsu Hansoh Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0,1.0,0,3,0,0
NCT02164266,COMPLETED,2014-06-15,2014-12-15,2014-12-15,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Healthy Volunteer, Type 2 Diabetes","DRUG, DRUG","Placebo, RO6799477",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0,6.0,1,15,1,5
NCT00239707,COMPLETED,2003-02-15,2006-12-15,2006-12-15,PHASE1,41.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG, DRUG","GIP, Modified GIP, Normal Saline",National Institute on Aging (NIA),NIH,False,0,0,0,0,0,46.0,0,1,0,3
NCT05081921,COMPLETED,2022-01-05,2024-02-20,2024-02-20,PHASE1,192.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Osteoarthritis of Knee,"DRUG, DRUG","MesoCellA-Ortho administration, HA administration",Jagiellonian University,OTHER,False,0,0,0,0,0,25.0,0,1,0,4
NCT06695598,COMPLETED,2024-11-06,2024-12-19,2024-12-08,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus (T2DM),DRUG,CKD-383,Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,1.0,0,32,0,2
NCT01780051,COMPLETED,2013-03-15,2013-04-15,2013-04-15,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Repaglinide/Metformin combination, Repaglinide, Metformin, Repaglinide/Metformin combination, Repaglinide, Metformin","Dalim BioTech Co., Ltd.",INDUSTRY,False,0,0,0,0,0,1.0,0,1,0,2
NCT01388153,COMPLETED,2011-06-15,2011-08-15,2011-07-15,PHASE1,33.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Acarbose (Glucobay ODT, BAYG5421), Acarbose (Glucobay ODT, BAYG5421), Acarbose (Glucobay, BAYG5421)",Bayer,INDUSTRY,False,0,0,0,0,0,1.0,1,4,0,2
NCT00833716,COMPLETED,2009-02-02,2010-07-26,2010-07-26,PHASE1,62.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2, Renal Impairment",DRUG,semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,18.0,1,126,0,1
NCT00949091,COMPLETED,2009-01-15,2009-07-15,2009-07-15,PHASE1,60.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,QUADRUPLE,"Diabetes Mellitus, Type 2",DRUG,TAK-875,Takeda,INDUSTRY,False,0,0,0,0,0,6.0,1,4,0,3
NCT01102673,COMPLETED,2010-04-15,2010-06-15,2010-06-15,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders","DRUG, DRUG","PF-04991532, Placebo",Pfizer,INDUSTRY,False,0,0,0,0,0,2.0,1,42,1,4
NCT04431141,COMPLETED,2020-09-15,2021-01-25,2020-11-16,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Teneligliptin, Empagliflozin, Teneligliptin and Empagliflozin",Handok Inc.,INDUSTRY,False,0,0,0,0,0,2.0,0,1,0,2
NCT01757756,COMPLETED,2012-10-15,2012-11-15,2012-11-15,PHASE1,12.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders","DRUG, DRUG, DRUG","Pf-05175157, placebo, midazolam",Pfizer,INDUSTRY,False,0,0,0,0,0,1.0,1,42,1,1
NCT03981627,COMPLETED,2019-06-06,2020-06-27,2020-06-27,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Type 1 Diabetes Mellitus,"DRUG, DRUG","ADO09 formulation, NovoRapid®",Adocia,INDUSTRY,False,0,0,0,0,0,13.0,0,9,0,3
NCT02430870,COMPLETED,2015-04-15,2015-11-15,2015-09-15,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","TAK-648, Placebo",Takeda,INDUSTRY,True,18,8,10,0,0,5.0,1,4,1,5
NCT02541734,COMPLETED,2015-08-15,2017-05-15,2017-05-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus","DRUG, RADIATION, DRUG","Gelofusine, 111In-exendin 4 SPECT/CT, Placebo",Radboud University Medical Center,OTHER,False,0,0,0,0,0,21.0,0,1,1,2
NCT01372163,TERMINATED,2011-07-15,2012-04-15,2012-04-15,PHASE1,35.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","PF-05190457 or Placebo, PF-05190457 or Placebo, PF-05190457 or Placebo, PF-05190457 or Placebo, PF-05190457 or Placebo, PF-05190457 or Placebo, PF-05190457 or Placebo",Pfizer,INDUSTRY,False,0,0,0,0,0,9.0,1,42,1,4
NCT01330563,COMPLETED,2011-03-15,2011-06-15,2011-06-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,"CKD-501, Ketoconazole",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0,3.0,0,32,0,2
NCT01525238,COMPLETED,2012-07-01,2014-09-01,2014-09-01,PHASE1,53.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,OTHER,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Dapagliflozin, Dapagliflozin, Dapagliflozin",AstraZeneca,INDUSTRY,True,20,7,13,0,0,26.0,1,79,0,2
NCT00768105,COMPLETED,2008-09-15,2009-03-15,2009-03-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,FACTORIAL,TREATMENT,SINGLE,Type 2 Diabetes,"DRUG, DRUG","AZD1656, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,6.0,1,79,1,3
NCT02351323,COMPLETED,2010-05-15,2014-08-15,2014-08-15,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Diabetes,"DRUG, BEHAVIORAL","Glutamine (Pharmacological doses), Lifestyle change",Boston Medical Center,OTHER,False,0,0,0,0,0,51.0,0,1,0,2
NCT00232362,WITHDRAWN,2007-06-15,2008-06-15,2008-06-15,PHASE1,0.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Pioglitazone (Actos), Anti-diabetic agent other than pioglitazone or rosiglitazone",Texas Tech University Health Sciences Center,OTHER,False,0,0,0,0,0,12.0,0,1,0,3
NCT06226727,COMPLETED,2024-02-14,2024-03-31,2024-03-31,PHASE1,52.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Essential Hypertension","DRUG, DRUG, DRUG","BR1019, BR1019-1, BR1019-2","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0,2.0,0,9,0,2
NCT02183415,COMPLETED,2005-08-15,2006-01-15,2006-01-15,PHASE1,77.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","BI 1356 BS, low dose, BI 1356 BS, medium dose, BI 1356 BS, high dose, Placebo",Boehringer Ingelheim,INDUSTRY,False,0,0,0,0,0,5.0,1,19,1,5
NCT01276288,COMPLETED,2011-01-15,2011-06-15,2011-06-15,PHASE1,23.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","BI 10773, hydrochlorothiazide, torasemide, BI 10773, torasemide, BI 10773, hydrochlorothiazide",Boehringer Ingelheim,INDUSTRY,True,27,20,7,0,0,5.0,1,19,0,2
NCT02354027,COMPLETED,2014-09-15,2015-01-15,2014-11-15,PHASE1,12.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,DRUG,SHR3824 metformin,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0,2.0,0,15,0,1
NCT00758680,TERMINATED,2008-08-15,2010-03-15,2010-03-15,PHASE1,112.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","MK-1006, Comparator: Placebo comparator",Merck Sharp & Dohme LLC,INDUSTRY,True,3,2,1,0,0,19.0,1,55,1,5
NCT00519727,COMPLETED,2007-08-15,2008-06-15,2008-04-15,PHASE1,60.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,DRUG,ISIS 325568,"Ionis Pharmaceuticals, Inc.",INDUSTRY,False,0,0,0,0,0,8.0,0,3,0,4
NCT02940379,COMPLETED,2016-10-15,2016-12-15,2016-12-15,PHASE1,24.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","sotagliflozin (SAR439954), midazolam, metoprolol",Sanofi,INDUSTRY,False,0,0,0,0,0,2.0,1,25,0,2
NCT01614782,TERMINATED,2012-06-15,2012-10-15,2012-10-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, OTHER","MK-5823, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0,4.0,1,55,1,5
NCT01422590,COMPLETED,2010-05-15,2011-04-15,2011-04-15,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Sitagliptin, Mitiglinide, Sitagliptin, Mitiglinide",Samsung Medical Center,OTHER,False,0,0,0,0,0,11.0,0,1,0,2
NCT06723691,COMPLETED,2024-12-18,2025-06-09,2025-06-09,PHASE1,57.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Acetaminophen, Metformin, Warfarin, Atorvastatin, Digoxin, HRS9531","Fujian Shengdi Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0,6.0,0,7,0,1
NCT00538174,COMPLETED,2007-11-15,2008-05-15,2008-05-15,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Dapagliflozin, placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0,6.0,1,79,1,4
NCT00184613,COMPLETED,2005-05-15,2006-01-15,2006-01-15,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2, Delivery Systems","DEVICE, DRUG, DRUG","pump, insulin glargine, insulin aspart",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,8.0,1,126,0,2
NCT01865279,COMPLETED,2005-12-15,2006-04-15,2006-04-15,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","insulin degludec, placebo, insulin degludec, isophane human insulin",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,4.0,1,126,1,4
NCT04515576,COMPLETED,2020-08-25,2021-03-09,2021-03-09,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","LY3493269, Dulaglutide, Placebo",Eli Lilly and Company,INDUSTRY,True,4,1,3,0,0,6.0,1,64,1,4
NCT04198948,COMPLETED,2019-03-04,2019-08-05,2019-08-05,PHASE1,15.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Omeprazole, Placebo oral tablet, Gliclazide",University of Sarajevo,OTHER,True,3,1,2,0,0,5.0,0,1,1,2
NCT01728740,COMPLETED,2012-09-15,2012-12-15,2012-12-15,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type II","DRUG, DRUG, DRUG","Acarbose/Metformin FDC (BAY81-9783), Acarbose (Glucobay, BAYG5421), Metformin",Bayer,INDUSTRY,False,0,0,0,0,0,3.0,1,4,0,2
NCT01615978,COMPLETED,2003-12-15,2004-03-15,2004-03-15,PHASE1,15.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","liraglutide, liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0,3.0,1,126,1,5
